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HIV-1 Gag virus-like-particles (VLPs) produced in various expression systems are 
potent stimulators of both cellular and humoral immune responses in animal models. 
The encapsidation of large concentrations of random cellular RNA species is known 
to accompany the assembly of HIV virus particles. This RNA plays a crucial role by 
serving as a molecular scaffold for the assembly of Gag structural proteins into 
particles.  
 
Non-pseudotyped VLPs that do not present any HIV envelope glycoproteins are 
regarded as inert particles as they contain no replicative nucleic acid and are 
presumed to be unable to deliver encapsidated RNA for expressio  in inoculated 
individuals. Live virus cellular entry studies have shown that non-pseudotyped Gag 
particles are destined for degradation in acidified vesicles subsequent to receptor 
independent cellular entry. In addition to host cell RNA incorporation, Gag VLPs 
produced in insect cell-based, baculovirus expression systems have been observed 
to incorporate the baculovirus-derived Gp64 envelope glycoprotein. Gp64 has been 
shown to be efficient at enabling the delivery and expression of genes from 
recombinant baculoviruses and other Gp64 pseudotyped live viruses in mammalian 
cell lines both in vivo and in vitro. This study, therefore, set out to establish for the 
first time whether inert, baculovirus-derived (Gp64 pseudotyped) Gag VLPs could 
mediate delivery and expression of randomly encapsidated RNAs in mammalian cell 
lines. 
 
Gp64 quantitation analyses on VLP extracts showed the incorporation of constant, 
high concentrations of Gp64, ~1650 Gp64 molecules/VLP. This suggested that Gp64 
could mediate VLP cellular entry and possibly the expression of encapsidated RNA. I 
co-expressed a CAT reporter RNA species in the VLP expression system for VLP 
encapsidation to determine if randomly encapsidated RNAs could be expressed in 
mammalian cell lines. Real-time RT-PCR results demonstrated that the levels of 
encapsidated CAT RNA were highly variable between VLP extractions (0.1-11 
copies/VLP) and were thus representative of randomly encapsidated cellular RNA.    
 
VLP cell-uptake assays were conducted using several mammalian cell lines (BHK-













encapsidated CAT RNAs. The use of a CAT ELISA post VLP uptake 
demonstrated for the first time that inert VLPs were capable of entering mammalian 
cell lines via a non-degradative pathway and CAT RNAs were expressed at 
comparable levels between the cell lines.  
 
Established virus inactivation techniques were investigated to prevent the undesired 
transmission and expression of VLP-encapsidated RNAs in mammalian cells. Virus 
inactivation by heat treatment demonstrated the greatest success in neutralizing CAT 
RNA expression, possibly functioning through the disruption of Gp64 envelope 
glycoproteins. The heat treatment of VLPs blocked all CAT expression in some cell 
lines, while other cell lines appeared unaffected by the VLP heat treatment. Heat 
treatment thus did not prevent RNA expression in all cell lines but rather appeared to 
limit the range of cells that the VLPs can enter and express their RNAs. 
 
Cellular entry mediated by functional envelope glycoproteins enables the stimulation 
of cellular immune responses, effective at controlling HIV infection. Heat treatment 
and hence Gp64 disruption was therefore expected to disrupt the cellular immune 
response. This study assessed whether there were any changes to VLP-stimulated 
immune responses subsequent to heat treatment. Mice were inoculated with VLP-
only (heated or non-heated) or DNA vaccine prime/VLP boost (heated or non-
heated) regimens. Mice inoculated with heated VLP only, displayed a significant 
reduction in cellular immune responses compared to unheated VLPs (60%-80% 
reduction). On the contrary, DNA prime/heated VLP boost inoculation regimens 
stimulated substantially enhanced cellular immune responses. Additionally, cellular 
immune responses stimulated by slightly higher concentrations of heat-treated VLP 
boosts, were very similar to responses stimulated by the non-heated VLP boost.  
 
These novel findings suggest that VLPs can be heat-treated to reduce transduction 
and expression of encapsidated RNAs in mammalian cells. To retain VLP 
immunogenicity, the only condition would be the use of slightly higher inoculation 
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1.1 Current HIV infection statistics 
In the present day, vaccines are considered to be an indispensable means of 
protection against an array of potentially lethal pathogens. Throughout recent 
history, they have provided an unsurpassed level of protection against several 
previously lethal pandemic diseases including smallpox and more recently, 
polio.  
 
This year (2008) marks 25 years since the reported isolation of Human 
immunodeficiency virus (HIV) as the causative agent of acquired 
immunodeficiency syndrome (AIDS). In spite of the continued efforts and 
investment in the battle against HIV, infection remains rife and the epidemic 
continues to spread. Current statistics of HIV infection highlight the problem 
the medical world is faced with. As of the end of 2007 the estimated number 
of individuals living with HIV was approximately 33.2 million worldwide (Figure 
1.1 (A, C)). More than two thirds of these people (~22.5 million) are located in 
sub-Saharan Africa, where approximately 1.7 million new infections occurred 
in 2007 (Figure 1.1 (B, D, E)). On a global scale an estimated 2.5 million new 
HIV infections occurred during 2007. This translates to 6850 infections per 
day, almost 70% of which occurred in developing countries (UNAIDS website, 
2008). Life expectancy in Southern Africa has thus fallen from 61 to 49 years 
over the last 20 years (Fauci 2007). Despite these alarming statistics 
however, the high infection rate does appear to have levelled off in the last 7-8 
years (Figure 1.1 (A, B)).   
 
An unvaccinated person will almost certainly fail to successfully combat an 
HIV infection, as infection is accompanied with an early immune dysfunction, 
which limits control of the virus. During HIV infection the virus is directed 
towards those cells of the immune system presenting CD4+ receptors at their 
surface (Popovic et al., 1989; Zack et al., 1990; Dalgleish et al., 1991; Douek 
et al., 2002; Lawson et al., 2004; Oxenius et al., 2004). Infection of these cells 
usually results in their lysis as a result of virus-induced and host immune 
system-induced consequences in response to infection, and a depletion of 















response pathways are interlinked, the host’s immune response is effectively 
crippled by the depletion of these cells. Most fatalities that arise from AIDS are 
therefore a consequence of opportunistic infections, which are sufficient to kill 






















An immune system which has been primed with an HIV vaccine however, 





Figure 1.1 Graphs illustrating the number of people living with HIV and deaths due to AIDS between 
1990 and 2007. (A) People living with HIV Globally and (B) in Sub-Saharan Africa. (C) Adult and child 
deaths due to AIDS globally and (D) in Sub-Saharan Africa. E: Estimated number of adults and 



















destruction of virus particles before they have an opportunity to multiply in 
the host (Mascola et al., 2000; Baba et al., 2000; Letvin, 2002). 
1.2 Drug therapy 
Drug therapy for the treatment of HIV-infected people is the alternative to 
vaccination (Figure 1.2). Currently more than 25 highly effective antiretroviral 
drugs (ARVs) exist, which include protease inhibitors (ritonavir, saquinavir), 
nucleoside-analogue reverse transcriptase inhibitors (AZT, lamivudine) and 
non-nucleoside reverse transcriptase inhibitors (nevirapine). These have 
contributed significantly to reducing AIDS-related morbidity and mortality 
(AEGIS website, 2008). The primary drawbacks of this form of therapy are 
that it is generally very expensive, often has unpleasant side effects and its 
use is generally limited only to those who can afford it. The effect of ARVs is 
curtailed by the fact that for every HIV-infected person that starts ARV 
treatment another 6 are newly infected (Fauci 2007). In South Africa it has 
been estimated that ~ 889000 people currently require ARV treatment and of 
this only ~ 350000 in the public health system have initiated treatment (South 
African Treatment Action Campaign website, 2008). In spite of the vast 
amounts of research, no form of drug therapy has to date been demonstrated 
to cure an HIV infection.  
 
Figure 1.2 Graph illustrating ARV therapy for AIDS patients. Estimated number of HIV-
infected people receiving ARV therapy in low- and middle-income countries as of 















1.3 HIV vaccine 
Vaccines have therefore been proposed as the best means other than 
celibacy to prevent the virus from establishing an infection within a previously 
uninfected person. Thus development of an effective HIV vaccine is regarded 
as one of the most important future prospects with respect to vaccine design. 
Ideally, as with other successful vaccines, a vaccine directed against HIV 
should induce a neutralizing antibody (NAb) response, which would clear all 
detectable levels of HIV within the infected person (sterilizing immunity). 
Several such vaccine strategies have been proposed/tested and yet a vaccine 
capable of stimulating a completely sterilizing immunity remains elusive (NIH 
website, 2008). In the ongoing battle against HIV, numerous potential vaccine 
strategies have reached pre-clinical and even clinical human trial levels 
(HVTN website, 2008). However, these studies have generally not generated 
encouraging results and specific reference is made here to the recent 
(AIDSVAX) phase III vaccine trials by VaxGen (HIV envelope based vaccine), 
as well as the phase II Step and Phambili trials conducted by the NIAID-
funded HIV Vaccine Trials Network (HVTN) and Merck (MRKAd5 HIV-1 
gag/pol/nef trivalent vaccine, based on a weakened adenovirus (adenovirus 
type 5)), which appeared to offer no significant protective efficacy 
(Anonymous, 2003; The Step study website, 2008; NLM website, 2008; NIAID 
website, 2008).    
 
1.4 HIV Vaccine development  
Live attenuated vaccines have historically proven to be the most effective, 
inducing protective cellular and humoral immune responses (e.g.: polio, yellow 
fever, measles, mumps and rubella vaccines). These vaccine types have 
typically been effective as they present epitopes in an immunologically 
relevant context (particulate form), and because they replicate, have facilitated 
prolonged production of specific epitopes within the host from a small 
inoculum (see Deml et al., 2005 for a review). The use of live-attenuated and 
other vaccine types, which includes DNA and recombinant viral vaccines does 
however have limitations, which are particularly relevant with respect to the 















reversion of the attenuated/recombinant virus to a virulent form by mutation 
or recombination, and viral genome insertion into host chromosomes, which 
could result in deleterious mutations (Redfield et al., 1987; Murphey-Corb et 
al., 1997; Senior. 2002; Deml et al., 2005 (review)). As DNA sequences 
produced in heterologous expression systems such as bacteria may possess 
foreign recognition motifes, they could be recognised as foreign bodies by the 
immune system (Bermann-Leitner et al., 2004 (review)). DNA vaccines 
therefore should preferably be made in mammalian cell expression systems, 
which are not as easy to bulk up DNA production for vaccine purposes 
(Bermann-Leitner et al., 2004 (review)). The aforementioned problems and 
risks make these vaccine types undesirable for HIV vaccination strategies. 
These vaccine types are well reviewed elsewhere and will not be discussed 
any further as the focus of this study is on the use of another vaccine type, 
subunit vaccines (Letvin et al., 2005; HVTN website, 2008; WHO website, 
2008).  
 
If live attenuated vaccines are regarded as the first generation of vaccines, 
subunit vaccines can be considered as the second generation. Most often 
subunit vaccines can consist of assembled viral components or individual 
peptides. As these often carry no nucleic acids and are unable to replicate 
and do not present the risks that any nucleic acid based (live attenuated, 
recombinant viral vector and DNA) vaccines do. The subunit group of 
vaccines may also include genetic vaccines,which therefore carry nucleic 
acids and replicate. Subunit vaccines have consisted of individual peptides, 
which were assumed to be immunogenic (envelope glycoproteins) 
(Anonymous, 2003 (AIDSVAX); Bellier et al., 2006; Deml et al., 2005 (review); 
WHO website, 2008). These individual peptide-based vaccines were often 
unable to stimulate strong immune responses and were therefore 
administered in very high concentrations and in several booster doses. This is 
most likely a result of the host’s immune system being stimulated with a linear 
subunit peptide that bears no structural similarity to the same epitope on the 
















As a result of their weak immunogenicity, peptide-based vaccines are often 
co-administered with adjuvants. Adjuvants available for use in humans 
(aluminium phosphate/hydroxide) unfortunately have shown to bias immune 
systems towards Th2-type responses (Nicklas, 1992). As will be discussed at 
a later point, control of HIV infections is mediated by strong cellular immune 
responses this would therefore exclude the use of these adjuvants for HIV 
vaccine purposes. Other adjuvant types such as CpG oligonucleotides and 
cholera toxin are capable of enhancing cellular immune responses, do exhibit 
side effects like toxicity and inflammation and are thus not licensed for use in 
human vaccines (Imaoka et al., 1998; Dumais et al., 2002; Kang et al., 2003; 
Yao et al., 2003).   
 
As a result of these weak immune responses, inert virus-like particles have 
been investigated as immunogens. Replicationally inert virus-like particles 
(VLP) are an ideal substitute for live attenuated and peptide based vaccines 
as they present epitopes in an immunologically relevant context, but lacks any 
replicative nucleic acid. Furthermore, VLP structural stability as well as their 
ability to be manipulated to present heterologous epitopes makes them 
attractive as vaccines. VLPs are easily produced in several heterologous 
expression systems and may be purified by established techniques. Several 
VLP vaccines have been developed for human viruses, such as Human 
papilloma virus (HPV) and Hepatitis B virus (HBV) (Garcea et al., 2004;  
Garland et al., 2007; Paavonen et al., 2007; Aires et al., 2006; Huang et al., 
2005).   
1.5 HIV structure and virion assembly 
The HIV Gag (Pr55Gag) structural protein plays a key role during the 
completion of the HIV life cycle, which concludes with the assembly, budding 
and maturation of infectious viral particles. Gag is expressed as a single 
polyprotein composed of several domains responsible for the movement of 
Gag to the plasma membrane, multimerization of Gag particles and 
encapsidation of viral genomic RNA (Figures 1.3 and 1.4). The unprocessed 
Gag initially assembles into immature particles which are subsequently 















rearrangement of the individual domains to form mature infectious particles. 
This PR-mediated cleavage of Gag yields the individual matrix protein 
(MA/P17), capsid protein (CA/P24), nucleocapsid (NC/P7), P6, P1 and P2 
domains in the assembled virion, which are crucial for ensuring viral infectivity 
(Figures 1.3 and 1.4)  (Mervis et al., 1988; Kohl et al., 1988 ; Gottlinger, et al., 
1989 ; Henderson et al., 1992; Kaplan et al., 1994; Vogt., 1996 ; Swanstrom 
et al., 1997; Garnier et al., 1998). Extensive research has implicated all of the 
above-mentioned components in infectious HIV virion production. This 
complex, multistep assembly process is theorised to facilitate the multiple and 
clearly opposing functions of the Gag proteins at different stages of the viral 
life cycle. The opposing functions include the fact that immature Gag enables 
assembly, membrane targeting and RNA binding while the processed Gag 
enable uncoating, disassembly and nuclear localization of the viral genome.       
 
During virion assembly the unprocessed Gag-Gag and Gag-Pol complexes 
are shown to predominantly concentrate at regions of the cell membrane 
referred to as barges. Cell membrane tropism is determined by a myristylation 
signal located at the N-terminus of Gag (Ono et al., 2001; Nguyen et al., 2000; 
Lindwasser et al., 2001; Gottlinger et al., 1989). Lipid barges are densely 
packed lipid regions enriched with cholesterol, sphingomyelin and 
glycosphingolipids, which are highly resistant to disruption by non-ionic 
detergents (Lindwasser et al., 2001). Electron microscopy (EM) has revealed 
that during assembly of immature Gag particles, the Gag precursor proteins 
are radially arranged below the viral membrane with the N-terminus at the 
membrane and C-terminus extending inwards (Figure 1.3 (C-E)) (Wilk et al., 
2001). The radial arrangement produces doughnut shaped immature particles 
presenting variable levels of electron density derived from the arrangement of 
the components (domains) of the Gag precursor. After proteolytic cleavage of 
Gag in immature viral particles a distinctive conical shape is assumed by the 
virion core consisting of the nucleocapsid (NC) protein and genomic RNA 
surrounded by the capsid (CA) protein (Figure 1.3 (E)) (Li et al., 2000). In this 
arrangement the MA protein is tightly associated with the inner surface of the 
viral membrane and lies above the CA protein. It is speculated that this 






































 Figure 1.3 Illustrating HIV virion components. (A) Simplified HIV genome structure, (B) Artists representation 
of a typical HIV replication cycle, (C) Artist representation of an immature HIV virion prior to Gag processing, 
(D) Electron micrograph of an immature virion displaying the concentric Gag component layers (Wilk et al., 
2001), (E) Artists representation of a mature HIV virion subsequent to Gag processing displaying the various 
layers within the virion structure. (images B, C, E are under license from Russell Kightley Media  


































1.5.1.1 MA protein functions 
In the assembled, mature HIV virion the MA protein lies beneath the viral 
membrane (Pepinsky et al., 1984; Gelderblom et al., 1989). This MA protein 
has been identified to be crucial in shuttling the Gag and Gag-Pol precursor to 
the plasma membrane. The N-terminus of MA in the Gag precursor serves as 
a myristylation site, which consequently along with other highly basic domains 
that form a charged patch for membrane binding, have been shown to 
facilitate the export to and anchorage of Gag precursors at the plasma 
membrane (Hill et al., 1996; Zhou et al., 1994; Gottlinger et al., 1989; Facke et 
al., 1993; Spearman et al., 1994). This protein domain has also been shown 
to facilitate the shuttling of the MA complex in assembled virions after 
infection, from the plasma membrane to the nucleus (Wang et al., 1998). This 
bidirectional transport activity has been suggested to be modulated by 
phosphorylation by cellular kinases incorporated into the assembled virion, 
whereby matrix phosphorylation induces the release of the MA complex from 
the viral membrane during infection (Gallay et al., 1995; Bukrinskaya et al., 
1996; Jacque et al., 1998).  
 
Of particular importance for the production of envelope glycoprotein-displaying 
(Env) virus particles is the finding that there may exist an interaction between 
the cytoplasmic tail of the HIV envelope glycoprotein and the N-terminal 
domain of MA. This is because the incorporation of Env into particles appears 
Figure 1.4 Various functional domains that constitute the unprocessed Gag polyprotein. MA: Matrix 
domain, CA: Capsid domain, NC: Nucleocapsid domain. 



















to be dependent on the integrity of the MA domain (Yu et al., 1992; 
Dorfman et al., 1994(a)). Mutagenesis and other Env-MA interaction studies 
have revealed that an interaction may exist between the N-terminal region of 
MA (Leu12) and the C-terminal 67 amino acids of Env (Freed et al., 1994; 
1995; 1996; Cosson., 1996). Similarly the length of the Gp41 cytoplasmic 
domain also plays a key role in Env-MA interaction studies as shorter domains 
were preferably incorporated into retroviral particles (Freed et al., 1995; 
Mammano et al., 1995; Haglund et al., 2000). A similar scenario was 
suggested in a study conducted by Haglund et al., (2000), in which HIV Gag 
VLPs could incorporate not only their own Gp41 (150 amino acid cytoplasmic 
domain) but also the shorter (29 amino acids) vesicular stomatitis virus (VSV) 
Gp41. Conversely, the VSV virion largely excluded the incorporation of the 
HIV-derived Env protein even when truncated to 10 amino acids. Although a 
separate study showed that incorporation was allowed when the HIV-Gp41 
was conjugated with the VSV Gp41 cytoplasmic domain (Johnson et al., 
1997). Thus length alone appears not to be the only determinant of Env 
incorporation and instead a study conducted by Johnson et al., (1998), 
indicated the presence of a plasma membrane localization sequence in the 
membrane proximal 10 amino acids f HIV Env that excludes it from sites of 
VSV budding.    
 
1.5.1.2 CA protein functions 
This domain is crucial for the multimerization of Gag and Gag-Pol hence 
contributes to virion core formation. CA is also involved in incorporating 
cellular factors and maturation of the virion (Luban et al., 1993; Smith et al., 
1993; Srinivasakumar et al., 1995; Wang and Barklis., 1993; Franke et al., 
1994; Thali et al., 1994). The C-terminal domain of CA (151-231) and P2 
spacer peptide is functional in virion assembly (multimerization) and 
membrane binding while the N-terminal domain (1-145) is functional in virion 
maturation and incorporation of Cyclophilin A (Krausslich et al., 1995; Guo et 
al., 2004; 2005; Melamed et al., 2004; Abdurahman et al., 2004; Chiu et al., 
2002; Borsetti et al., 1998; Huang et al., 1997; Chen et al 1997; Yoo et al., 















association of Gag multimerization activity with membrane binding or the 
simultaneous elimination of either by a simple mutation in CA has led to the 
proposal of a “myristyl switch” model (Hermida-Matsumoto L et al., 1999; 
Paillart et al., 1999; Spearman at al., 1997). This model suggests that the 
myristyl group attached to the 5’ terminus of MA is buried inside the Gag 
monomer and subsequent to multimerization the myristyl moiety is exposed, 
resulting in an increased affinity for the cell membrane. Cyclophilin A has 
been shown to facilitate virion uncoating and is predicted to do this by 
intercalating in between the consecutive capsid domains to loosen CA-CA 
interactions (Franke et al., 1994; Thali et al., 1994). The C-terminal domain of 
CA contains the conserved 20 amino acid major homology region (MHR). 
Mutations at the N-terminus of MHR prevent virus replication, while virions are 
still assembled and released at levels comparable to wild-type Gag (Melamed 
et al., 2004; Abdurahman et al., 2004; Dorfman et al., 1994; Mammano et al., 
1994).  
 
Virus assembly and release on the other hand are significantly affected by 
mutations that lie within or at the C-terminus of the MHR, resulting in a 
decrease in particle yields (Abdurahman et al., 2004; Chiu et al., 2002; Furata 
et al., 2002; Chen et al., 1997; Huang et al., 1997; Dorfman et al., 1994(b); 
Mammano et al., 1994; von Poblotzki et al., 1993). The C-terminal of MHR of 
CA is shown to contain 2 highly conserved sequences present in HIV-1, HIV -
2 and SIV (Zhang et al., 1996, Myers et al., 1991). (sequences: 
ALGpGATLEE and CQGVGGpG) and mutations here have shown to inhibit 
virus replication by more than 90% (SU et al., 2000). Mutational analysis of 
individual amino acids occurring within these conserved regions emphasize 
their importance for proper virion assembly, release and maturation from 
transfected HeLa cells (Abdurahman et al., 2004). Most mutations in this 
experiment did not affect protein synthesis but did impair virion assembly and 
infectivity. The exact correlates of proper virion assembly, release and 
infectivity are not fully determined as results in the above-mentioned study 
and others appear cell-line specific (Parker and Hunter., 2000; Lee et al., 















1.5.1.3 NC functions 
The nucleocapsid domain contains several structural elements crucial for the 
dimerization and encapsidation of viral genomic RNA. The NC domain is 
found to be tightly associated with viral RNA in the virion core (Aldovini et al., 
1990; Berkowitz et al., 1993; Clavel et al., 1990; Gorelick et al., 1990; Zhang 
et al., 1995). As will be discussed later, the ability to coordinate RNA 
dimerization and encapsidation is enabled by the presence of two Zn finger-
like motifs within NC, which are flanked by highly basic domains. Research 
has also suggested that the NC domain may play a role as a virion assembly 
determinant and be crucial for the release of assembled virus particles from 
the infected cell (Cimarelli et al., 2000; De Guzman et al., 1998; Dawson et 
al., 1998; Zhang et al., 1997; Krausslich et al., 1995; Carriere et al., 1995; 
Campbell et al., 1995; Wang et al., 1998). Data from these studies have 
shown that basic residues distributed throughout NC contribute to virion 
assembly by promoting interaction between Gag molecules.  
 
1.5.2 RNA Encapsidation 
During assembly, HIV encapsidates 2 copies of the viral genomic RNA 
displaying the HIV packaging signal. Encapsidation is a highly selective 
process facilitated primarily by the HIV Gag-NC, which selectively 
encapsidates viral genomic RNA over the entire pool of cellular RNAs, 
including spliced viral RNA and various cellular RNAs (Zhang et al., 1995; 
Aldovini et al., 1990; Clever et al., 1995; Dannull et al., 1994; Berkowitz et al., 
1994; Berkowitz et al., 1995; Luban et al., 1991; Dorfman et al., 1993). RNA 
recognition involves an interaction between the NC domain of the Gag 
precursor with specific stem–loop domains found within the 5’ LTR up to the 
beginning of the Gag open reading frame of the genomic RNA (Figure 1.5). As 
previously mentioned, the two Zn-finger like structural domains within NC 
along with the flanking basic amino acid residues (4-5 amino acids) are crucial 
for viral genomic RNA encapsidation (Dannull et al., 1994; Gorelick et al., 
1993; 1996; Poon et al., 1996; Schmalzbauer et al., 1996; Zhang et al., 1995; 















finger-like domains and basic residues have been shown to cause defects 
in RNA binding activity (RNA encapsidation) while having a negligible effect 
on virion assembly (Ott et al., 2005; Alfadhli et al., 2005; Wang et al., 2003; 
Dawson et al., 1998; Cimarelli et al., 2000; Zhang et al., 1995, 1997; Dorfman 
et al., 1993; Schmalzbauer et al., 1996; Poon et al., 1996; Berkowitz et al., 
1995; Dupraz et al., 1992). The basic amino acid residues flanking the first of 
the 2 Zn fingers were shown to play a crucial role in selective packaging of 
genomic viral RNA (Schmalzbauer et al., 1996). The aforementioned study 
also showed that the basic residues flanking the first Zn finger vary in their 
significance in terms of RNA packaging. This was noted when a single 
mutation (R7-N) reduced the RNA binding affinity more than any other 
mutation. While at the C-terminus of the first Zn finger, 2 of the 4 basic amino 
acid residues (R-32 and K-33) caused the most significant reduction in RNA 
binding affinity. The authors also noted that the identified R-7, R-32 and K-33 
residues also constitute known RNA binding motifs, which resemble RxxRR or 
RxxRK. Other than their importance in RNA packaging, mutations of the basic 
residues flanking the Zn fingers of NC has resulted in several assembly 
defects not commonly observed in Zn finger mutants (Poon et al., 1996; 
Cimarelli et al., 2000; Dorfman et al., 1993; Bowzard et al., 1998; Dawson et 
al., 1998; Wang et al., 1998; Wang et al., 2002). 
 
The cis-acting domain within retroviral genomic viral RNA responsible for 
specific viral RNA recognition and encapsidation is known as the Psi (ψ) site, 
which is located within the 5’ long terminal repeat (Ltr) up to the beginning of 
the Gag open reading frame (Figure 1.5. nucleotides 230-352) (Berkowitz et 
al., 1993, 1994; McBride et al., 1996; Clever et al., 1995; Linial et al., 1990; 
Aldovini et al., 1990; Luban et al., 1994). Structural predictions reveal a 
system of 4 stem-loop (SL) secondary structures comprising the ψ site (SL1, 
SL2, SL3, SL4) (Clever et al., 1995; Baudin et al., 1993; Harrison et al., 1992). 
In vitro studies have shown that the stem loop secondary structures are 
functional in mediating the binding of synthetic RNAs (Berkowitz et al., 1994; 

















Mutational analysis of individual stem loop structures only marginally 
affected viral genomic RNA encapsidation (McBride et al., 1996). An SL3 
mutation on the other hand resulted in an increased encapsidation of spliced 
viral RNA, which may indicate a role in distinguishing between spliced and 
unspliced viral RNA. An SL1+SL3 double mutant (deletion or base 
substitution) significantly impaired viral genomic RNA encapsidation. In 
particular this study highlighted the presence of two important structural 
elements in the ψ element (SL1 and SL3), one of which needs to be present 
to ensure viral RNA encapsidation and suggests a co-operative relationship to 












This finding is in agreement with other studies that have also demonstrated 
the importance of SL3 for RNA encapsidation (Aldovini et al., 1990; Berkowitz 
et al., 1996; Clever et al., 1995; 2000; Harrison et al., 1998; Luban et al., 
1994). Thus, since the major splice donor site resides within SL2 (in-between 
SL1 and SL3), this would explain why primarily unspliced viral genomic RNA 
is selectively packaged into virus particles. In spite of the severe reduction in 
RNA encapsidation resulting from SL1 and SL3 dual mutations, encapsidation 
was still observed and therefore these stem-loop structures are not 
considered to be solely responsible for optimal viral RNA encapsidation in wt 
Figure 1.5 The secondary stem-looped RNA structure at the 5’ end of the HIV genome – 
















HIV. Additional research has implicated domains within the C-terminus 
domain of Gag for packaging and specificity (P1, P2 and P6 domains) of viral 
genomic RNA (Zhang et al., 1997; Luban et al., 1994; Parolin et al., 1994; Kim 
et al., 1994).  
 
The 2 copies of the viral genome that are packaged within the assembled 
virion are non-covalently associated in a parallel orientation (Freed et al., 
1998). SL1 has also been shown to be indispensable for the RNA dimerization 
process (Marquet et al., 1994; Muriaux et al., 1996;  Russell et al., 2002; 
2004; Paillart et al., 1994; Skripkin et al., 1994; Clever et al., 1996; Laughrea 
et al., 1994). This sequence is referred to as the dimerization initiation site 
(DIS), which via a 6-nucleotide palindromic sequence within SL1 can initiate 
dimerization through a kissing loop mechanism by complimentary base pairing 
with another viral genomic RNA (Skripkin et al., 1994; Clever et al., 1996; 
Laughrea et al., 1996; Muriaux et al., 1996; Paillart et al., 1996; Russell et al., 
2002). More recent research though, has also implicated the involvement of 
the SL3 sequence as well as a downstream GA-rich sequence (nt 325-336) in 
RNA dimerization and encapsidation (Russell et al., 2003; Zhang et al., 1997). 
As observed previously the overall secondary structure rather than the 
primary sequence of these stem-loop structures appears paramount in 
maintaining functional integrity.   
 
Researchers have suggested a relationship between the viral RNA 
dimerization, RNA encapsidation and virus particle assembly. It has been 
demonstrated that the HIV-1 UTR can assume two mutually exclusive 
conformations that effectively regulate RNA dimerization by varying the 
display of the DIS hairpin (Huthoff et al., 2001; Abbink et al., 2003; Ooms et 
al., 2004; Nikolaitchik et al., 2006). Specifically, the 2 conformations are the 
dimerization-incompetent long-distance interaction (LDI) conformation, where 
the DIS is masked by an upstream poly-A domain and a branched multiple 
hairpin (BMH) conformation which exposes the DIS hairpin to enable 
dimerization. These related studies revealed a direct correlation between the 
status of the DIS conformation with RNA dimerization and consequently virus 
















Most studies have focussed on the psi (ψ) site as the cis-acting functional 
region for packaging of viral genomic RNA. Several studies though, have 
shown that the process of optimal encapsidation involves several other 
elements that map throughout the 5’-end of the genomic RNA including the 
stem-loop structures within the ψ site (Berkowitz et al., 1995; Kaye et al., 
1995; Helga-Maria et al., 1999; Kim et al., 1994; Luban et al., 1994; McBride 
et al., 1996; 1997; Richardson et al., 1993). Other regions identified to be 
crucial for RNA packaging include the HIV TAR element as well as the poly-A 
stem loop structure (Clever et al., 1999; Das et al., 1997; McBride et al., 1997) 
The TAR element is a 57-nucleotide sequence that forms a stem-loop 
structure at both ends of the viral genome and regulates transcription through 
its interaction with the HIV Tat protein (Dayton et al., 1986; Jeang et al., 1998; 
Jones et al., 1997). In particular, compensatory double mutations have 
indicated that the structure rather than specific sequence of the TAR element 
stem loop and the neighbouring poly-A stem loop was found to be the most 
crucial for RNA packaging (Clever et al., 1999; Helga-Maria et al., 1999). As 
expected, a series of missense mutations throughout the TAR structure 
resulted in striking effects on RNA packaging. The mutations that caused the 
most striking effects by hampering RNA packaging resided in the lower 
portion of the TAR stem and not in the looped region.  
 
Therefore the packaging signal of HIV-1 genomic RNA has been shown to 
consist of several hairpin structures residing on either side of the multiple 
splice donor site. It has also been shown that the primary sequence of these 
sites is not as crucial as the overall secondary structure and physiochemical 
properties for RNA encapsidation. Helga-Maria et al. (1999) have suggested 
that each identified packaging element could be a unique domain for the 
binding of a host or viral factor that somehow mediates the encapsidation. An 
alternative suggestion is that not all elements are involved in binding. Instead 
they may only provide the correct structural context for RNA folding enabling 
















1.5.2.1 Encapsidation of random RNAs  
As discussed, HIV incorporates several highly selective mechanisms to 
ensure the encapsidation of genomic RNA. It selectively encapsidates the ψ 
site containing viral genomic RNA. Almost exclusive encapsidation of HIV full 
length RNA is accomplished despite evidence that it may only constitute less 
than 1% of the total cellular mRNA in an infected cell (Berkowitz et al., 1996; 
Swanstrom et al., 1997). To elucidate a mechanism by which HIV Gag 
encapsidation overcomes this hurdle, researchers have proposed a cis 
packaging model. This model proposes that during Gag translation from 
genomic RNA, expressed Gag will encapsidate its cognate RNA and no 
second order function is required to bring Gag and RNA together. The cis 
packaging model was investigated by Poon et al. (2002) using in vivo 
packaging experiments for wild type and full length mutants that do not 
express Gag. It was shown that even though the mutant RNA was 
encapsidated, the wild type RNA was preferentially packaged even in the 
presence of excessive levels of competitor RNA. This study therefore verified 
that the cis packaging model for selective packaging of Gag encoding viral 
RNA does occur, and the linkage of this packaging mechanism with ψ site 
recognition by Gag NC could provide an enhanced degree of specificity.  
 
Although the cis model has been verified by the above study, the authors still 
acknowledge that a trans packaging model in which RNA functions solely to 
produce viral proteins, or serves as genomic RNA for packaging could still 
occur. This study therefore also suggests that to selectively target a particular 
RNA for encapsidation, the process would be largely independent of the 
cellular levels of this RNA species. For the cis packaging model to be 
plausible it would suggest that mutant Gag unable to bind RNA, and similarly, 
mutant RNAs unable to express Gag, should be unable to generate infectious 
virus particles and would not be rescued by wt-Gag.  
 
Several studies have, however, demonstrated several strong lines of evidence 















findings contrasts with those of Muriaux et al. (2002) (discussed earlier) 
who analysed MuLV Gag expression from SFV-derived vectors. Here it was 
noted that the vector derived RNA formed the predominant species within 
infected cells, which despite lacking the ψ site, was encapsidated by virions. 
Other studies have also shown that Gag mutants possessing mutations in the 
NC-zinc finger, CA or MA domains were still able to produce infectious virus 
particles, and dual mutations that prevented assembly could be rescued in the 
presence of wt Gag in which recombination occurred (Ott et al., 2005; 
Nikolaitchik et al., 2006). The study by Nikolaitchik et al., (2006), mutations 
abolishing RNA translation by Gag AUG-mutation had no effect on the 
packaging of this RNA species and these RNAs frequently recombined with wt 
viruses. The contradictory nature of the above research results suggests that 
both trans and cis RNA packaging models more than likely occur. 
 
These studies dealt with non-specific packaging and suggest that HIV VLPs 
produced in insect cell tissue culture expression systems should contain 
significant levels of insect cell-derived RNA species irrespective of the 
absence of the HIV ψ site. The incorporation of viral RNA (spliced or 
unspliced) has also been shown not to be a prerequisite for virion assembly 
and release as NC-deleted Gag or ψ site-deleted RNA still produce viral 
particles (Ott et al., 2005; Wang et al., 2003; Muriaux et al., 2001; Muriaux et 
al., 2002; Zhang et al., 1997; Aldovini et al., 1990; Clavel et al., 1990). In spite 
of this, in vitro studies have shown that Gag protein assembly occurs more 
efficiently in the presence of RNA and it has been suggested that RNA is 
required for particle assembly and may play a structural role in assembly as it 
may serve as a scaffold upon which multiple Gag molecules can assemble 
(Ott et al., 2005; Wang et al., 2002; Cimarelli et al., 2000; Burniston et al., 
1999; Campbell et al., 1995; Gross et al., 1997; Campbell et al., 1995; 1999; 
Ganser et al., 1999; Zuber et al., 2000). Various studies have also shown that, 
other than the viral genomic RNA, HIV particles also encapsidate the various 
cellular RNAs (Muriaux et al., 2001; Berkowitz et al., 1996; Darlix et al., 1995). 
This non-specific RNA binding has also been shown to be mediated by the 
basic residues distributed throughout the NC domain of Gag (Prats et al., 
















The indiscriminate packaging of RNA to enable virion assembly was further 
demonstrated in a study conducted by Ott et al,. (2005). This study showed 
that virion assembly occurred despite the absence of the NC domain in Gag 
and hence the inability to specifically package viral RNA. Double Gag mutants 
on the contrary, that possessed mutations in the MA RNA binding domains as 
well the NC were unable to package RNA and hence were unable assemble 
into particles. Either mutation on their own however had no effect on virion 
assembly and revealed a redundant role for the RNA binding domains in both 
NC and MA. Double mutant assembly could be rescued though in the 
presence of WT Gag or single MA or NC mutants. The requirement for Gag 
RNA binding to facilitate Gag-Gag interaction was also highlighted in this 
study when it was demonstrated that a leucine zipper domain that enables 
tetramerization, inserted into the deleted NC domain could enable virion 
assembly. A study conducted by Alfadhli et al., (2005) yielded similar results 
and proposed the following assembly pathway: Gag protein pairing through 
NC-RNA interactions enables RNA dimerization; this conformational change 
converts assembly-restricted domains to assembly-competent domains; final 
assembly occurs through a set of larger intermediates. Specifically, this study 
also demonstrated that the virion assembly function provided by NC RNA 
binding domains could be substituted by peptide domains that 
dimerize/multimerize. 
 
In view of these results Muriaux et al. (2001, 2002) also noted that ψ-deleted 
retroviral particles (MuLV) not encapsidating genomic viral RNA, efficiently 
compensated for this by packaging increased amounts of various other 
cellular RNAs. It was also found that both wild-type and ψ-deleted particles 
encapsidated roughly similar levels of RNA be it viral-genomic or cell-derived. 
It is also important to note that even wild-type particles contained significant 
amounts of cellular RNAs although only 25-50% of what was contained by the 
ψ-deleted particles. This adds to the idea that RNA encapsidation by the 
retroviral virion retains a certain level of non-specificity. RNase treatment of 
either the ψ-deleted or wild type virion cores resulted in the disassembly of 















study in which CA-NC complexes treated with RNase did not assemble into 
virions, indicating a role for Gag-RNA (cellular or viral) interactions in 
maintaining particle structure (Campbell et al., 1995). Muriaux et al. (2001) 
therefore proposed that viral particles lacking genomic RNA use other, cell-
derived RNAs as scaffolding. 
 
A follow-up study was later conducted to determine the content and role of 
RNA in retroviral particles (MuLV) that lack viral genomic RNA as a result of 
mutations in the Gag NC domain (Muriaux et al 2002). Similar to the ψ 
element mutants, the NC mutant particles contained comparative levels of 
RNA to wild-type particles, but in this circumstance the viral genomic RNA 
was compensated for by the incorporation of rRNA, which has also been 
observed in other studies (Wang et al., 2002; Berkowitz et al., 1995; Poon et 
al., 1998; Zhang et al., 1995). NC mutant virus-like particles were found to be 
highly unstable, some of which were solubilized even before RNase 
treatment. The marked increase in VLP instability and sensitivity observed in 
NC mutant particles compared to ψ-deleted mutants could be accounted for 
by the increased encapsidation of rRNA and the corresponding decrease of 
mRNA incorporation into VLP. Results of this study therefore indicated that 
the basic regions on the N-terminal side of the Zn-finger (R16-R23) including 
residues on the C-terminal side of R23 of NC are critical for virion core 
stability and might participate in Gag-Gag or Gag-RNA interactions to 
maintain the structure of wild-type Gag VLP. It has also been suggested that 
NC may be responsible for discriminating between the incorporation of mRNA 
and rRNA into VLP for scaffold purposes. 
The VLP instability defects resulting from mutation of the above-mentioned 
NC basic amino acids is corroborated in a study conducted by Wang et al. 
(2002). As expected, the mutation of 10-13 basic amino acids by replacement 
with alanine residues prevented viral genomic RNA packaging while not 
affecting Gag virion assembly at the cell membrane. Despite this, it was found 
that only 10% of the Gag protein found in the supernatant sedimented at the 
appropriate density for a retroviral particle while the other 90% sedimented as 















positively charged residues adversely affected both specific and non-
specific RNA binding and a direct correlation was observed between the 
percentage of Gag sedimented as particles and the amount of incorporated 
RNA. From this study it was concluded that RNA binding by Gag (cellular or 
viral) appears more critical to maintaining VLP integrity after cell membrane 
assembly and release, as opposed to being required on a temporal basis for 
assembly. RNA therefore appears to play a role more than suggested by a 
scaffolding label, which insinuates a temporal function and indicates that it 
could be removed following assembly. This is contrary to results of RNase 
treatment studies of VLPs.      
This hypothesis was previously investigated in a study conducted by Cimarelli 
et al. (2000), who investigated the requirement for non-specific nucleic acid 
binding during Gag-Gag interaction and particle assembly by using a panel of 
HIV-1 NC mutants in which 2-10 basic amino acids were replaced with 
alanine. Results of this study demonstrated that NC basic residues mediate 
both specific and non-specific RNA recognition and encapsidation in vitro, 
which corroborates other studies (Wang et al., 2002; Schmalzbauer et al., 
1996; Lapadat-Tapolsky et al., 1993; De Rocquigny et al., 1992). Also, the 
number of mutated basic residues correlated with the magnitude of defects in 
virion assembly.  In contrast, mutations within the Zn finger-like domains had 
no effect on non-specific RNA encapsidation or virion assembly. These and 
other results have lead to the proposal of two arguments to elucidate the 
function of RNA during virion assembly. The first, postulated that RNA acted 
as a scaffold for Gag multimerization, where binding of Gag would drive the 
accumulation of Gag and thus create an environment which would drive virion 
assembly (Cimarelli et al., 2000). The other hypothesis describes the function 
of RNA in neutralizing the positively charged basic residues within NC, hence 
neutralizing repulsion between Gag monomers and thus permitting protein-
protein contacts to initiate virion assembly (Burniston et al., 1999; Gamble et 
al., 1997).                                                                                                                               
 
Although these expression systems have provided invaluable details of HIV 















appear to differ depending on the exact expression system used 
(Abdurahman et al., 2004; Parker and Hunter., 2000; Lee et al., 1998; Wang 
et al., 1998; Sakuragi et al., 1995).  
 
1.6 Immune responses stimulated by Gag VLP 
HIV/SIV Gag VLPs have been shown to be potent stimulators of both cellular 
and humoral immune responses. They take advantage of the fact that the 
immune system responds well to particulate antigens that emulate infectious 
virus particles compared to their soluble component peptides. To date, several 
studies have documented the effectiveness of HIV Gag VLPs produced in 
various expression systems as vaccines (Table 1.1). These studies have 
investigated various aspects of vaccinology including using alternate routes 
and mechanisms of VLP administration and VLP formulations (adjuvants). 
They have also varied the VLP administration protocol (prime/boost) and 
evaluated the ability of VLPs to stimulate the required arms of an immune 
response to mount an effective defence against an HIV infection.   
1.6.1 Site of vaccine administration 
The mucosal surfaces that are prominent in gastrointestinal, urogenital and 
respiratory tracts are the most common routes of viral acquisition. The 
mucosal surfaces serve as the first barrier of defence against invading 
pathogens and include the physical barriers (mucous and epithelium), innate 
immune mechanisms (inflammation, complement) as well as adaptive immune 
responses (humoral and cellular memory immune responses). To mount an 
effective immune response against HIV infection it is desirable to stimulate a 
disseminated mucosal immune response.  In addition, protective systemic 
(cellular/humoral) immune responses would also be desired to complete the 
barrier of protection against HIV infection (Table 1.1; Buonaguro et al., 2005; 
Ogg et al., 1998; Mascola et al., 1999; Koup et al., 1994; Bruck et al., 1994; 
Baba et al., 2000).  
The site of vaccine administration is paramount for stimulating a particular 
type of immune response, be it mucosal or systemic. Parenteral 

















 Immunogen Expression Adjuvant Animal model Antibody response   Neutralisation CTL response Reference 
   system     Serum Mucosal       
1 HIV GagVLP+env (TM 
domain Epstein Bar virus) 
Baculovirus/insect cell N/A New Zealand White rabbits i.m. Strong N/A Strong N/A Deml et al. (1997) 
   N/A BALB/c mice i.p., s.c., i.v. N/A N/A N/A Strong (vs multiple epitopes)  
          
2 HIV GagVLP+env (TM 
domain Epstein Bar virus) 
Baculovirus/insect cell N/A Rhesus macaques i.m. Strong N/A Weak Weak (limited cross 
reactivity) 
Wagner et al. (1998) 
          
 SIV GagVLP N/A Cholera toxin Rhesus macaques i.n. N/A Strong (enhanced by 
adjuvant) 
N/A Weak Imaoka et al. (1998) 
          
 HIV GagVLP Baculovirus/insect cell N/A Rhesus macaques i.m. N/A N/A N/A Strong Paliard et al. (2000) 
          
3 HIV GagVLP+env R5 primary 
isolate HIV-1Bx08 
Vero cell transfection QS21 Rhesus macaques i.m. Moderate  N/A Weak (strain specific) Weak Montefiori et al. (2001) 
          
4 SIV GagVLP +SIV env Baculovirus/insect cell Cholera toxin BALB/c mice i.p. Strong (enhanced by adjuvant) Weak but (enhanced by 
adjuvant) 
Strong (enhanced by 
adjuvant) 
Strong (enhanced by 
adjuvant) 
Yao et al. (2002) 
    + i.n. Weak (enhanced by adjuvant) Moderate (enhanced by 
adjuvant) 
Weak (enhanced by 
adjuvant) 
Weak (enhanced by 
adjuvant) 
 
          
5 Gp120-depleted inactivated 
HIV particles 
N/A CpG-ODN BALB/c mice i.n. Strong (enhanced by adjuvant) Strong (enhanced by 
adjuvant) 
Strong (enhanced by 
adjuvant) 
N/A Dumais et al. (2002) 
          
6 HIV GagVLP+VSVG env DNA vaccine N/A BALB/c mice N/A N/A N/A Strong Marsac et al. (2002) 
          
7 SHIV GagVLP Baculovirus/insect cell Cholera toxin BALB/c mice i.n. Strong (enhanced by adjuvant) Moderate to Strong 
(enhanced by adjuvant) when 
i.n. not by i.p. 
Strong Moderate- (enhanced by 
adjuvant by i.n but i.p better 
response even without 
adjuvant 
Yao et al. (2003) 
          
8 SIV GagVLP +SIV env Baculovirus/insect cell Rantes BALB/c mice i.n. Moderate (enhanced by adjuvant) Moderate (enhanced by 
adjuvant) 
Strong (enhanced by 
adjuvant) 
Strong (enhanced by 
adjuvant) 
Kang et al. (2003) 
   CpG-ODN       
   Cholera toxin       
          
9 HIV GagVLP  Yeast N/A in vitro DC uptake analysis N/A N/A N/A Strong  Tsunetsuga et al. 
(2003) 
          
10 HIV-1 Gag DNA + VLP DNA prime/ Baculovirus VLP 
boost 
N/A DNA i.m. / VLP i.p. N/A N/A N/A Strong (enhanced by protein 
boost) 
Jaffray et al. (2004) 
          
11 HIV GagVLP+ HIV-1A env Baculovirus/insect cell N/A BALB/c mice i.p. Strong Moderate Moderate Strong Buonaguro et al. (2005) 
    i.n. Moderate Moderate Moderate Moderate  
    oral Weak Weak N/A No response  
          
12 HIV GagVLP+ HIV-1A env Baculovirus/insect cell N/A In vitro immature MDDC uptake N/A N/A N/A Strong  Buonaguro et al. (2006) 
    analysis      
          
13 HIV GagVLP+ VSVG env 293T-cell N/A Rhesus macaques i.m. Strong Strong Strong Strong Kuate et al. (2006) 
          
14 HIV GagVLP+MLV env DNA vaccine N/A BALB/c mice i.v., s.c. N/A N/A Strong Strong Bellier et al. (2006) 
15 HIV-1 A, B, C, D, E env DNA 
+ soluble env 
DNA prime/Protein boost N/A Human i.m. Strong N/A Moderate- weak Moderate- strong (enhanced 
by protein boost) 
Wang et al. (2008) 
          
 
Table 1.1 Summarised results of VLP based immunogenicity studies 











Introduction and Literature review 
 
25
strong systemic immunogenicity although very often no mucosal immune 
responses are observed. Several studies have revealed that mucosal 
immunization (intranasal (i.n.); oral) can effectively induce systemic as well as 
mucosal immune responses at sites of inoculation as well as at distal mucosal 
surfaces at moderate levels (Table 1.1; Kang et al., 2003; Yao et al., 2002). 
This is highlighted in a study conducted by Buonaguro et al. (2005), where 
HIV VLPs pseudotyped with gp120 derived from a Ugandan clade-A isolate 
were administered to mice using multiple routes. Both intraperitoneal (i.p.) and 
i.n. administration stimulated systemic as well as mucosal IgA and IgG 
responses. Immune sera exhibited more than 50% neutralization of 
autologous and heterologous primary isolates. Oral VLP administration failed 
to induce systemic or mucosal immune responses. While both i.p. and i.n. 
VLP administration stimulated specific CTL activity, i.n. administration 
stimulated this response at a lower efficiency. Intranasal VLP administration 
induced specific IgA though, which could not be accomplished by i.p. 
administration. This VLP based vaccine was therefore able to stimulate both 
arms of the immune response and results from this study serve as an ideal 
example and motivation for delivery of proposed vaccines by multiple routes. 
Noteworthy observations were also made in several studies in which nasal as 
opposed to oral mucosal vaccine administration was able to stimulate IgA 
responses in a broader range of mucosal tissues (Table 1.1: 2; 4; 5; 7; 8; 11). 
The precise mechanism and site of vaccine administration therefore plays an 
important role in priming appropriate parts of the immune system.  
 
1.6.2 Plasmo-VLPs 
The production of VLPs can be a time-consuming and expensive process, 
which has motivated the development of plasmo-VLP vaccines. Plasmo-VLPs 
are DNA vaccines that encode proteins which subsequently form VLPs in an 
inoculated individual. This process thus only requires DNA production 
(Akahata et al., 2005; Bellier et al., 2006; Young et al., 2006). The plasmo-
VLP strategy takes advantage of endogenous production and particulate 
nature of the antigen in stimulating CD8+ and CD4+ T- and B-cell responses. 
Bellier et al. (2006) produced a MLV Gag VLPs pseudotyped with MLV Env 
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responses in mice and protected them from a lethal virus challenge. The 
production of VLPs from this DNA vaccine was shown to induce an immune 
response that was 106-fold more effective than the same vaccine producing 
non-particulate peptides. 
 
1.6.3 Inoculation regime 
Often peptide or DNA-based vaccines stimulate weak to moderate immune 
responses. Researchers have overcome this problem by making use of 
vaccine prime-boost regimes in which the animal/human model tested is 
initially primed with either a peptide-based/DNA vaccine/live attenuated vector 
and later boosted with another immunogen. This strategy has been used in 
several animal as well as human models and shown significantly enhanced 
immune responses compared to responses developed by immunogens used 
on their own (Table 1.1, Jaffray et al., 2004; Wang et al., 2008; Paliard et al., 
2000; Montefiori et al., 2001; Meyers et al., 2008; Chege et al., 2008). 
 
1.6.4 Adjuvants 
Studies have also made use of co-stimulatory molecules/adjuvants as either 
part of the vaccine formulation or as an attachment to the SIV/HIV chimeric 
particles (Table 1.1; Skountzou et al., 2007; Yao et al., 2002; Sailaja et al., 
2007; Kang et al., 2003; Dumais et al., 2002). These co-stimulatory factors 
have included bacterial enterotoxins: Cholera toxin and the E.coli heat-labile 
toxin, Rantes, CpG oligodeoxynucleotides (ODN), the dendritic cell growth 
factor Flt3 ligand, granulocyte-macrophage colony-stimulating factor (GM-
CSF) and CD40 ligand. Co-administration of either cholera toxin or the E.coli 
heat-labile toxin mucosal adjuvants is able to enhance serum as well as 
mucosal antibody responses (Table 1.1: 2; 4; 7; 8). Co-administration of 
cholera toxin with SIV VLPs in mice enhanced immunogenicity of the VLP and 
improved cellular and humoral immune responses systemically and at distal 
mucosal surfaces and sites of application compared to VLPs delivered to mice 
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Despite promising results in mice, due to the toxic nature of the cholera 
toxin, alternate adjuvants have been investigated for use in humans. The 
innate immune system recognises a wide range of pathogen-associated 
molecular patterns (PAMPs), which it perceives as danger signals rather than 
specific epitopes as used by the adaptive immune response. As a result the 
innate immune responses occur more rapidly and are believed to provide time 
for an effective adaptive immune response (Levy, 2001). Stimulated cellular 
immune responses in response to PAMP recognition is mediated by 
transmembrane pattern recognition receptors (PRRs), which may include 
surface receptors on phagocytic cells and Toll-like receptors found on DCs 
and macrophages. PAMP recognition by these receptors upregulates co-
stimulatory molecules (CD80/86), cytokines IL-12 and IL-18 and hence 
promotes the induction of Th-1 biased cellular and humoral immune 
responses (Deml et al., 2005).  
 
Researchers have successfully manipulated these innate immune responses 
by delivering antigen as cocktails containing molecules with PAMPs to 
enhance responses. Kang et al. (2003) demonstrated that co-administration of 
either RANTES or CpG-ODN (common motifs in unmethylated bacterial 
nucleic acid recognised as danger signals by Toll-like receptors-9 signalling 
pathways) in mice was more effective at stimulating neutralizing antibody 
titres than cholera toxin. These co-administered factors also stimulated 
interferon-gamma and CTL responses in spleen and lymph nodes to 
equivalent levels observed for cholera toxin. RANTES and CPG-ODN were 
also able to enhance serum and mucosal antibody responses to SIV-env at 
levels equivalent to cholera toxin. Chimaeric SIV VLPs that display 
immunostimulatory molecules such as GM-CSF or the CD40 ligand have also 
been investigated as vaccines (Skountzou et al., 2007). Incorporation of these 
molecules into VLPs enhanced both humoral and cellular immune responses 
to levels greater than those observed when administering VLPs without any 
GM-CSF or CD40 ligand attached or VLPs administered with soluble 
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1.6.5 Influence of expression system 
Expression systems used to produce the VLPs may also have a bearing on 
the immune response (see Baculovirus Gp64 pseudotyping 1.7.5 and 4.1.2). 
In particular, the expression systems appear to have an effect on innate 
immune responses. Yeast-derived VLPs have previously been shown to 
induce DC maturation, which was accompanied by IL-12 production 
(Tsunetsuga-Yokota et al., 2003). In this study the combination of VLP 
structure and yeast membrane components incorporated into the VLP could 
bias DCs to develop strong Th-1 responses and this was found to be 
mediated by TLR-2 signalling.  
 
Insect cell based baculovirus expression systems are routinely used to 
produce VLPs (Table 1.1) as they allow for the production of high 
concentrations of heterologous proteins, amongst other reasons which will be 
discussed at a later point. VLP purification techniques which include gradient 
centrifugation to isolate VLPs are fairly crude and don’t easily discriminate 
between heterologous VLP and baculovirus particles. The contaminating 
baculovirus particles are speculated to act as adjuvants as their nucleic acids 
may possess CpG motifs similar to bacteria, which are recognised as danger 
signals by Toll-like receptor-9 signalling pathways (Ludwig et al., 2007). 
These adjuvant properties of contaminating baculoviruses were corroborated 
in a study that demonstrated that baculoviruses enhanced the immune 
response to VLPs by directly maturing MDDCs via IFN-γ secretion. (Hervas-
Stubbs et al., 2005). The observed immune response to the VLPs was 
significantly reduced when baculovirus contaminants were removed from the 
inoculum. Baculovirus based insect cell produced VLPs also display 
significant levels of the baculovirus Gp64 envelope glycoprotein. It is 
speculated that these envelope glycoproteins may direct fusion of the VLPs 
with the membranes of antigen presenting cells and hence be a major 
determinant with respect to the processing and presentation of VLP epitopes 















1.7 Baculovirus based insect cell expression systems 
The taxonomic family Baculoviridae comprises a family of large enveloped 
rod-shaped viruses that are 30-60nm in diameter and 250-300nm in length 
(Figure 1.6) (O’Reilly et al., 1994). The rod-shaped capsids are composed of 
the major capsid protein VP39 and enclose a double stranded DNA genome 
(80-180 kbp). The enveloped capsids also display envelope glycoproteins. 
Baculoviruses can be divided into 2 genera: Nucleopolyhedrovirus (NPVs) 
and Granulovirus (Fauquet et al., 2008 (ICTV virus taxonomy); Theilmann et 
al., 2005; Fields et al., 1996).  Both NPVs and granuloviruses are known to be 
exclusively pathogenic to arthropods. 
 
NPVs can produce 2 virion phenotypes during infection. These include the 
occluded-derived virus (OV) and the budded virus (BV) (O’Reilly et al., 1994; 
Fauquet et al., 2008 (ICTV virus taxonomy)). The OV phenotype is adapted 
for stability and allows transmission between insects via oral transmission. 
These particles assemble within the nucleus and become enveloped when 
budding through the nuclear membrane (Figure 1.6). OV are often engulfed 
within a crystalline protein matrix of polyhedrin. BV particles on the contrary 
are adapted for cell to cell transmission within an infected insect and thus 
facilitate systemic spread within the host. These BV particles assemble at the 
plasma membrane and acquire their envelope as well as any membrane 
associated factors (glycoproteins) when budding here.  
 
1.7.1 Baculovirus replication 
In tissue culture baculoviruses undergo an infection cycle of 3 phases: early; 
late and very late phases. These phases correspond to the “reprogramming” 
the cellular machinery to create a favourable environment for viral replication; 
production of BV and the OV. During the very late infection phases, during OV 
production in the nucleus, large arrays of fibrous material begin to 
accumulate. The fibrous material consists of the 10 kDa polypeptide known as 
p10, which is suggested to aid the lysis of infected cells during the late phases 
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expressed. The AcMNPV strong very late phase polyhedrin and p10 
Baculovirus promoters, have been manipulated for use as insect cell based 
expression vectors for the large scale production of heterologous proteins, 















These types of expression systems have been very successful in producing 
foreign gene products as both polyhedrin and p10 genes are non-essential for 
replication in cell culture. As both polyhedrin and p10 expression occurs 
during the very late phase to enable occlusion, heterologous gene expression 
from their promoters should not interfere with BV production that occurs 
during the late phase. This would also therefore minimise any selective 
mutational pressure to delete or inactivate the transgene.  Polyhedrin and p10 
deletions result in an occlusion negative phenotype, and the resulting 
recombinant viruses are not very effective at infecting their arthropod hosts 







Figure 1.6 Illustrating various NPV phenotypes. (A)  The virion components and sizes of OV and BV 
phenotypes (http://content.answers.com/main/content/wp/en/thumb/4/4a/428px-Nucleopolyhedrovirus. jpg); (B) 
Electron micrograph of budded form of a nuclear polyhedrosis virus. Rod shaped nucleocapsid is 
encapsidated by lipid bilayer derived from the host cell. The top end of the polar virion contains the Gp64 
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1.7.2 Baculovirus insect cell infection 
The NPVs can be sub-divided into 2 groups. Group I NPVs such as the 
Autographa californica multiple nucleopolyhedroviruses (AcMNPV) have 
Gp64 as the major envelope glycoprotein. Group II NPVs lack a Gp64 
homologue and instead possess unrelated fusion proteins collectively known 
as F-proteins (Pearson et al., 2000; Chen et al., 2001). Gp64 along with the 
VP39 major capsid protein comprises one of the most abundant proteins 
within the virion (Oomens et al., 1999). 
 
Baculoviruses enter host cells by receptor mediated endocytosis, which is 
envelope glycoprotein dependent. Studies on AcMNPV in particular have 
shown that the assembled, disulphide-linked Gp64 trimers alone are sufficient 
to mediate cellular entry through low pH induced membrane fusion (Blissard 
et al., 1992; 1996; Oomens et al., 1995; Monsma et al., 1996; Markovic et al., 
1998; Hefferon et al., 1999; Hefferon et al., 1999). This has been 
demonstrated in studies where antibodies directed against Gp64 envelope 
glycoproteins are capable of neutralizing BV infection (Zhou et al., 2006; 
Hohmann et al., 1983; Volkman et al., 1984; Keddie et al., 1985). Similarly, 
deletion of the AcMNPV Gp64 gene prevents the production of infectious virus 
(Monsma et al., 1996; Oomens et al., 1999).  
 
Viruses utilise several entry pathways to enter target cells: these include 
phagocytosis, macropinocytosis, caveola-mediated endocytosis and clathrin 
mediated endocytosis. A study by Long et al. (2006) utilised various cellular 
entry inhibitors to identify possible paths of entry for baculovirus. The study 
revealed that baculoviruses chiefly enter host cells via the clathrin-mediated, 
pH-dependent endocytic pathway. Inhibition of caveola-mediated endocytosis 
on the contrary enhanced the transduction of virus particles. This observation 
was suggested to be a result of channelling more virus particles towards 
clathrin mediated endocytosis.     
 
To mediate cellular entry, Gp64 utilises a mechanism similar to the influenza 
virus, which enters the cell by virion and endosome membrane fusion 
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1992; Monsma et al., 1995; Markovic et al., 1998; Kingsley et al., 1999; 
Plonsky et al., 1999; Long et al., 2006). Endosome acidification is crucial for 
mediating baculovirus cellular entry by membrane fusion as demonstrated by 
using inhibitors of endosome acidification (Blissard et al., 1992; Long et al., 
2006). Tani et al. (2001) has demonstrated that an over-expression of Gp64 
on the baculovirus surface has led to enhanced transduction efficiency. Group 
II baculoviruses that lack Gp64 were shown to be unable to transduce 
mammalian cells but this ability could be conferred by pseudotyping the 
baculovirus with Gp64 (Liang et al., 2005).   
 
1.7.3 Baculovirus mammalian cell entry 
Initially baculovirus transduction was assumed to be limited to insect cells. 
However a study by Hofmann et al., (1995) demonstrated first that a 
recombinant baculovirus carrying a reporter gene under the control of a CMV 
promoter was able to transduce human hepatocytes and express the reporter 
gene. Since then numerous studies have demonstrated the ability of 
recombinant baculoviruses to deliver and express foreign genes in vivo in 
mouse nasal epithelia, mouse skeletal muscle cells, rabbit endothelial cells, 
and in vitro in various mammalian cell lines including HeLa, Vero, BHK21, 293 
T-cells, rat hepatocytes and human hemocytes (Boyce et al., 1996; Shoji et 
al., 1997; Condreay et al., 1999; Duisit et al., 1999; Airenne et al., 2000; 
Pieroni et al., 2001;  Abe et al., 2003; Gao et al., 2007).  
In spite of the efficient baculovirus transduction of mammalian cells, viral 
replication does not occur here and all vectors required the presence of 
promoters functional in mammalian cell lines to enable transgene expression. 
For this reason baculoviruses (AcMNPV) have recently been considered as 
attractive mammalian gene delivery vectors (Boyce et al., 1996; Delaney et 
al., 1998; Kost et al., 2002; Tani et al., 2003; Abe et al., 2003; Kitagawa et al., 
2005; Changyong et al., 2005; Masayuki et al., 2006; Song et al., 2006; Gao 
et al., 2007). Intranasal inoculation with recombinant AcMNPV has shown to 
induce strong immune responses protecting mice from lethal challenges of 
influenza A or B virus (Abe et al., 2003). Related technologies have also led to 
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Gp64 envelope glycoprotein, foreign promoters like the white spot 
syndrome virus (WSSV) ie1 promoter have enabled recombinant baculovirus 
vectors to attain high levels of reporter gene expression in both insect and 
mammalian cell lines (Gao et al., 2007). These studies have all demonstrated 
that Gp64 on the surface of AcMNPV is essential for transduction of 
mammalian cells and the baculovirus vectors here entered mammalian cells 
by means of the same pH-dependent entry pathway used during insect cell 
infection.  
 
Not all mammalian cell lines are permissive to baculovirus transduction: these 
include haematopoietic and human T-cell lines. Permissivity would infer 
susceptibility to recombinant baculovirus uptake and gene expression. 
Permissive (Huh-7 and B16) and non-permissive haematopoietic (RAW 264.7 
and YAC-1) mouse cell lines have been investigated to establish mechanisms 
by which baculovirus transduction is prevented (Schauber et al., 2004; 
Masayuki et al., 2006). Results from this study demonstrated that baculovirus 
entered both permissive and non-permissive cell lines, while only permissive 
cell lines were transduced (i.e. the expression cassette was expressed). Viral 
DNA was detectable in the permissive cell lines for up to 96 hours, while only 
detectable for up to 48 hours in non-permissive cell lines. This suggests that 
permissive cell lines take up DNA more easily or viral DNA degrades slower.  
1.7.4 Pseudotyping baculovirus particles 
The vesicular stomatitus virus-G envelope glycoprotein (VSV-G) is often used 
to pseudotype lentiviral particles used as vector delivery vehicles because of 
its broad tropism and the ability to confer stability and infectivity to virus 
particles (Burns et al., 1993; Yee et al., 1994; Kitagawa et al., 2005). 
 
Several groups have reported improved transduction efficiency in a variety of 
mammalian and insect cell lines infected with recombinant baculoviruses 
expressing foreign viral envelope proteins such as VSV-G (Barsoum et al., 
1997; Tani et al., 2001; 2003; Mangor et al., 2001; Facciabene et al., 2004; 
Kitagawa et al., 2005; Matilainen et al., 2006; Ernst et al., 2006; Zhou et al., 
2008). VSV-G can also complement Gp64-null baculoviruses, which suggests 
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et al., 2008). Using VSV-G to pseudotype heterologous virus particles does 
pose certain problems, which include the fact that it can cause cell death as a 
result of rapid syncytium formation (Ory et al., 1996). Also, because of its 
broad tropism it is able to transduce antigen presenting cells, which could 
potentially result in a deleterious immune response (Liu et al., 1996; DePolo 
et al., 2000). As a result of these undesirable effects when pseudotyping with 
VSV-G, alternate envelope glycoproteins have been investigated. Gp64 has 
been proposed as a potential envelope glycoprotein to pseudotype lentiviral 
particles (Kumar et al., 2003; Schauber et al., 2004; Oomens et al., 2004). 
Gp64 has demonstrated an ability to functionally complement heterologous 
virus membrane glycoproteins (HIV; MLV; HSRV; FIV) and has shown to be 
very effective at mediating uptake of lentiviral particles into target cells. Upon 
further analysis, the Gp64 mediated virus entry by the established pH-directed 
membrane fusion pathway, which was also prevented by anti-Gp64 
antibodies. 
1.7.5 Gp64 Pseudotyping heterologous viral vectors 
Studies by Kumar et al. (2003) and Schauber et al. (2004) demonstrated that 
HIV based vectors pseudotyped with Gp64 were able to successfully 
transduce cells of hepatic origin, 293 T-cells, HeLa and HuH-7 human cell 
lines, while haematopoietic cells were not transduced. In addition, the 
Schauber study demonstrated efficient gene transfer potential of Gp64 in vivo. 
FIV-based vectors pseudotyped with Gp64 were shown to efficiently tranduce 
primary cell cultures of human airway epithelia and in vivo mediated gene 
transfer and expression in mouse nasal epithelia, which persisted for more 
than 11 months, while a previous study that utilised a VSV-G pseudotyped 
HIV-1 only persisted for 3 months (Limberis et al., 2002; Sinn et al., 2005). A 
study by Schauber et al. (2004) has also shown that Gp64 could be used to 
pseudotype an MLV-based oncoretroviral vector. These studies demonstrated 
that Gp64 conveyed similar transduction efficiency to VSV-G but had a more 
restricted tropism. The restricted tropism would therefore avoid the 
transduction of immune cells and effectively avoid vector inactivation by host 
sera. Tani et al., (2001) has suggested that this difference in tropism arises as 
Gp64 interacts directly with general phospholipids on the surface of 
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phosphatidyl serines. It is suggested that phospholipid molecules including 
phosphatidylinositol and phosphatidic acid as well as proteins are possible 
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1.8 Research project outline  
This literature review has discussed the importance of encapsidating RNA to 
enable HIV virion/VLP assembly. HIV-1 Gag utilises RNA binding as a form of 
molecular scaffold for the construction of virus particles. With respect to RNA 
encapsidation it is particularly significant that HIV genomic RNA constitutes a 
relatively small proportion of encapsidated RNA within assembled virions. 
Instead, the greater proportion of encapsidated nucleic acids consists of 
random cellular RNA species.  
 
In this study we have for the first time questioned the potential for the 
transmission and expression of RNA species encapsidated by HIV VLPs 
(derived from an insect cell based baculovirus expression system). The 
transmission and expression of foreign-insect cell derived nucleic acids within 
a vaccinated individual is regarded as a problematic trait with respect to 
vaccine regulatory bodies, such as the United States Food and Drug 
Administration (US FDA). The FDA specifically requires the VLP vaccine 
developers to show that no live virus is produced during vaccine production 
(Shapiro, 2002). Similarly the FDA is also concerned with the possible 
generation of novel viruses and requires vaccine developers to show that 
VLPs do not encapsidate “specific” nucleic acid sequences from the 
expression system especially those encoding VLP components. The vaccine 
producer should also be able to demonstrate a level of control with respect 
that VLP consistency. This consistency might be hard to maintain as a result 
of the random nature of RNA packaging during VLP assembly.  
 
Results from HIV-1 infection assays have clearly noted that in the absence of 
any functional envelope glycoproteins on the virion/VLP surface, the particles 
will be predisposed to degradation within acidified endosomal compartments. 
Degradation here should effectively prevent the transmission and expression 
of VLP contained nucleic acids (RNAs) and this would be consistent with the 
notion that VLPs are “inert” particles.  
Insect cell based baculovirus expression systems are one of the most 
common expression systems used for the production of HIV-1 VLPs. As 
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enables them to transduce not only insect but mammalian cell lines as well 
via pH-dependent cell surface receptor mediated endocytosis. Gp64 
inadvertently pseudotypes HIV-1 VLPs when budding from insect cells in 
baculovirus based expression systems. The amount of Gp64 on the surface 
of insect cell produced HIV-1 VLPs has not been determined and hence 
this study also set about to determine the relative levels of Gp64 on HIV-
1 VLPs. Owing to the presence of Gp64 on the surface of VLPs a possibility 
exists for it to function as an RNA transmission vector. A recent study by 
Schauber et al. 2004, recently demonstrated that an infectious HIV particle 
produced in 293T cell lines and pseudotyped in this system with a Gp64 
transgene was able to transduce mammalian cells and express a GFP gene 
carried by the viral genome. This study in contrast will be conducted on a 
far simpler, non-replicative HIV Gag VLP system consisting only of gag and 
CAT genes expressed by a recombinant baculovirus in an insect cell line. The 
assembled Gag VLPs were assessed for its ability to encapsidate the CAT 
RNAs produced in the insect cell line. This study was therefore the first to 
my knowledge to analyse the potential transfer and expression of 
encapsidated reporter CAT RNAs from non-replicative Gag VLPs in 
mammalian cell lines. These VLPs were, in comparison to the Schauber et 
al. 2004 study, not pseudotyped by any additional mechanism other than that 
utilised by the baculovirus expression system in the insect cell line. Thus the 
suspected ability of the so-called inert particles to enter mammalian cell lines 
and express encapsidated RNA species was assessed using cell lines 
previously shown to be permissive to Baculovirus transduction.  
 
For VLP vaccine purposes, the presence of randomly encapsidated RNAs, 
which are random in both content and possibly concentration, could pose as 
an obstacle for vaccine regulatory bodies (if transmission and expression 
occurs). For vaccine producers to still assert a level of control on the vaccine 
content, they could simply rule out/neutralize the possible transmission and 
expression of RNA from VLPs out of the immunization equation by 
“inactivating” purified VLP preparations. This was the first study to 
document the neutralisation of RNA transmission and expression from 
Gp64 pseudotyped HIV Gag VLPs. VLPs were subjected to temperatures 
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virion, prior to cell uptake assays. The effect of this form of virus 
neutralisation on VLP immunogenicity was next questioned by 
inoculating the “heat-inactivated” VLPs into mice. This allowed a 
comparison of cellular immune responses stimulated by heat treated VLPs to 
responses stimulated by non-heat treated particles. Results from this 
immunogenicity study will give an indication of the significance of Gp64 
pseudotyping of HIV VLPs and whether a conferred ability to transduce 
mammalian cells contributes to VLP immunogenicity. Also it allowed us to 
determine if VLP heat treatment is a viable method to reduce the transmission 
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2.1 VLP Production for Vaccines 
The HIV-1 Gag precursor protein (Pr55Gag) is independently capable of 
driving the assembly of immature HIV VLPs in a number of expression 
systems. These particles appear as doughnut shaped particles that are 120-
150nm in diameter and are estimated to contain ~ 5000 structural Gag 
proteins (Figure 2.1 (C I-III)) (Briggs et al., 2004). Following Gag expression 
within the selected expression system, Gag proteins are targeted to the inner 
surface of the host plasma membrane by the N-terminal myristylation signal 
(Figure 2.1 (B I)). Assembled aggregates of Gag induce budding of particles 
from the host cell surface, which then acquire a host cell-derived membrane 
as well as membrane associated factors such as envelope glycoproteins 
(Figure 2.1 (B II, III)). 
 
HIV VLPs have been produced in various expression systems in the absence 
of any other viral components involved in HIV virion assembly and maturation 
(Table 1.1; Gheysen et al., 1989; Haglund et al., 2000; Gelderblom et al., 
1991; Karacostas et al., 1989; Royer et al., 1992, Mergener et al., 1992; 
Krausslich et al., 1993; Porter et al., 1996; Swanstrom et al., 1997). Results of 
these studies have greatly advanced our understanding of the assembly 
determinants of HIV particles expressed in various expression systems. 
These include insect cells (using a Baculovirus expression vector), yeast 
spheroplasts, T-cell lines, BHK cells (using a vesicular stomatitus virus 
expression vector), HeLa cells (Table 1.1; Abdurahman et al., 2004; Geysen  
1989; Wagner et al., 1996; 1998; Haglund et al., 2000; Sakarugi et al., 2002; 
Deml et al., 2004; 2005). Other studies have also established that the entire 
gag coding sequence is not necessary for particle assembly. Wang et al. 
(1998) showed that HIV Gag mutants with 80% of MA deleted, are proficient 
at particle assembly. Similarly, studies conducted using C-terminally truncated 
forms of Gag in combination with the above-mentioned MA deletion of HIV 
Gag have established that the smallest Gag precursor capable of assembling 
into VLPs consists of a 28kDa protein made up of only a few MA amino acids 
































Figure 2.1 Simplified illustration of HIV VLP assembly. (A) Unprocessed Gag polyprotein. (B) 
Expression/production of the Gag polyprotein within cell, followed by the export, accumulation (I)+(II) 
of the Gag polyprotein at the plasma membrane and budding of immature HIV particles/VLP (II)+(III) 
(Yao et al., 2003). (C) Artists representation of an immature HIV virion (I), compared to an HIV VLP 
(II), (III) Electron micrograph of one of my insect cell-produced HIV VLP preparation. ((images B I 
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2.1.1 Manipulation of Gag VLPs 
Gag VLPs can be manipulated to enhance their immunogenicity by the 
inclusion of heterologous epitopes in the particle. Such epitopes can be added 
to the VLP by the co-expression of heterologous envelope glycoproteins 
(type-2 VLPs) or by in-frame insertion of epitope sequences either internally or 
at the gag 3’-terminal (type-1 VLPs) (Wagner et al., 1996; Deml et al., 2005). 
Gag is capable of accommodating the addition of a large size range of 
heterologous epitopes on the 3’ terminus: a study by Halsey et al. (2008) from 
this laboratory has shown that particles with C-terminal inserts in Gag as large 
as 778 amino acids can still be successfully produced. This study has also 
demonstrated that the addition of epitopes to Gag VLPs is more likely to be 
limited by the properties of the epitope itself as opposed to its size. As 
discussed in the literature review, the exact VLP assembly determinants 
appear to be expression system dependent. RNA encapsidation on the other 
hand is known to be crucial for Gag VLP assembly, where the assembling 
particle requires RNA to serve as a form of molecular scaffold. As discussed 
earlier, during particle assembly large amounts of cellular RNAs are also 
encapsidated by the particle. 
 
Insect cells used with BEVS provide an ideal eukaryotic environment for the 
production of biologically active proteins as they enable post-translational 
modifications such as the proper protein folding, disulphide bond formation, 
oligomerization and proteolytic cleavage (O’Reilly et al., 1994). As a result, 
post-translational modifications in the insect cell expression systems are most 
often identical to proteins produced in insect and mammalian cells. As 
indicated, BEVS have been very successful at producing high concentrations 
of heterologous proteins through the manipulation of the very late infection 
p10 and PH gene promoters (Table 1.1). Deletion of these p10 and PH open 
reading frames has no effect on virus replication and provides an additional 
advantage of not producing the OV phenotype (O’Reilly et al., 1994). These 
recombinant vectors are therefore very unlikely to be transmissible to their 
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As discussed earlier the NPV envelope glycoprotein, Gp64 is one of the 
most abundant proteins within the BV, and its inclusion on BV is crucial for 
infectivity in insect and mammalian cells. Gp64 envelope glycoproteins are 
presented in high concentrations on the insect cell surface. As a result, any 
protein bodies produced within baculovirus infected insect cells that bud 
through this membrane (BV, HIV VLPs) will simultaneously collect high 
concentrations of Gp64. Pseudotyping of the inert Gag VLPs here may 
subsequently confer the Gp64-mediated cell entry ability to the VLP that it 
confers to baculovirus. 
 
2.1.2 Aims: 
This study required the use of BEVS-produced Gag-VLPs that had 
encapsidated CAT RNA as a reporter RNA species. As discussed at the end 
of chapter 1, these VLPs could serve as a tool to determine whether the RNAs 
encapsidated by VLPs during assembly can enter the cells of an inoculated 
host and be expressed. 
 
 This chapter describes the cloning steps taken for the 
manipulation/construction of a dual BEVS that co-expressed both an HIV gag 
as well as a CAT ORF. Gene products of these co-expressed ORFs should 
assemble into Gag-VLPs that may have encapsidated a CAT encoding RNA 
species within infected insect cell lines at relatively high concentrations. The 
expression of the Gag ORF and subsequent assembly into VLPs was 
assessed by means of Gag-specific western blotting and electron microscopy 
of infected insect cell supernatant. The expression of the CAT open reading 
frame was confirmed by means of CAT ELISA analysis of infected insect cell 
supernatant. 
 
The Gp64 content of produced Gag VLPs was also assessed on purified Gag 
VLPs. It was surmised that a quantitative analysis of Gp64 on the surface of 
Gag VLPs would therefore give an indication of whether sufficient Gp64 is 
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2.2 Materials and Methods 
2.2.1 Vectors used: 
 
The pFastBacTM Dual (pFBD) baculovirus insect cell expression vector 
(Invitrogen) was used for the co-expression of a chloramphenicol 
acetyltransferase (CAT) reporter open reading frame (ORF) along with a 
human codon optimized Pr55 gag (hmgag) ORF (Appendix B (2, 4)).  
 
2.2.2 DNA Sequences used:  
The hmGag ORF used for cloning was derived from the Du422 clinical isolate 
identified by Williamson et al. (2003) and was human codon optimized by 
Operon Technologies, USA. This hmGag ORF was kindly provided by Mr. 
Richard Halsey (MCB, UCT) as a clone in a pGEM®-T Easy 
cloning/sequencing vector (Promega). The CAT reporter ORF was obtained 
from the pcDNA3.1/Zeo/CAT Cloning vector (Invitrogen) (Appendix B (3)). The 
hmGag and CAT ORFs were cloned into the pFBD vector multiple cloning 




2.2.3 Construction of baculovirus expression vector (BEV) clones 
Initially both the pFBD vector and the pGEM®-T easy vectors containing 
hmgag ORF were subjected to an NcoI/NsiI (Fermentas) double restriction 
enzyme digest using 1 unit of enzyme/ug of DNA (Figure 2.2 (A and B)). 
Digest reactions were set up as per suppliers protocol using supplier provided 
buffers and bovine serum albumin (BSA). Digests were incubated at 37oC for 
2 hours before analysis. The NcoI/NsiI excised hmGag gene and pFBD vector 
were gel-purified as described in Appendix A (4). The hmGag ORF insert was 
subsequently ligated to the NcoI/NsiI restriction sites of the pFBD vector under 
the control of the p10 promoter (Figure 2.2 (C)). Ligations were conducted in 
10μl reaction volumes using 1 unit of T4-DNA ligase (Roche) at a 10:1 insert 
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Competent E. coli DH5α cells were then transformed with this ligation 
product (Appendix A (5)) and resulting recombinant plasmids were isolated 
using a small-scale plasmid DNA extraction protocol (Appendix A (2.1)). The 
sequences of recombinant pFBD+ Gag clones were verified by sequencing 
using P10 forward and reverse primers (Appendix A (6)). A selected 
pFBD+Gag clone was isolated and plasmid DNA was purified by means of a 
large-scale plasmid DNA extraction method (Appendix A (2.2)).  
 
Both pFBD+Gag and the pcDNA3.1/Zeo/CAT cloning vectors were subjected 
to XbaI/NotI double digests using 1 unit of enzyme/ug of DNA as before 
(Figure 2.2 (D and E)). The pcDNA3.1/Zeo/CAT cloning vectors contained the 
relevant CAT ORF with either no attached ψ-encoding sequence or with a ψ-
encoding sequence at either the 5’ or 3’ end of the CAT ORF. The contained 
CAT ORF was kindly provided by Dr Ann Meyers (Appendix B (8)). The 
XbaI/NotI digested pFBD+Gag vector and excised CAT ORF, 5’ψ-CAT or 3’ψ-
CAT were gel purified as described in Appendix A (4). The CAT ORF insert 
was ligated to the XbaI/NotI restriction sites of the pFBD+Gag vector under 
the control of the PH promoter using the same reaction conditions as for the 
pFBD+hmGag ligation (Figure 2.2 (F)). Competent E. coli DH5α cells were 
then transformed with this ligation product (Appendix A (5)) and resulting 
recombinant plasmids were isolated using a small-scale plasmid DNA 
extraction protocol (Appendix A (2a)).  The sequences of several recombinant 
pFBD+Gag+CAT, pFBD+Gag+5’ψ-CAT and pFBD+Gag+3’ψ-CAT clones 
were verified by sequencing the final vector product using PH forward and 





















































Figure 2.2 Cloning steps used to produce the baculovirus based dual expression construct that co-
expressed both the hmGag ORF and CAT ORF in infected insect cell lines (pFBD+Gag+CAT). (A and B) 
Initial NcoI/NsiI digestion of the pFBD cloning vector and pGEM cloning vector containing the hmGag ORF 
to (C) enable insertion/ligation of the hmGag ORF into the pFBD vector (pFBD+Gag(p10)). (D and E) 
XbaI/NotI digestion of pFBD+Gag vector and pcDNA-vector containing CAT ORF to (F) enable 
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2.2.4 Production and Isolation of recombinant bacmid DNA 
2.2.4.1 Transposition of pFBD+Gag+CAT into a bacmid containing E.coli 
strain (DH10Bac™ Invitrogen) 
 
Competent DH10Bac cells (Invitrogen) were thawed on ice followed by the 
addition of 8ng of pFBD+Gag+CAT plasmid DNA (Appendix B (6 and 7)). This 
transformation protocol deviated from that described in Appendix A (5), by 
requiring a 45 minute initial incubation on ice, a heat shock for 45 seconds 
(37oC) and incubating the DNA/competent cell mixture at 37oC for 4 hours. At 
this point 200μl of the transformation mix was plated onto Luria agar plates 
(Appendix A (1)) supplemented with 50μg/ml kanamycin, 7μg/ml gentamycin, 
10μg/ml tetracycline, 40μg/ml X-gal and 40μg/ml IPTG and incubated for 24-
48 hours at 37oC. Positive bacmid clones produced large white colonies. 
 
2.2.4.2 Isolation of Recombinant Bacmid DNA 
 
A single bacmid colony was inoculated into 2ml Luria broth (Appendix A (1)) 
supplemented with 50μg/ml kanamycin, 7μg/ml gentamycin and 10μg/ml 
tetracycline and incubated overnight at 37oC with agitation. Bacmid DNA was 
extracted using a protocol based on the alkaline hydrolysis technique of 
Sambrook et al., (1998). Bacmid DNA was handled with care and samples 
were not subjected to vigorous pipetting or agitation to minimise shearing of 
the ~130kb bacmid construct.  
 
2.2.5 Insect Cell Culture 
All insect cell culture was carried out under sterile conditions in a biological 
safety cabinet (Baker SterilGARD® III Advance). The Spodoptera frugiperda 
(SF21) insect cell line (Invitrogen) was used in all VLP production procedures. 
Cells were cultured in supplemented TC-100 insect cell growth medium (TC-
100, Sigma®). The growth medium was supplemented with 10% (v/v) foetal 
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neomycin, 69.2μg/ml penicillin G and 100μg/ml streptomycin 
(supplemented/ complete medium). Cells were grown as monolayers in sterile 
Nunclon cell culture flasks (Nunc™) at a constant temperature of 27oC. All 
steps during transfection were carried out using preheated (27oC) cell culture 
medium. Continuous SF-21 cultures were maintained by seeding mid-log cells 
at 5x105 cells/ml every 48-72 hours. Cell viability was determined by staining 
cells with trypan blue stain and counting cells in a Neubauer counting 
chamber.     
 
2.2.5.1 Transfection of SF21 insect cells with recombinant bacmid DNA/ 
Production of recombinant baculovirus infectant 
 
A 35mm Falcon tissue culture dish (Becton Dickinson) was seeded with 1x106 
SF-21 cells in 2ml supplemented TC-100 and the cells allowed to settle for 1-2 
hours. The following solutions (A and B) were prepared in separate 
polycarbonate tubes: Solution A – approximately 250ng recombinant bacmid 
DNA (5μl) was combined with 100μl of unsupplemented TC-100; Solution B – 
6μl cellfectin transfection reagent (Invitrogen) was combined with 100μl 
unsupplemented TC-100. Solutions A and B were mixed together and 
incubated at room temperature for 45 minutes to allow micelle formation. 
Unsupplemented TC-100 (800μl) was gently added to the cellfectin-DNA 
mixture and mixed. The seeded SF-21 cell monolayer was washed twice with 
2ml unsupplemented TC-100 and overlayed with the above cellfectin-DNA mix 
(~1ml) and incubated at 27oC for 5 hours. Supplemented TC-100 (1ml) was 
added to the overlayed cells and incubated at 27oC for 72 hours in a humid 
environment. The first virus-containing supernatant (SN1) (2ml) was 
harvested from the cells and replaced with another 2ml of supplemented TC-
100, which was incubated in the same manner for another 72 hours before the 
harvesting of the second virus-containing supernatant (SN2). Following the 
removal of each supernatant at time points 1 and 2 (SN1 and SN2) they were 
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2.2.6 Insect cell infection for the production of HIV-1 Gag VLPs: 
2.2.6.1 Infection: 
 
Four 500ml Nunclon cell culture plates (Nunc™) were seeded with 1x106 SF-
21 cells in 25ml supplemented TC-100 growth medium and cells were allowed 
to settle for 1-2 hours. Cells were infected by the addition of SN2 (infectious 
second supernatant above) and incubated for 72 hours at 27oC. 
 
2.2.6.2 VLP purification: 
 
One hundred ml of cell culture medium was harvested from the 4 plates and 
clarified by centrifugation at 1000g for 15 minutes. The cell culture medium 
was further clarified by filtering through a 0.45μm syringe filter (Acrodisc® 
Syringe filters). VLPs in the clarified cell culture medium was next 
concentrated by means of cross-flow filtration. For this technique the 
MidGee™ cross-flow filter unit (GE Healthcare) with a 300kDa cut off 
MidGee™ cross-flow filter cartridge was used to concentrate the 100ml cell 
culture supernatant to 40ml according to the manufacturers instructions. 
Cross-flow filter cartridges were flushed with 100ml of pre-heated (50oC) ultra-
pure water (MilliQ) prior to each filtration and were stored in 30% ethanol. 
VLPs were next isolated from the concentrated 40ml cell culture supernatant 
by centrifuging the sample at 83000g in an Optima™ L-100 XP ultracentrifuge 
(Beckman Coulter). The VLP pellets were resuspended in 300μl of 1x sterile 
Dulbecco’s phosphate buffered saline (PBS, Sigma®). VLPs were treated with 
7.5u RNase A and 1.33u RNase T1 for 2 hours at 37oC to remove any 
residual RNA (Ott et al., 2005). VLPs were purified from RNase by 
centrifugation through a 20% sucrose cushion at 83000g as before. VLP 
pellets were resuspended in 300μl of Dulbecco’s PBS and stored as a 15% 
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2.2.7 Electron microscopy 
Transmission electron microscopy (TEM) was used to confirm the formation of 
HIV-1 Gag VLPs as follows. Carbon coated copper grids (200 mesh) were 
floated carbon coated side down onto a 15μl volume of undiluted VLP extract 
for 60 minutes. Grids were then washed twice with distilled water. Excess 
moisture was blotted from the grid between each wash. Grids were next 
stained with 2% uranyl acetate for 2 minutes, before excess stain was blotted 
from the grid. Grids were allowed to dry and stored in a grid holder. Sample 
grids were analysed using a LEO 912 OMEGA Energy Filter Transmission 
Electron Microscope. 
 
2.2.8 Gag detection and quantitation 
 HIV-1 Gag was detected and quantified by means of anti-Gag western blots. 
The basic protocol for the polyacrylamide gel el ctrophoresis (PAGE) and 
subsequent western blotting are in Appendix A (7) and (8). Gag blots were 
probed with a 1/5000 dilution of anti-p24 polyclonal antiserum (ARP432) (Dr G 
Reid, Programme EVA, centre for AIDS reagents, NIBSC). Subsequently an 
anti-rabbit IgG (whole molecule) - alkaline phosphatase conjugated secondary 
antibody produced in goat (Sigma®) and was used at a 1/5000 dilution to 
probe the blot. 
 
2.2.8.1 Gag Quantitation: 
 
For Gag VLP quantitation an HIV-1 p17/24 C clade protein standard 
(ARP695.2) was used to generate a standard curve (FIT Biotech, Programme 
EVA, centre for AIDS reagents, NIBSC). This p17/p24 (Gag) standard was 
diluted to concentrations of 2.4, 7.2, 12 and 24ng dilutions on the PAGE along 
with a 10-1, 10-2, 10-3 and 10-4 VLP dilution series. The amount of Gag in 
samples on the blot was determined using densitometric analysis. For this 
analysis the Gene Genius Bio imaging system was used (Syngene) along with 
Gene tools program (Syngene) to quantitate Gag using a standard curve 
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2.2.8.2 Gp64 detection and quantitation on VLPs 
 
(a) The Gp64 content of VLPs was determined by means of western blotting 
(Appendix A (7), (8)). VLP samples blotted onto nitrocellulose membranes 
were probed with a purified anti-Baculovirus Gp64 envelope glycoprotein 
mouse primary antibody AcV5 (eBiosciences). The secondary antibody 
used for these blots was an anti-mouse IgG (whole molecule) - alkaline 
phosphatase conjugated antibody produced in goat (Sigma®) and was 
used at a 1/5000 dilution. 
 
(b) Gp64 was quantified by means of quantitive PAGE. PAGE was carried out 
as indicated in Appendix A (7) The amount of Gp64 loaded on the gel was 
determined by using a BSA standard curve in which BSA was loaded as 
100, 200, 500, 1000ng concentrations. Densitometric analysis was again 
used to estimate protein concentration as used above.   
 
2.2.9 CAT expression analysis 
CAT ELISA kit (Roche) was used for this assay according to the method 
described in Appendix A (9). Transfected insect cell lines were lysed using 
CAT ELISA kit lysis buffer and lysates were diluted in provided sample buffer 


















2.3.1 Manipulation of the Baculovirus Expression Vector System (BEVS) 
The human codon optimised Gag ORF (hmGag) as well as the CAT ORF 
were successfully cloned into the pFBD BEVS under the control of the p10 
and polyhedrin (PH) promoters, to yield the clone pFBD+Gag+CAT, 
respectively. Sequencing of putative clones confirmed the presence of both 
genes under appropriate promoter control (Appendix B (6 and 7)). The cloning 
procedure is detailed in Figure 2.2. 
2.3.2 Expression of Gag and CAT ORFs in Sf-21 insect cell line 
The pFBD+Gag+CAT construct was subsequently transformed into the 
DH10Bac™ cell line to facilitate the transposition of the relevant Gag and CAT 
ORFs and their respective promoter elements into the bacmid. Recombinant 
bacmids were then assessed for their ability to express Gag and CAT in 

























Figure 2.3 Expression analysis of Bacmid clone. Anti-Gag western blot of infectious supernatants derived from 
2ml Sf-21 transfections at time points 1 and 2 (SN1: 76 hours, SN2: 152 hours) arrow identifies the p55 Gag 
band . Bar graph illustrating CAT ELISA results of transfected Sf-21 cell lysates at dilutions 0-10-4. Expression 
levels of above 600ng/ml were beyond the maximum detection limits of the assay. Error bars display the 
variance between 3 separate experiments 
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Equivalent amounts of the first and second cell culture supernatants (SN1 
and SN2) derived from the 2ml Sf-21 transfections were analyzed for the 
expression of the hmGag ORF. An anti-p24 western blot confirmed the 
expression of the 55 kDa Gag protein in the transfected Sf-21 cell line, 
illustrated by the arrow (Figure 2.3 A).  The supernatants as well as the Gag 
positive control developed several bands on the anti-Gag western blot, which 
are most likely a result of Gag degradation products. The 55 kDa Gag band 
for both SN1 and SN2 appeared slightly distorted/curved on the blot as these 
crude SN samples still contained BSA. The BSA is visible on the blot as a 
non-specific smear/blob above the 55 kDA Gag band in both SN1 and SN2 
samples. It was also noted that Gag expression levels from the SN isolated at 
time-point 2 (SN2-152 hours) was higher in concentration than SN1 (76 
hours), which is congruent with the understanding that by the second time-
point post transfection the concentrations of recombinant, infectious 
baculovirus is significantly higher.  
 
As the ultimate function of the CAT ORF in this clone was to produce a 
reporter RNA species for encapsidation by assembling VLPs, I needed to 
confirm whether this RNA species was produced by the BEVS. This was 
indirectly accomplished by monitoring for the production of the CAT enzyme in 
transfected cell lines.  Cells transfected with the recombinant bacmid clone 
containing the Gag and CAT ORFs were lysed and lysates were used in a 
CAT ELISA (Figure 2.3 B). ELISA results showed that the CAT ORF was 
expressed at high concentrations. Expression levels of the undiluted, 10-1 and 
10-2 samples were beyond the detection limits of this assay and as such only 
10-3 and 10-4 dilutions were quantified to be 1.75ng/ml and 0.19ng/ml 
respectively. 
 
2.3.3 VLP assembly 
Transmission electron microscopy was used to confirm whether the 
expressed pFBD+Gag+CAT produced Gag VLPs using the purified VLP 







































The electron micrograph seen in figure 2.4 demonstrates the presence of 
numerous doughnut-shaped particles 120-150nm in diameter, which indicates 
that Gag VLPs are produced by the recombinant BEVS. From this electron 
micrograph it is also evident that the baculovirus content of the VLP sample 
has been significantly reduced by means of cross-flow filtration (Figure 2.4, 
yellow arrows). VLPs purified without cross-flow filtration very often contain 
high concentrations of contaminating baculovirus. 
 
2.3.4 Gp64 Quantitation 
The Gp64 envelope glycoprotein plays a crucial role in the baculovirus life 
cycle in mediating virus entry into the host cell and is one of the most 
abundant proteins in baculovirus virions. Gp64 envelope glycoproteins are 
displayed in high concentrations on the infected cell’s surface and are thus 
included in the membrane of budded Gag VLPs. To confirm the presence of 
baculovirus Gp64 envelope glycoprotein on Gag VLPs produced by 
pFBD+Gag+CAT, it was detected by means of qualitative anti-Gp64 Gag 
western blots (figure 2.5). For this method 2 SDS PAGE gels were loaded with 
identical sample sets consisting of 3 VLP preparations and used for western 
blotting. One blot was probed with an anti-Gag primary antibody while the 
Figure 2.4 Transmission electron micrograph of purified VLP sample. Arrows indicate the 













VLP Production and Gp64 quantitation 
 
55
other was probed with an anti-Gp64 primary antibody to confirm the co-





















The anti-Gag western blot shown in Figure 2.5 (A) confirmed the presence of 
55kDa Gag protein in each of the 3 VLP extracts. This anti-Gag western blot 
also displayed several bands per VLP sample to suggest the presence of Gag 
degradation products. The identical blot shown in Figure 2.5 (B), probed with 
the anti-Gp64 primary antibody displayed a broad 64kDa band for each of the 
3 VLP extracts. This therefore confirmed the incorporation of large amounts of 
Gp64 in Gag VLPs  
 
Following this, the relative amount of Gp64 incorporated into the Gag VLPs 
per microgram of VLP Gag protein was determined. As no quantified Gp64 
standard was available to allow quantitive western blotting or ELISA, the VLP 
Gp64 concentration was determined by means of a quantitive PAGE, which 
used BSA as the quantified protein standard for densitometric analysis (Figure 
 
Figure 2.5 Comparative western blots of purified VLP extracts. (A) Probed with anti-Gag primary 
antibody, (B) Probed with anti-Gp64 primary antibody. VLP 1, 2, 3 denotes 3 separate VLP 
preparations. Red arrows indicate the position of 55KDa HIV Gag and 64KDa VSV Gp64 
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2.6). To ensure that the correct band on the PAGE was quantified an anti-
Gp64 quantitive western blot was run in parallel with an identical set of VLP 


















The VLP sample dilutions run on the quantitive PAGEs yielded a 64kDa 
bands that aligned with 64kDa Gp64 bands on the identical western blots 
(Figure 2.6 (A and B)). Results from repeated quantitive PAGEs of several 
VLP extracts estimated an average of 382.94ng Gp64/ug of Gag in the Gag 


































Figure 2.6 Gp64 quantitation analysis, arrows indicate the position of quantified bands. Typical 
illustration of (A) Anti-Gp64 western blot of VLP extracts (1μg Gag), (B) corresponding quantitive PAGE 
gel of VLP extracts (1μg Gag). Red arrows indicate the position of the quantified Gp64 band. (C) Bar 
graph illustrating the estimated amount of Gp64 in 1μg of Gag VLP. Error bars display the variance 
between 4 separate VLP preparations
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A recombinant BEVS was made which enabled the successful co-expression 
of Gag and CAT proteins in transfected SF-21 cell lines. Production of Gag 
was confirmed by means of anti-Gag western blotting.  Electron microscopy of 
VLP preparations confirmed the production of ~120-150nm doughnut shaped 
particles (VLPs) in this system. Transcription of the CAT ORF and hence the 
production of CAT RNA species was indirectly confirmed by assaying for the 
production of the CAT enzyme using the CAT ELISA. High levels of CAT 
expression were measured. 
 
As indicated previously, the baculovirus Gp64 envelope glycoprotein is 
abundantly produced and presented on the plasma membrane of cell lines 
infected with this virus. VLPs produced using the BEVS appeared to contain 
very high levels of this Gp64 envelope glycoprotein. Despite previous studies 
documenting the presence of Gp64 on the VLP surface, this is the first study 
to make quantitive estimates of the amount of Gp64 on the VLP surface. 
Quantitive analysis of the amount of Gp64 incorporated into Gag VLPs 
determined that ~ 383ng of Gp64 was detected per 1μg of Gag VLP sample. 
From sequence analysis I established that the relative molecular mass of 
hmGag and Gp64 are 55kDa and 64kDa respectively. A study by Briggs et al. 
(2004) has found that an average HIV Gag VLP/immature particle of 120-
150nm contains ~5000 structural Gag proteins, which would therefore mean 
the mass of a VLP is ~275000kDa. In the analysed 1μg of Gag VLP, the total 
molecular mass is assumed to be 6.022173643 x 1014kDa, which equates to 
Gp64 in ~2.2x109 Gag VLPs (1μg). In this 1μg of Gag VLPs I detected 
~380ng of Gp64, corresponding to ~2.3x1014kDa, and therefore contained 
~3.6x1012 Gp64 molecules (64kDa). This data therefore suggests that each 
VLP contains ~ 1600 Gp64s, which is roughly 1 Gp64 envelope glycoprotein 
for every 3 Gag proteins in each VLP. This value may be distorted by the 
presence of contaminating baculoviruses, which carry their own Gp64: 
however it has been observed in our laboratory that any baculovirus 
contamination during VLP extraction by means of the cross-flow filtration 
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Initial estimates by means of EM have estimated the presence of 
approximately 72 envelope spikes on infectious HIV virions (Gelderblom et al., 
1991), while more recent studies have indicated that this number may be as 
low as 2 to 14 trimers (expressed trimers) (Chertova et al., 2002; Zhu et al., 
2003; 2006). All together these results indicate that the baculovirus Gp64 is 
presented in high densities on the surface of BEVS produced Gag VLPs, 
greatly exceeding that of HIV Gp120 on infectious HIV virions. Properties that 
this high density of Gp64 confers on the VLP surface is investigated in the 
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Chapter 3  
VLP Cellular Entry and RNA Expression 
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3.1 HIV cellular entry 
Enveloped viruses gain entry to their target cells by means of membrane 
fusion. This fusion can occur either at the cell surface or from within acidified 
intracellular vesicles. Until recently the primary mode of productive HIV 
cellular entry was assumed to proceed via pH-independent cell surface 
receptor mediated endocytosis exclusively at the plasma membrane (Stein et 
al., 1987; Dimitrov et al., 2001). The HIV genome encodes its envelope 
glycoproteins as a single 160 kDa precursor (Gp160), which is subsequently 
cleaved into 120 kDa (Gp120) and 41 kDa (Gp41) functional glycoproteins by 
a cellular protease. The 550 amino acid gp120 envelope glycoprotein is 
displayed at the exterior surface of the virion membrane (Figure 1.3 (E)) 
(Fields et al., 1996). This surface envelope glycoprotein is non-covalently 
associated with the transmembrane protein Gp41 (Figure. 1.3 (E)) and 
contains a binding domain for CD4 receptors and chemokine co-receptors 
(CCR5/CXCR4) found on the surface of T-lymphocytes, monocytes, 
macrophages, mature B-cells and dendritic cells. These Gp120/41 
associations form clusters of tri-molecular complexes on the virion membrane 
surface (Lu et al., 1995; Chan et al., 1997; Farzan et al., 1998). Gp120 
interaction with target CD4 receptors and chemokine co-receptors 
(CCR5/CXCR4) plays an important role during virus infection by initiating the 
fusion of the virion membrane to the host cell membrane, and thus allowing 
entry of the virus into the host cell (Dalgleish et al., 1991; Deng et al., 1996; 
Wyatt et al., 1998 A).  
 
During cellular infection, if Gp120 interaction with the CD4 receptors and 
chemokine co-receptors is considered as the initiation step, the activity of the 
Gp41 transmembrane protein is viewed as the functional unit that facilitates 
actual membrane fusion as follows (Chan et al., 1998). Free virions are 
assumed to be in a native or non-fusogenic conformation, in which the Gp41 
fusion peptide is buried inside the trimeric glycoprotein complex. Upon CD4 
and chemokine receptor binding by Gp120, structural rearrangement alters 
the Gp120/41 interaction and triggers Gp41 to undergo its own structural 
rearrangement.  This rearrangement results in the exposure of hydrophobic 
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into the target cell membrane. Further structural rearrangement within the 
Gp41 trimeric-coiled coil results in membrane apposition and allows fusion of 
the virion and cell membranes (Dimitrov et al., 2005; Wyss et al., 2005). 
 
3.1.1 Alternate routes of HIV cellular entry 
In spite of the above highly detailed pathway that leads to productive cellular 
entry, other studies have documented viral entry into cells via receptor 
independent endocytosis, and shown the presence of HIV particles contained 
within acidified endocytic vesicles (Fredericksen et al., 2002; Marēchal et al., 
1998; Marechal et al., 2001; Pauza et al., 1988; Schaeffer et al., 2004; Fackler 
et al., 2000). This path of cellular entry frequently leads to HIV inactivation/ 
degradation in these acidified compartments (Grewe et al., 1990; Marechal et 
al., 1998; Schaeffer et al., 2001; Stein et al., 1987; Schaeffer et al., 2004). 
Despite this, several studies have also demonstrated that endocytic entry can 
lead to productive infection if under the appropriate conditions (Fackler et al., 
2000; Fredericksen et al., 2002; Marechal et al., 2001; Schaeffer et al., 2004). 
Optimal infection of endocytosed virions was shown to require target cell line 
treatment with pharmacological agents that raise the endosomal/lysosomal pH 
(Fredericksen et al., 2002; Marēchal et al., 1998; Pauza et al., 1988; 
Schaeffer et al., 2004; Marechal et al., 2001; Fackler et al., 2000).  
 
Marechal et al. (1998) have shown that even in the presence of receptor 
mediated HIV infection/uptake in various CD4-displaying cell lines, the 
cytosolic fraction of p24 only represented 10-40% of intracellular p24. This 
suggests that the endocytic/degradative pathway of cellular entry represents 
the primary route of entry. Thus, even with appropriate envelope glycoprotein-
receptor interactions, 50-90% of viral material has been shown to enter the 
cell by the endosomal pathway. These results have been corroborated in 
several other studies (Fackler et al., 2000; Fredericksen et al., 2002; 
Schaeffer et al., 2004). Schaeffer et al. (2004) have demonstrated a 
“compensatory” relationship between HIV-1 fusion and endocytosis, whereby 
inhibiting fusion enhances endocytic uptake and inhibiting endosome 
acidification or trafficking enhances the fusion pathway. Unlike most other 
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al., 2002; Marechal et al., 1998, Fackler et al., 2000), this study utilised 
SupT1 T-cells or PHA-activated lymphoblasts. With these cell lines, a 
dependence on CD4 was established to enable both fusion and endocytosis 
of HIV virions. Thus, after the initial envelope-receptor interaction a 
competition ensued between the endocytic and fusion pathways, determined 
by secondary co-receptor interactions. A similar compensatory relationship 
between virion fusion and endocytosis was revealed in a study conducted by 
Fackler et al., (2000), which also demonstrated the presence of an HIV strain 
(HIV-1SF2) that has an enhanced infectivity when entering the Target 293T 
cells via the endocytic route. Researchers also suggested here that the 
excessive use of therapies that block CD4 and chemokine receptor binding 
could select for those HIV variants that preferentially utilise the endocytic 
pathway. 
 
Cells of the immune system have evolved several methods to enable the 
uptake of exogenous materials. These include clathrin mediated endocytosis; 
non-clathrin mediated endocytosis (caveolae); phagocytosis and 
macropinocytosis. Different viruses have also evolved mechanisms to utilise 
these distinct cellular structures to enter target cells. Macropinocytosis in 
particular is a key mechanism used in antigen uptake (Lanzavecchia et al., 
1996; Yewdell et al., 1999), which is cell type specific (constitutive in dendritic 
cells). It is a receptor-independent process of extracellular antigen capture 
using macropinosomes which are large vesicles 0.2-3 μm in size. Virus 
particle uptake studies have demonstrated that HIV uptake by 
macropinocytosis is a receptor and pH-independent process, as 
macropinosomes were shown to internalize non-infectious HIV lacking Env as 
well as virions displaying the envelope glycoproteins (Marechal et al., 2001; 
Schaeffer et al., 2004). Despite this, only the Env-displaying virions, which 
could enable vesicular membrane fusion, accessed the cytosol and resulted in 
a productive infection by engaging the CD4 receptors and chemokine co-
receptors on the internal surface of the macropinosome.  
 
The contribution of clathrin and caveola-mediated endocytic uptake pathways 
during productive HIV infection has been evaluated in CD4-positive HeLa cell 
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mutations that prevented the development of endocytic vesicles from the 
inner surface of the cell membrane to effectively disrupt these uptake 
pathways. Clathrin dependent endosomal entry in this study was shown to 
contribute significantly to productive HIV entry in this cell line. Mutations 
interfering with this uptake pathway led to a 40-90% (experimental condition-
dependent) reduction in the number of cells productively infected with HIV-1. 
The caveolin mutant, which inhibited caveola mediated entry had no 
significant effect on productive HIV-infection. Daecke et al. (2005) have also 
suggested that entry via the endocytic route may have advantages over 
plasma membrane fusion. Entry via the endocytic pathway sees the HIV 
particle delivered directly to the cytosol and avoids the sub-cortical actin 
cytoskeleton, which is regarded as a difficult barrier to overcome. 
 
The general consensus of the aforementioned studies is therefore, that HIV 
endocytosis can lead to a productive infection if provided with proper 
conditions. Also, an important prerequisite in enhancing infectivity from 
endosomal compartments is the inhibition/arrest of endosomal acidification. A 
common trend emphasized in all the above studies strongly suggests that, 
irrespective of the path of entry into the target cell, productive HIV infection is 
dependent on receptor/co-receptor interactions at the cell surface or within 
vesicles. Hence, the gradual decrease of pH in endocytic vesicles may permit 
escape to the cytoplasm for some HIV particles before they are disrupted by 
low pH. The inactivation of HIV particles by the disruption of their envelope 
glycoproteins should therefore prevent escape from endosomes before 
acidification and hence prevent infection by this uptake pathway.  
 
3.1.2 Virus inactivation 
Several chemical and physical methods have been assessed for the 
inactivation of putative live virus vaccines. Whole inactivated vaccines have 
been produced using these inactivation methods for several retroviruses, 
which have included feline immunodeficiency virus (FIV) (Yamamoto et al., 
1993; 1991); SIV (Stott et al., 1990; Cranage et al., 1992; Johnson et al., 
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et al., 2005 (A) and (B)) all of which have shown promise as potential 
vaccines. 
 
Chemical agents for virus inactivation have included formalin, beta-
propiolactone, formaldehyde and binary ethylenimines (Race et al., 1995; 
Grovit Ferbas et al., 2000; Poon et al., 2005). In general these chemical 
agents function as “fixing agents” by interacting with organic groups on virus 
particles. Interactions with these groups lead to cross linking of proteins and 
often render them non-functional. The use of these chemical agents for virus 
inactivation do have limitations as they often produce toxic by-products, which 
are unacceptable for vaccine formulations.  
 
Thermal inactivation has been tested as an alternate means of inactivating 
retroviruses and has shown great success (McDougal et al., 1985; Grovit 
Ferbas et al., 2000; Poon et al., 2005; Piszkiewicz et al., 1986; Quinnan et al., 
1986). Thermal inactivation overcomes the problem of production of toxic by-
products, which can reduce the effect of potential vaccines. It has been shown 
with HIV virion isolation, that thermal inactivation results in further shedding of 
Gp120 from the virion surface. This has a detrimental effect on the type of 
immune response stimulated. Poon et al. (2005) have demonstrated, 
however, that a large proportion of Gp120 can be retained on the virion 
surface by treating virions with low concentrations of formaldehyde prior to 
heat inactivation. This stabilises Gp120 on the virion surface by facilitating 
cross linking with reactive groups (amino) on the virion surface. 
 
These physical and chemical means of virus inactivation predominantly 
function by disrupting the virion structure including surface glycoproteins. This 
in turn affects the eventual immunogenicity of the virion. Short wavelength 
(254nm) ultraviolet (UV) radiation serves as a more “delicate” method for virus 
inactivation. Virus inactivation by UV has been shown to be highly effective for 
a range of different DNA and RNA viruses including tobacco mosaic virus, 
feline calcivirus, canine calcivirus; adenovirus 41 and poliovirus 1 where dose 
dependent UV radiation decreased viral infectivity by several log values 
(Evans et al., 1969; de Roda Husman et al., 2004; Ko et al., 2005; Simonet et 
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to the viral genome (Simonet et al., 2006; Lytle et al., 2005). Short 
wavelength UV is absorbed by the nucleic acids (DNA and RNA) of micro 
organisms/viruses and results in the development of pyrimidine: thymine 
dimers on the same strand, pyrimidine hydrates and cyclobutane, which, if not 
repaired obstruct replication/expression. Generally pyrimidines are more 
sensitive than purines and thymine and uridine are the most sensitive bases in 
DNA and RNA respectively (Cadet et al., 1991; Durbeej et al., 2003; Harm et 
al., 1980; Kuluncsics et al., 1999). UV radiation produces limited toxic by-
products compared to chemical virus inactivation treatments and has a 
minimal effect on virion structure (Haider et al., 2002).  
 
3.1.3 Aims: 
The studies above suggest that HIV-1 Gag VLPs that lack functional envelope 
glycoproteins may be predisposed to degradation within acidified endosomal 
compartments as endocytic uptake would be the only mechanism of cellular 
entry. This reflects the “inert particle” title given to non-pseudotyped Gag 
VLPs but does not take into account the presence of baculovirus Gp64 on the 
surface of BEVS-produced Gag VLPs. The Gp64 envelope glycoproteins 
enable baculovirus as well as other heterologous live viruses like VSV to 
successfully enter mammalian cell lines by means of receptor mediated pH-
dependent endosomal fusion. Results in Chapter 2 showed that there are high 
concentrations of Gp64 on the surface of BEVS-produced Gag VLPs. The aim 
of the investigation described in this chapter is to determine whether these 
envelope glycoproteins confer the mammalian cell entry ability to otherwise 
inert Gag VLPs. This was determined by conducting cell uptake assays with 
several mammalian cell lines previously shown to be receptive to baculovirus 
entry. As the Gag VLPs encapsidated quantified concentrations of a CAT 
reporter RNA, successful cellular entry was confirmed by conducting CAT 
ELISAs on cell lysates 24 hours after VLP uptake. Subsequently, control of 
VLP cellular entry and RNA expression was assayed following virus 
inactivation techniques.  
 
This would be the first instance that this type of analysis would be done 
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been conducted on more complex live virus models that carried 
reporter genes as part of the viral genome (Schauber et al., 2004; Kumar 
et al., 2003). This system, on the contrary, represents an actual vaccine 
candidate that lacks any replicative nucleic acids and hence the reporter 
RNA is representative of the random nucleic acids encapsidated by 
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3.2 Materials and Methods 
3.2.1 In vitro transcription 
Poly-A tailed and capped RNA transcripts of the CAT ORF were generated as 
positive controls for RT-PCR and cell uptake assays using the RibomaxTM 
Large Scale RNA Production System – T7 kit (Promega). Transcription 
reactions were carried out according to the manufacturer’s instructions using 
5μg of template pcDNA3.1/Zeo/CAT vector DNA per 50μl reaction. Prior to the 
transcription reaction, DNA templates were treated with 1u/μg DNA of human 
placental RNase inhibitor (Roche) for 1 hour at 37o C. After synthesis RNA 
samples were stored at -70o C. RNA product derived from the in vitro 




3.2.2 Reverse transcriptase-PCR (RT-PCR) 
RT-PCR to detect the encapsidation of CAT RNA transcript by Gag VLPs was 
carried out using the Access RT-PCR System (Promega), which provided all 
enzymes, buffers and reaction constituents. RT-PCRs were run on the 
Mastercycler Gradient (Eppendorf) PCR machine. All RT-PCRs were made-
up in 50μl reaction volumes using 1mM MgCl2 and 50pmol of each primer, 
which amplified a ~350bp DNA fragment. As this was a qualitative assay, 
each reaction was made up using 10-2 VLP preparation dilution, while in-vitro 
transcribed CAT RNA was used as a positive control.  
RT-PCR Primers 
(a) CAT Forward primer: 5’ GCA ATG AAA GAC GGT GAG C 3’ 
(b) CAT Reverse primer: 5’ ATG AAC CTG AAT CGC CAG C 3’ 
 
RT-PCR reaction profile:  45o C     45 min        RT 
94o C        2 min       RT inactivation 
94o C      30 sec 
57o C       30 sec         x25 cycles 
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3.2.3 RNA Extraction 
Total RNA was extracted from Gag VLPs using the RTP Virus DNA-RNA 
Isolation Kit (Invitek). Extractions were carried out according to manufacturer’s 
protocol and each RNA extraction was carried out on 5μg of quantified Gag 
VLPs and final RNA extracts were eluted into 50μl of the extraction kit elution 
buffer. 
 
3.2.4 Real-time RT-PCR kit 
The CAT RNA content of the total VLP RNA extracts were analysed using the 
SensiMix One-Step real-time RT-PCR kit (Quantace), which through the use 
of SYBR® green enabled RNA quantitation in a single reaction setup (source: 
470nm/detector: 510nm). Real-time RT-PCRs were run on the Rotor-Gene 
RG-3000A real-time PCR machine (Corbett Research). All reactions were 
setup according to manufacturer’s protocol in 25μl reaction volumes using 
50mM MgCl2 and 50pmol of each primer, which amplified a ~150bp DNA 
fragment. As this was a quantitive assay RNA derived from the equivalent of 
1μg of Gag VLPs was used per reaction and in-vitro transcribed CAT RNA 
dilutions was used as a quantified positive control.   
 
Primers 
(a) Real time CAT Forward primer: 5’ AGA TGT GGC GTG TTA CGG T 3’ 
(b) Real time CAT Reverse primer: 5’ ATG AAC CTG AAT CGC CAG C 3’ 
 
Real-time RT-PCR reaction Profile:  49o C    45 min        RT 
                                                               95o C   10 min         RT inactivation 
                                                               95o C    15 sec 
                                                               57o C    15 sec         x 30 cycles 
                                                               72o C    15 sec 
 
Following the above PCR profile a melt curve was also run to confirm 
homogeneity of the quantified PCR product. Melt curve reaction profile: Ramp 
from 57o C to 95o C, raising temperature by 1o C each step. Waited for 45 sec 
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was analysed using the Rotor-gene 6, Version 6.0 (Build 27) software 
(Corbett Research). 
 
3.2.5 Mammalian Cell Culture 
3.2.5.1 Cell lines and growth conditions 
 
All mammalian cell culture was done under sterile conditions in a biological 
safety cabinet (Labomark Lab Series 1800mm Class II). Mammalian cell 
uptake assays were conducted using the Murine RAW 264.7 macrophage 
(RAW 264.7), Baby Hamster kidney (BHK-21), Human Embryonic Kidney 
(HEK 293) and HeLa cell lines. All cell lines were maintained as continuous 
cultures and were incubated in a H2O jacketed, CO2 incubator at 37o C at 5% 
CO2 (Forma Scientific). Continuous RAW 264.7, BHK-21, HEK 293 and HeLa 
cell cultures were maintained by seeding mid-log phase cells at 1-2 x 106 
cells/ml every 48-72 hours. Cell viability was determined by staining cells with 
Trypan blue stain and counting cells in a Neubauer counting chamber. 
 
3.2.5.2 Growth medium 
 
The RAW 264.7 cells were cultured in supplemented Roswell Park Memorial 
Institute (RPMI) medium (RPMI 1640+GlutaMAX™-1, Gibco®), while the 
BHK-21, HEK 293 and HeLa cells were cultured in supplemented Dulbecco’s 
modified eagles medium, DMEM (DMEM+GlutaMAX™-1, Gibco®). Cell 
growth media were supplemented with 10% (v/v) foetal calf serum (FCS, 
containing up to 50mg/ml serum proteins) (Gibco), 1% penicillin G / 
streptomycin and 1% Fungin (supplemented/ complete medium). Continuous 
culture cell monolayers were grown in medium-sized (200ml) sterile Nunclon 
cell culture flasks (Nunc™) in 20ml culture volumes at a constant temperature 
of 37oC. All steps during transfection and Gag VLP uptake were carried out 
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3.2.6 Transfection of mammalian cells/ Uptake assays 
3.2.6.1 Seeding of cell lines 
 
For RNA transfection/ Gag VLP uptake assays the RAW 264.7, BHK-21and 
HeLa cell cultures were seeded in sterile 6 well plates (Nunc™) in 2ml 
complete/supplemented at a concentration of 0.5 x 105 cells/ml per well, while 
HEK 293 cells were seeded as 0.2 x 105 cells/ml per well 24 hours prior to the 
assay.  
 
3.2.6.2 RNA transfection 
 
Quantitated in vitro-transcribed CAT RNA transfection into the above cell lines 
was carried out using a non lipid cationic reagent, Transmessenger™ 
Transfection Reagent (Qiagen). This transfection reagent is used specifically 
for the transfection of eukaryotic cells with RNA/siRNA. The transfection 
assay was carried out using kit components according to the manufacturer’s 
protocol. Cells seeded in the 6-well plates were washed twice with 2ml 
unsupplemented cell culture medium to remove all traces of FCS prior to the 
addition of the transfection reagent/ specific [CAT RNA] mixture. Each well 
was then topped up to 1ml with unsupplemented cell culture medium and 
plates were incubated at 37o C for 4 hours to allow for transfection. The cell 
culture medium was then removed from the wells and replaced with 2ml of 
complete medium and plates incubated for a further 24 hours at 37o C.   
 
3.2.6.3 VLP uptake    
 
Gag VLP cell uptake assays were carried out using 5μg of quantified Gag 
VLPs that contained a known amount of CAT RNA. Cells seeded in the 6-well 
plates were washed twice with 2ml PBS to remove all traces of FCS prior to 
the addition of Gag VLPs containing the CAT RNA. Well volumes were then 
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incubated at 37o C for 2 hours to allow VLP uptake. The cell culture 
medium was then removed from the wells and replaced with 2ml of complete 
medium and plates were incubated for a further 24 hours at 37o C.  
 
3.2.6.4 Analysis of RNA transfection/cell uptake assays 
 
A CAT ELISA kit (Roche) was used for the analysis of the RNA 
transfection/cell uptake assays according to the method described in 
Appendix A (9). Mammalian cell lines were lysed using the CAT ELISA kit 
lysis buffer and lysates were diluted in the provided sample buffer before 
assaying. Assay negative controls were not displayed in results as they fell 
within the background reading range. 
 
3.2.6.5 RNA/VLP treatment: 
 
Prior to RNA transfection or Gag VLP uptake in mammalian cells, RNA/VLP 
samples were treated with short wavelength (260nm) ultraviolet radiation or 
heat  treatment at 62o C. 
 
For UV treatment, CAT RNA/Gag VLP samples were irradiated with a UV 
source that delivered 1J/sec/cm3 for 1-2 minutes during which samples were 
removed periodically for the transfection/uptake assays.  
 
Heat treatment of CAT RNA/Gag VLP samples was based on the method 
derived from Poon et al., (2005) used for inactivating live HIV. CAT RNA/Gag 
VLP samples were incubated at 62oC for 10 or 20 minute periods prior to their 















3.3.1 CAT RNA quantitation: 
Gag-VLPs produced by the co-expression of the hmgag ORF and a CAT ORF 
described in the previous chapter were analysed for the encapsidation of the 
CAT-encoding RNA species.  
 
A preliminary qualitative reverse transcriptase (RT)-PCR was carried out on 
RNase-treated VLP extracts using CAT-specific primers to detect the 
encapsidation of CAT RNAs. As this was simply a qualitative test to detect 
CAT encapsidation, 10-2 diluted VLP extracts were added directly to the RT-
PCR. Positive RT-PCR results were identified by the amplification of a 350bp 
band as seen for the positive control, which was generated by utilising in vitro 
transcribed CAT RNA (Figure 3.1). The negative control derived from 
uninfected insect cell supernatant correspondingly did not amplify RNA in the 
RT-PCR. RT-PCRs of 3 individual VLP preparations (5’ psi, 3’ psi, no psi) 
each amplified a 350bp band, which confirmed the encapsidation of the CAT 

















  Size    CAT              5’        3’       no           Size    CAT             5’      3’      no 
Marker  +ve   –ve     psi      psi     psi          Marker +ve   –ve     psi    psi     psi 
 
Figure 3.1 Agarose gel displaying CAT-specific PCR and RT-PCR products made from VLP 
extracts. 5’psi and 3’psi denotes CAT RNA species that contained the HIV psi-site at the 5’ and 
3’ ends of the CAT ORF respectively, while no-psi refers to a CAT RNA species that lacks any 
psi-tag. Positive controls for RT-PCR and PCR consisted of in vitro transcribed CAT RNA and 
CAT ORF respectively. Red arrow indicates the position of the 400bp reaction product. 
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The observed positive result could have arisen due to the presence of 
contaminating recombinant baculovirus that carried CAT encoding DNA in the 
VLP preparation. To confirm that the positive results observed on the gel was 
a result of CAT RNA encapsidation by VLPs, the VLP preparations were also 
subjected to a CAT-specific PCR using the same primer set (Figure 3.1). This 
PCR would amplify any CAT containing DNA present in the VLP preparation, 
which could only be present in the form of a baculovirus contamination. All 
VLP preparations (5’ psi, 3’ psi, no psi) subjected to this PCR failed to amplify 
a 350bp band, which confirmed the absence of CAT DNA.  Negative PCR 
results from this reaction thus confirm the absence or undetectable levels of 
contaminating baculovirus or encapsidated baculovirus DNA. 
 
Initially, attempts were made to enhance CAT RNA encapsidation through the 
addition of the described HIV-RNA packaging signal (psi-site) to either the 3’ 
or 5’ end of the CAT encoding RNA species. Results from the above 
qualitative analysis (RT-PCR) and the following quantitive analysis (real-time 
RT-PCR) show that there is no particular enc psidation bias conferred to psi-
tagged CAT RNA during VLP assembly (results not shown). The addition of 
the ψ-sequence to the CAT sequence did not only not lead to an enhanced 
CAT RNA encapsidation, it also conferred no particular level of control to CAT 
RNA encapsidation. This variable level of CAT RNA encapsidation exhibited 
by the 5’ or 3’ ψ-tagged CAT RNA was similar to that exhibited by untagged 
CAT RNA. High levels of CAT expression from the very strong PH baculovirus 
promoters coupled with the fairly indiscriminate nature of RNA encapsidation 
could account for the inability of the psi-tagged RNA to be encapsidated at 
higher concentrations than non psi-tagged CAT RNA. As a result, further 
experiments in these studies only utilised non-psi tagged CAT RNA. 
 
Real-time RT-PCR was used to determine the amounts of CAT RNA 
encapsidated by the Gag-VLPs. As this was a quantitive assay, VLP 
preparations were first quantified by means of quantitive western blot (Figure 
3.2 (A)), which enabled RNA extraction from specifically determined 
concentrations (5μg) of Gag/VLP. Real-time RT-PCR was therefore 
conducted on VLP extracted RNA samples derived from an equivalent of 1μg 
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(duplicate or triplicate) and each of these was quantified in triplicate. The 
positive control for this reaction consisted of an in vitro-transcribed CAT RNA 
species. A dilution series of this positive control was used to form a standard 
curve to enable VLP-CAT RNA quantitation. Following each real-time RT-
PCR, the homogeneity of the quantified reaction product was confirmed with a 
melt curve (Figure 3.2 (C)). The melt curve from these reactions displayed a 
single peak for all analysed RNA extracts as well as the in vitro-transcribed 
CAT RNA positive control. This indicated that all quantified, amplified product 
from the reaction was from the CAT RNA species. The negative control 
displayed a distinct melting curve peak as indicated by the arrow (Figure 3.2 
(C)). The negative control very often produces this separate peak as a result 
of primer dimer formation.  
 
The real-time RT-PCRs were successful at determining the amount of CAT 
RNA encapsidated per μg of Gag/VLP and each reaction typically displayed a 
reaction efficiency of 0.94 (94%) based on standard curve accuracy data 
(Figure 3.2 (B)). A compilation of the real-time RT-PCR results for 9 separate 
VLP extractions is displayed in figure 3.2 (D). There was no common trend 
with respect to the amount of encapsidated CAT RNA/μg Gag VLPs. The 
encapsidated CAT RNA content was observed to vary from anything between 
0.1ng to as high as 8ng/ug of Gag VLP. This variation of the encapsidated 
CAT RNA content was observed between VLP preparations despite infecting 
cells with the baculovirus infectant at the same multiplicity of infection.   
       
Multiple RNA extractions form the same VLP extract in contrast encapsidated 
similar amounts of CAT RNA/μg Gag VLP. An inverse trend was noted 
between the yield of Gag in the VLP extraction and the amount of 
encapsidated CAT RNA. As this observed trend was beyond the scope of this 






















































Figure 3.2 VLP encapsidated CAT RNA quantitation. (A) Typical quantitive Gag western blot used to 
determine Gag concentration of VLP extracts. (B) Typical real-time RT-PCR quantitation curves used to 
determine CAT RNA concentration, arrow illustrates negative control. (C) Typical melt curve to determine real-
time RT-PCR homogeneity, arrow illustrates negative control. (D) Bar graph illustrating a compilation of real-
time RT-PCR results of multiple RNA extractions from 9 individual VLP extracts. Error bars display the 
variance between 3 separate real-time RT-PCRs 
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3.3.2 Cell uptake assays: 
Once I had confirmed and quantified encapsidation of CAT RNA by Gag-
VLPs, I proceeded with mammalian cell uptake assays to determine whether 
the Gp64 pseudotyping of Gag VLPs facilitates Gag VLP cellular entry and 
expression of the encapsidated CAT RNA. The mammalian cell lines selected 
for these assays are known to be receptive to transduction by baculoviruses 
(BHK-21, HEK 293 and HeLa cells) (Boyce et al., 1996; Shoji et al., 1997; 
Condreay et al., 1999; Duisit et al., 1999; Airenne et al., 2000; Pieroni et al., 
2001;  Abe et al., 2003; Gao et al., 2007). It was thought that due to the 
presence of the Gp64 envelope glycoprotein on the VLP surface, the selected 
cell lines would be ideal to assess whether Gp64 confers the ability to enter 
these cell lines and express the contained CAT RNA. As a cell uptake control 
to confirm whether the encapsidated RNA can be expressed within a 
mammalian cell line, an in vitro-transcribed CAT RNA species was transfected 



















Figure 3.3 Bar graph illustrating CAT expression levels in cell lysates 24 hours after transfection 
of BHK-21 cells with various amounts of in vitro transcribed RNA. Error bars display the variance 























































VLP Cellular Entry and RNA Expression 
 
77
Twenty four hours post transfection, the cells were lysed and lysates were 
analysed for CAT expression by means of a CAT ELISA. RNA transfection 
results shown in figure 3.3 demonstrate that the VLP encapsidated CAT RNA 
species can be translated/expressed within mammalian cells. It was observed 
that 50 to 500ng of transfected CAT RNA exhibited a linear relationship 
between the amount of transfected RNA and CAT expression levels. Optimal 
transfected CAT expression levels were observed for the 500ng CAT RNA 
transfection. When more than 1000ng of CAT RNA was transfected into cell 
lines, CAT expression levels were observed to decrease. This is most likely 


















Once it was established that the CAT RNA species could be expressed in 
mammalian cell lines, we proceeded with the VLP-cell uptake assays. Gag 
VLPs that contained known concentrations of CAT RNA were subsequently 
analysed for their ability to enter mammalian cells and express the foreign 
CAT RNA species. The selected BHK-21, HeLa and HEK-293 cell lines were 
grown as 2ml culture volume monolayers in 6 well plates. These cell 
monolayers were exposed to Gag VLP concentrations that contained a total of 






































     BHK-21                     HeLa                      HEK 293
Figure 3.4 Bar graph illustrating CAT expression levels of BHK-21, HeLa and HEK 293 cell 
lysates 24 hours after VLP uptake assay. Figure key indicates the amount of CAT RNA within 
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uptake before washing cells and incubating them for a further 24 hours (to 
allow for CAT expression).  CAT ELISA results of the cell lysates shown in 
figure 3.4, indicate that CAT was produced in all cell lines. Expression levels 
between the 3 different cell lines appeared similar ranging from 0.15 – 0.22; 
0.44 – 0.5; 0.7 - 0.86ng/ml of CAT, when transfected with 2, 5 and 10ng of 
VLP CAT RNA respectively and thus appeared directly proportional to the 
amount of VLP/encapsidated CAT RNA used in the uptake assays. Thus 
baculovirus-derived, and hence Gp64 pseudotyped Gag VLPs that 
encapsidate foreign RNA species are capable of entering mammalian cell 
lines and expressing the encapsidated RNAs.  
 
These CAT-containing Gag VLPs were also used to conduct a cell uptake 
assay with a cell line previously shown not to be receptive to baculovirus-
Gp64 mediated transfection (macrophage RAW 264.7) (Schauber et al., 2004; 
Masayuki et al., 2006). CAT-specific ELISA of the RAW 264.7 cell lysates did 
not yield any quantifiable results that were above background levels and 
therefore failed to detect any CAT expression (not shown). This cell line 
appeared to be equally resistant to the expression of RNA carried by the 
Gp64-pseudotyped Gag VLPs as well. As a control in this instance to 
determine whether the CAT RNA can be expressed in this cell line, CAT RNA 
was also transfected into the RAW 264.7 cell line. Cell lysates were analysed 













































VLP Cellular Entry and RNA Expression 
 
79
It was here established that the productive transmission of a foreign nucleic 
acid from a so-called “inert” vaccine is possible and as previously indicated 
this is regarded as a problematic trait. As the transmission and expression of 
the RNA content encapsidated by the Gag VLPs pose a problem for vaccine 
regulatory bodies, attempts were made to “neutralize” transmission/ 
expression of CAT RNA from VLPs by means of virus inactivation.  
 
It was initially decided to expose the VLPs to various doses of short 
wavelength (254nm) UV radiation previously shown to be sufficient to 
inactivate RNA viruses. Gag VLPs carrying 23ng CAT RNA/cell uptake assay 
was irradiated with specific amounts (0 – 60 Joules/cm2) of short wave UV 
light prior to the cell uptake assay in BHK-21 cells. The BHK-21 cell line was 
randomly selected as the test mammalian cell line. Results of individual cell 
uptake assays using the UV irradiated VLPs are shown in Figure 3.6. The UV 
irradiation of Gag VLPs evidently reduced CAT expression to almost 50% of 
the non-UV treated (0 Joules) Gag VLPs. It must be noted though that despite 
the approximately 50% decrease in expression levels, CAT expression still 
remained quite high. The levels to which the expression of CAT has been 
reduced appears to be independent of the amount of UV exposure as CAT 
expression remained constant for the entire UV exposure range (0-60 Joules 
cm2), which was previously shown to be more than sufficient to neutralize 
RNA viruses. Frequently, UV exposure doses that fall into the 100-1000 
millijoule range have decreased virus activity by several log values (Simonet 








































To determine if the observed decrease in CAT expression resulted from RNA 
damage caused by UV, in vitro-transcribed CAT RNA was also subjected to 
UV irradiation. In this control experiment in vitro-transcribed CAT RNA 
samples (1000ng) were irradiated with a larger 0-120 Joules/cm2 UV 
exposure range before transfection into BHK-21 cells (Figure 3.7). UV 
irradiation resulted in CAT expression levels decreasing to ~20% of the 
expression levels resulting from unexposed CAT RNA transfection. RNA 
samples appeared to be more sensitive to UV than encapsidated RNA, as 
determined by CAT expression levels, which exhibited an approximate 50% 
expression level following UV exposure. Results from this control assay, 
therefore, suggested that the decreased CAT expression could have resulted 
from RNA damage. However, as with the previous assay, expression was still 
detectable after 120 Joules/cm2 of exposure and CAT expression levels also 
appeared to be independent of the amount of UV exposure in this range.  
 
The combined results from these 2 VLP/RNA – UV exposure cell uptake 
assays suggest that the diminished ability of the VLP to express the 
encapsidated CAT RNA arises through RNA damage caused by UV 





























































Figure 3.6 Bar graph illustrating CAT expression levels of BHK-21 cell lysates 24 hours after 
VLP uptake assay with UV (254nm) irradiated Gag VLPs. Each bar represents a separate 
uptake assay with VLP irradiated with 0, 10, 20, 30, 40, 50 or 60 Joules/cm2. Error bars display 































UV irradiation of VLPs was therefore unable to completely neutralize CAT 
expression. Additionally, it was determined that encapsidated RNA is less UV 
sensitive than naked RNA, suggesting an effective shielding provided by the 
capsid. An alternative HIV heat-based inactivation technique derived from 
Poon et al. (2005), was therefore used. The original technique required 
formaldehyde treatment of live virus particles followed by heat inactivation. As 
described, formaldehyde is used as a cross-linking agent and serves to 
stabilize or prevent the shedding of Gp120. As the VLPs currently under 
investigation did not possess any Gp120 that needed to be retained we 
therefore overlooked this step. Furthermore, formaldehyde treatment of VLPs 
could pose a complication with respect to toxic effects caused by residual 
formaldehyde in the final VLP sample. Heat was required to “disrupt” the 
surface particle structure, after which a heat inactivated Gp64 could be tested 
for its ability to mediate entry and CAT expression in mammalian cell lines. 
Gag VLPs carrying 2, 5 and 10ng of CAT RNA were incubated at 62o C for 10 
or 20 minutes periods prior to cell uptake in BHK-21, HEK 293 and HeLa cell 
lines. Twenty four hours following cell uptake, cell lysates were analysed for 






































































Figure 3.7 Bar graph illustrating CAT expression levels of BHK-21 cell lysates 24 hours after 
control in vitro transcribed RNA transfections. RNA was irradiated with UV (254nm) Each bar 
represents a separate RNA transfection with RNA irradiated with 0, 10, 20, 40, 60, 90 or 120 
Joules. RNA was also exposed to 62oC for 20 minutes prior to transfection. Error bars display the 
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VLPs not exposed to heat exhibited high CAT expression levels in the 
transfected BHK-21; HeLa and HEK-293 cell lines. CAT expression levels in 
the BHK-21 cell line were: 0.15, 0.50 and 0.73ng/ml; the HeLa cell line 
exhibited expression levels at 0.20, 0.43 and 0.87ng/ml and the HEK-293 cell 
line exhibited expression levels at 0.15, 0.45 and 0.70ng/ml when transfected 
with Gag VLPs containing 2, 5 and 10ng of CAT RNA respectively (Figure 3.8 
(A), (B) and (C)). Heat treatment of VLPs for either 10 or 20 minutes in both 
BHK-21 and HeLa cell lines resulted in a significant reduction in CAT 
expression levels.  
 
CAT expression levels in the BHK-21 cell line appeared strongly restricted by 
the VLP heat treatment as it exhibited CAT expression levels that approached 
practically undetectable levels. The HeLa cell line exhibited slightly higher 
expression levels for each concentration of heat treated VLPs used in the 
uptake assay in comparison to the BHK-21 cell line. These results show that 
heat - treatment of VLPs prior to exposure to cell BHK21 and HeLa cell lines 
can cause a significant reduction in CAT/RNA expression levels.  
 
Cell uptake assays using heat treated VLPs with the HEK-293 cell line, on the 
contrary, appeared to have very little effect on VLP uptake and CAT RNA 
expression for higher VLP/encapsidated RNA concentrations. This may 
suggest that the HEK-293 cell line employs an alternate uptake mechanism to 
the proposed Gp64-mediated uptake pathway that may be used by the BHK-
21 and HeLa cells lines. 
 


























































Figure 3.8 Bar graphs illustrating CAT expression levels of (A) BHK-21, (B) HeLa and (C) HEK 
293 cell lysates 24 hours after a heat treated VLP uptake assay. Gag VLP containing 2, 5 and 
10ng of CAT RNA were used for the cell uptake assays in each cell line and prior to each 
uptake, VLP were not exposed to heat, incubated for 10 min at 62oC or for 20min at 62oC. Error 
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To determine whether the reduction of CAT expression caused by heat 
treatment of VLPs is a result of RNA damage or possible Gp64 damage, in 
vitro-transcribed RNA was also incubated at 62oC for 20 min prior to 
transfection into BHK-21 cell lines. Cell lysates were analysed by CAT ELISA 
24 hours later and results shown in figure 3.7 demonstrate that heated CAT 
RNA express almost identical levels of CAT when compared to non-heated 
CAT RNA. Results suggest that as heat has no effect on CAT-expressing 
RNA, the reduced levels of CAT expression is most likely due to Gp64 






















The significant reduction of CAT expression levels in BHK-21 and HeLa cell 
lines is more than likely a product of disrupted Gp64 envelope glycoprotein 
but it could also have resulted from VLP disruption/lysis during heat treatment. 
A counter argument was that if any significant disruption to the heat-treated 
VLPs had occurred, the non-heat affected expression levels in the HEK 293 
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cell line would not have been observed. To nevertheless visually determine 
whether the heat treated VLPs were structurally damaged or lysed by the heat 
treatment, these VLPs were visualized by TEM. Figure 3.9 displays a series 
VLP electron micrographs of VLP heated to 62oC for 20 minutes. The images 
here display VLPs as intact doughnut shaped particles similar to the non-
heated particles displayed in figure 2.4. The frequency of these intact particles 
when visualized by TEM also appeared unaffected. This suggests that heat 
treatment of Gag VLPs, as with similar live HIV inactivation techniques, does 

























The results presented in this chapter comprehensively show that BEVS-
produced, Gp64 pseudotyped Gag VLPs are able to enter mammalian cell 
lines and deliver non-specifically encapsidated RNA for expression.  
 
3.4.1 RNA encapsidation: 
Encapsidation of the reporter CAT RNA was initially confirmed by means of 
RT-PCR, where all VLP preparations that were produced during CAT RNA co-
expression in the BEVS encapsidated this RNA species. On the contrary, CAT 
ORF-specific PCR of the same VLP preparations failed to detect any CAT-
encoding DNA in the VLP preparation, which could only be derived from 
recombinant baculoviruses. The absence of CAT-encoding DNA suggests that 
baculovirus contamination of the VLP preparation was either absent or had 
been kept to an undetectable minimum. This lack of baculovirus 
contamination could be attributed to the cross-flow filtration technique used 
during the isolation of VLPs. The negative PCR result obtained here also 
suggests that the Gag VLP-Gp64 quantitation analysis performed in Chapter 2 
was either minimally or completely unaffected by the presence of 
contaminating baculoviruses. 
 
Real time RT-PCR quantitation analyses of RNA extracts from VLP 
preparations indicated that encapsidated CAT RNA levels varied significantly 
(0.1 – 8ng CAT RNA/μg Gag VLPs) between individual VLP preparations. If 
we accept that 1ug of Gag VLPs is made up of ~2.2 x 109 VLPs (Refer to 2.4), 
this would indicate that ~2.2 x 109 VLPs would encapsidate between 0.1 and 
8ng of CAT RNA. If we also accept that a CAT-encoding RNA has a total 
relative molecular mass of 212 kDa, which is 3.5 x 10-10ng, this suggests that 
1μg of Gag VLPs encapsidates between 2.8 x 108 and 2.3 x 1010 copies of 
CAT RNA which also equates to between 0.1 and 11 copies of CAT RNA per 
Gag VLP. 
 
Attempts were made to control the amount of encapsidated RNA in Gag VLPs 
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5’ or 3’ ends of the CAT RNA. Data not presented in this thesis indicated 
that the incorporation of this encapsidation signal was unable to confer any 
level of consistency with respect to the amount of CAT RNA encapsidated. As 
suggested, the reason for this was most likely a result of the strong 
baculovirus promoters used in the BEVS to express CAT, along with the fairly 
indiscriminate nature of RNA encapsidation which occurs during VLP 
assembly. In other words, the CAT mRNA concentration was probably so high 
that whether or not it had the ψ-site, it would be the predominant species 
encapsidated. As a control to detect any ψ-site directed packaging I could 
express the reporter, ψ-tagged RNA from a weaker promoter and monitor 
encapsidation and compare encapsidation levels in NC deleted and WT Gag  
 
 
3.4.2 Uptake assays: 
Research discussed earlier (refer to 3.1.1) demonstrated that HIV particles 
that lack envelope glycoproteins are most likely to be degraded in endocytic 
vesicles. The presence of high concentrations of Gp64 on the VLPs were 
therefore tested to determine if they enabled Gag VLP entry and encapsidated 
CAT RNA expression in mammalian cell lines. Cell lines tested in the uptake 
assays (BHK-21, HEK 293, HeLa) were all previously shown to be permissive 
to recombinant baculovirus uptake and expression of their nucleic acids. 
These cell lines, when used in VLP uptake assays, expressed encapsidated 
CAT RNAs at similar levels. In these assays, expression of recombinant 
baculovirus CAT DNA is unlikely to contribute to the overall CAT expression 
levels as expression in mammalian cell lines requires mammalian promoter 
sequences. These encapsidated CAT RNAs are representative of other RNAs 
normally present in the VLP expression system, which are encapsidated 
during assembly.  
 
Results in this study therefore for the first time demonstrate that there is 
a strong probability for the expression of randomly encapsidated, 
expression system produced CAT RNAs in mammalian cell lines 
following VLP inoculation. The mouse macrophage RAW 264.7 cell line, 
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gene expression, was similarly unable to express CAT RNA carried by 
Gp64 pseudotyped Gag VLPs (data not shown). Results therefore suggest 
that Gag VLP entry into the tested cell lines is mediated by baculovirus Gp64. 
This notion is supported by the VLP inactivation experiments conducted. The 
VLP heat inactivation experiments showed that incubation of VLPs at 62oC 
could reduce CAT expression in certain cell lines (BHK-21 and HeLa) to 
almost undetectable levels. Heat treatment was also shown to have no effect 
on the virion CAT RNA content over a time course of 20 minutes, while it also 
did not detectably disrupt/ lyse the VLPs. Inhibition of CAT expression is 
therefore assumed to be a result of Gp64 damage on the VLP surface.  
 
CAT expression levels at higher uptake concentration in the HEK 293 cell line 
on the contrary appeared unaffected by VLP heat treatment. This may 
suggest that HEK-293 cell lines employ an additional/alternate VLP cell 
uptake pathway to that used by the BHK-21 and HeLa cell line. This unknown 
pathway would thus be biased for VLP entry upon VLP Gp64 disruption. As 
the delineation of the exact VLP uptake pathw ys that lead to RNA expression 
was beyond the scope of this study, these were not further investigated. 
Future studies could investigate these uptake pathways through the use of 
specific cell pathway uptake inhibitors or antibodies specific for functional 
receptors on the virion surface such as Gp64. Similarly it may therefore be 
more effective to heat treat as well as UV irradiate VLPs prior to inoculation to 
prevent encapsidated RNA expression. Alternately formaldehyde treatment of 
the VLPs could also have been used in combination with the heat treatment. 
As formaldehyde is a cross linking reagent, it could function by simultaneously 
inactivating any receptors used for alternate VLP uptake pathways used by 
the HEK-293 cell line. 
 
CAT RNA transfection control experiments were also conducted to determine 
if the RNA could be expressed in mammalian cell lines as well as to determine 
the effect of heat and UV on the CAT RNA. It was clear that when CAT RNA 
was encapsidated by Gag VLPs, very low concentrations (2, 5, 10ng) 
produced relatively high expression levels in the tested cell lines. Transfection 
of in vitro-transcribed CAT RNAs, on the contrary, required much higher RNA 
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This may suggest that if the concentration of the Gag VLPs encapsidated 
RNA could be modulated, they could serve as highly efficient gene 
delivery/transient expression vectors. 
 
Heat treatment of VLPs (at 62oC for 10 – 20 minutes) effectively reduced 
transmission and expression of RNA carried by Gag VLPs in BHK-21 and 
HeLa cell lines through the disruption of Gp64. Functional Gp64 is suggested 
to play an important role in stimulating cellular immune responses to BEVS-
produced Gag VLPs by enabling cellular entry (refer to 1.6.5; 4.1.2). 
Disruption of Gp64 after heat treatment possibly does not alone contribute to 
the reduced CAT expression levels and the reduced CAT expression could 
result form the disruption of any of several unexplored membrane factors 
affected during heat treatment. Alternatively, the separate pathway utilized by 
the HEK-293 cell lines may still enable cell entry and hence cellular immune 
responses despite Gp64 disruption. Whether heat treatment/inactivation of 
VLPs therefore has any bearing on VLP stimulated cellular immune responses 
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4.1 HIV-1 Cellular immune responses: 
The precise correlates of protection for an adequate/protective immune 
response against HIV remain unclear. Data presented in numerous 
immunology studies, though, have aided towards achieving an understanding 
and towards the decrypting of the requirements for a protective immune 
response. 
 
Several studies have documented the importance of stimulating effective 
cellular immune responses in combination with a neutralizing humoral immune 
response to control/prevent an HIV infection. Effective host anti-HIV immune 
responses do not exhibit the classical protective immune response paradigm, 
where humoral immune responses would prevent viral infection. Instead, 
cellular immune responses reduce viraemia in HIV-infected individuals and 
prevent the development of disease in long-term-non-progressors (LTNPs) 
(see references below). 
 
Several convincing lines of evidence highlight the importance of cellular 
immune responses. Protective cytotoxic T-cell responses have been 
demonstrated in human LTNPs before the development of symptoms and 
parallel a decrease in plasma viral RNA (Pantaleo et al., 2004; Rowland–
Jones et al., 1998; Kaul et al., 2001; Harari et al 2003). Furthermore, the 
maintenance of HIV-1 specific T cell responses following the disruption of 
antiviral therapy in HIV-1 infected individuals is associated with viraemia 
control (Rosenberg et al., 2000). Vaccine-induced, cell-mediated immune 
responses in monkeys have successfully controlled challenges by the 
SHIV89.6 AIDS virus model (Amara et al., 2002; Barouch et al., 2000; Shiver 
et al., 2002; Belyakov et al., 2001). The role of CD8 T cells has been 
highlighted in studies where depletion of CD8 T cells in infected monkeys 
resulted in a loss of virus control, but virus levels were subsequently 
controlled following the restoration of CD8 T cell responses (Jin et al., 1999; 
Schmitz et al., 1999; Table 1.1, Rowland-Jones et al., 1997; Borrow et al., 
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4.1.1 VLP-stimulated immune responses 
Distinct antigen processing pathways have been established for the 
presentation of foreign antigens. Endogenous antigens derived from 
viral/bacterial infections and DNA vaccines, typically enter the CD8, MHC-1-
driven CTL immune response. The CTL response plays a key role in the 
adaptive/memory immune response by eliminating cells infected with 
intracellular pathogens. Several studies have demonstrated the importance of 
strong specific CTL responses during acute HIV infections (see references in 
next paragraph).  
 
Non-infectious HIV VLPs are like “inactivated viruses” in that they are 
considered exogenous antigens. They induce the MHC-2-restricted cellular 
and humoral immune responses and should typically be unable to induce a 
MHC-1-driven CTL response. HIV/SIV-derived VLPs have been found, 
nevertheless, to efficiently stimulate the MHC-1-driven CTL responses as well 
as humoral immune responses in spite of the absence of cellular infection or 
intracellular replication (Table 1.1, Jaffray et al., 2004; Marsac et al., 2002; 
Bachmann et al., 1996; Buonaguro et al., 2002; 2006; Ruedl et al., 2002; 
2005, Kuate et al., 2006; Deml et al., 1997; Paliard et al., 2000; Deml et al 
2005). 
 
4.1.2 Pseudotyped VLPs 
Pseudotyping VLPs has often been used to manipulate particle fusogenicity 
and hence their immunogenicity. This is achieved by the presentation of 
modified/stabilised HIV or heterologous (MLV, VSV, Baculovirus) envelope 
glycoproteins on the VLP surface to facilitate their entry into antigen 
presenting cells. This, in turn, enhanced Gag and Env-directed antibody as 
well as CTL responses (Table 1.1; Guo et al., 2003; Bellier et al. 2006; 
Marsac et al., 2002; Kuate et al., 2006; Granelli-Piperno et al., 2000; 
Schauber et al., 2004). In a study conducted by Buonaguro et al. (2006), HIV 
VLPs displaying HIV-gp120 derived from a Ugandan HIV isolate were 
efficiently taken up by monocyte-derived dendritic cells (MDDC). Uptake 
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which induced maturation and activation of MDDC (Buonaguro et al., 2006). 
These activated MDDC showed enhanced Th1- and Th2-cytokine production 
and were able to activate autologous naïve CD4 T-cells and drive them 
towards a Th-1 response. In a previous study these VLPs were shown to 
successfully stimulate strong CD4 and CD8 T-cell responses in mice and 
generated cross clade neutralizing antibody responses in the absence of 
adjuvant (Buonaguro et al., 2002; 2005).  
 
The vesicular stomatitis virus G-envelope  glycoprotein (VSV-G) has also 
commonly been used to pseudotype HIV/SIV VLPs to enhance immune 
responses, by allowing entry into a broad range of cells including dendritic 
cells (Bellier et al. 2006; Marsac et al., 2002; Granelli-Piperno et al., 2000; 
Kuate et al., 2006; 2003). Immunization of monkeys with VSV-G pseudotyped 
SIV particles generated SIV-specific humoral and cellular immune responses, 
which significantly reduced peak viraemia levels of a challenge virus (Kuate et 
al., 2003; 2006).  Peak viraemia dropped to almost 20-fold lower in VLP-
inoculated monkeys in the 2006 study, which in general remained below 
detection limits for 120 weeks post infection. In mice, HIV VSV G-
pseudotyped VLPs stimulated Gag-specific IgG and IgG1 antibody titres that 
were ~100 fold higher than non-pseudotyped VLPs. As a control, a fusion 
defective VSVG envelope was also displayed on the HIV VLPs and was not 
able to enhance the VLP immune response. These researchers speculate that 
the fusion competent VSV G enabled cytoplasmic delivery of VLP 
components, which resulted in enhanced MHC presentation of epitopes. Due 
to the broad target cell range of the VSV G envelope glycoprotein 
pseudotyped particles, toxic effects have been observed. Alternate envelope 
glycoproteins have been investigated that could confer the same enhanced 
immunogenicity to the pseudotyped particle but with a limited target cell 
range.   
 
Enhanced immunogenicity results have been corroborated in several other 
studies, which have pseudotyped HIV VLPs with influenza HA, MLV env, 
VSV-G Env and Baculovirus Gp64, where the presence of fusion competent 
envelope glycoproteins enabled both MHC-1 and -2 Gag protein processing 
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et al., 2004). The previously described vaccine study by Bellier et al., 
(2006) that utilised MLV+Env based plasmo-VLPs has also partly attributed 
the successful stimulation of strong T-cell responses to the presence of the 
MLV Env. In relation to this study, Wong et al., (2005) showed that VLPs that 
did not display Env were unable to induce immune responses that were 
stronger than a DNA vaccine that produced soluble polypeptides unable to 
assemble into particles. 
 
Pseudotyping Gag VLPs with functional/fusion competent envelope 
glycoproteins thus appears to be of paramount importance in stimulating both 
MHC-1 and MHC-2 Gag processing pathways. The envelope glycoproteins 
mediate an enhanced immune response by enabling cellular entry, in a 
manner which does not result in VLP lysosomal degradation.  
 
Results shown in chapter 3 demonstrated, though, that the entry of 
Gp64 pseudotyped Gag VLPs into several mammalian cell lines is 
accompanied by the expression of reporter CAT RNAs carried by the 
VLPs. As expression of the foreign encapsidated nucleic acids is not a 
desired VLP trait,  data in chapter 3 indicated that disruption of Gp64 
envelope glycoprotein by heat treatment could prevent uptake in several cell 
lines. Heat inactivation of the Gp64 envelope glycoprotein significantly 
reduced expression in the tested BHK-21 and HeLa cell lines. CAT expression 
levels within the HEK 293 cell line on the contrary appeared unaffected by 
VLP heat treatment. This may suggest an alternate route of VLP cellular entry 
in this cell line that, as with Gp64-mediated uptake, also does not result in 
VLP lysosomal degradation. This alternate pathway would suggest that VLP 
heat treatment and hence reduced non-degradative cellular entry in some cell 
lines may not completely terminate MHC-1 driven cellular immune response.  
 
Several other studies have been conducted to further characterize protective 
cellular immune responses. These studies have shown that the co-production 
of immune cytokines interferon-γ (IFN-γ) and interleukin-2 (IL-2) are 
necessary (but not sufficient) for protective cellular immune responses (Harari 
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et al., 2003; Boaz et al., 2002; Iyasere et al., 2003; Younes et al., 2003; 
Robinson et al., 2007).  
 
4.1.3 Aims: 
Heated/inactivated Gag VLPs were thus inoculated into mice to determine 
whether these had a reduced capacity to stimulate the MHC-1 and MHC-2 
arm of the immune response. Heated VLPs stimulated cellular immune 
responses in mice were gauged by assaying for IFN-γ and IL-2 production in 
mouse spleens.  This immunogenicity analysis is the first instance where 
the viability of heat treatment and hence the restriction of foreign RNA 
expression in an inoculated host was carried out to determine its effect 
on VLP immunogenicity. Also, since VLPs have sho n to be potent 
immunogens when administered as boosts, mice that were initially primed 
with a DNA vaccine, received a heated VLP boost. This prime boost 
inoculation regimen allowed us to determine if there are any differences 
between the immunogenicity profiles of heated VLPs when used as single 
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4.2 Materials and Methods 
4.2.1 Inoculation of mice 
All animal procedures were approved by the University of Cape Town, Faculty 
of Health Sciences Animal Ethics Committee. Female H-2d BALB/c mice were 
purchased from South Africa Vaccine producers Pty Ltd (Johannesburg, 
South Africa) and housed at the University of Cape Town Animal Unit. They 
were allowed to acclimatize for a minimum of 10 days prior to vaccination.  
 
Gag VLPs used for inoculation into mice was prepared and quantified as 
described in 2.2.6 and 2.2.8 materials and methods. VLP dilutions were 
heated prior to inoculation as described in 3.2.6.4 materials and methods. The 
pTHGagC DNA vaccine, which expresses the Du422 HIV-1 C gag gene (the 
same isolate that the VLP Pr55Gag amino acid sequence was derived from), 
was used either as a positive control or as a DNA prime in the mouse 
inoculation schedule aimed at assessing cellular immune responses (Table 
4.1). The Du422 HIV-1 C gag gene was previously selected for this DNA 
vaccine as it had closest amino acid similarity (98.2%) to a derived South 
African subtype C consensus sequence and would thus maximize the number 
of potential epitopes in common between the vaccine and circulating viruses 
(van Harmelen et al., 2003). The gag gene from Du422 was human codon 
optimised by Operon T chnologies Inc., USA. The myristylation site was 
mutated from MGA to MAA, which prevented virions budding and hence VLP 
assembly. This DNA vaccine was manufactured by Aldevron and supplied at 
DNA concentrations of 2mg/ml PBS.  
 
As shown in the mouse inoculation schedule, 14 groups (n = 3) of mice were 
either primed with the pTHgagC DNA vaccine (100μg) and boosted with 
varying concentrations of heated or unheated VLPs or given an inoculation of 
these VLPs (Table 4.1). VLP and pTHgagC inocula were made up in 100μl 
total volumes made up in sterile Dulbecco’s PBS (Sigma®). Mice were 
inoculated intramuscularly with 50μl per tibialis muscle. At 12 days post VLP 
inoculation, mice were sacrificed and spleens were removed to analyse 
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Table 4.1. Mouse inoculation schedule. (pTHgag: DNA vaccine, 






















4.2.2 Preparation of mouse splenocytes:  
Mouse spleens from each group were pooled from the three mice in each 
group in 10ml supplemented RPMI (refer to 3.2.5.2) and broken up into single 
cells by mashing them with a rubber stopper through a metal grid (Sigma®) 
placed in a Petri dish. The cell suspension was made up to 50ml with RPMI 












1 pTHgag  
100ug (DNA) 
Sacrifice - - 
2 pTHgag  
100ug (DNA) 
- pTHGag  
100ug (DNA) 
Sacrifice 
3 pTHgag  
100ug (DNA) 
- GagRNA 
100ng (VLP 1) 
Sacrifice 
4 pTHgag  
100ug (DNA) 
- GagRNA 
200ng (VLP 2) 
Sacrifice 
5 pTHgag  
100ug (DNA) 
- GagRNA 
400ng (VLP 4) 
Sacrifice 
6 pTHgag  
100ug (DNA) 
- GagRNAHI 
100ng (VLP H1) 
Sacrifice 
7 pTHgag  
100ug (DNA) 
- GagRNAHI 
200 ng (VLP H2) 
Sacrifice 
8 pTHgag  
100ug (DNA) 
- GagRNAHI 
400ng (VLP H4) 
Sacrifice 
9 GagRNA 
100ng (VLP 1) 
Sacrifice - - 
10 GagRNA 
200ng (VLP 2) 
Sacrifice - - 
11 GagRNA 
400ng (VLP 4) 
Sacrifice - - 
12 GagRNAHI 
100ng (VLP H1) 
Sacrifice - - 
13 GagRNAHI 
200 ng (VLP H2) 
Sacrifice - - 
14 GagRNAHI 
400ng (VLP H4) 
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(supplemented, 3.2.5.2) and transferred to a 50ml centrifuge tube. The cell 
suspension was centrifuged for 5 minutes at 450g. Cell pellets were 
resuspended in 50ml RPMI and centrifuged as before. After each cell pellet 
wash, extracellular matter was removed from the suspension using a Pasteur 
pipette. Cells were next resuspended in 50ml RPMI (supplemented) and 
viability was determined by staining cells with trypan blue stain and counting 
them in a Neubauer counting chamber. Erythrocytes were lysed by 
suspending 50x106 cells in 1ml of RBC lysis buffer (1ml/50x106 cells/ml) (5mM 
Tris-HCL, 140mM NH4CL, pH 7.3, Sigma) for 2 minutes. The cell suspension 
was centrifuged at 400 g for 7 minutes and the lysed erythrocytes in 
suspension was discarded. Splenocytes were resuspended in 5ml RPMI 
(supplemented) and samples of this suspension were stained with trypan blue 
and counted in a Neubauer chamber. Cells were then prepared to a final 
concentration of 5 x 106 cells/ml in supplemented RPMI medium. The 
frequencies of antigen (Gag)-specific CD4 or CD8 T cells secreting cytokines 
in the spleen of inoculated mice were determined by means of interferon-
gamma (IFN-γ) and interleukin-2 (IL-2) ELISPOT assays. 
 
4.2.3 ELISPOT assay: 
ELISPOT assays were conducted to detect Gag-specific IFN-γ and IL-2 
secreting splenocytes using the BD Biosciences kit according to 
manufacturer’s recommendations, which provided all reagents for the assay. 
Ninety six well ELISPOT plates were coated with IFN-γ or IL-2 capture 
antibody (5μg/ml in PBS), sealed and incubated at 4oC for 16 hours. Wells 
were washed once with 200μl/well blocking solution (R10 medium: RPMI; 1% 
penicillin G/streptomycin; 10% FCS; 0.1% 2-mercaptoethanol). Blocking 
solution (200μl/well) was added to the wells and plates were incubated for 2 
hours at ambient temperature. The Blocking solution was discarded and Gag 
as well as control peptide stimulants were added (100μl) in triplicate to the 
wells in the ELISPOT plate.  
 
Amino acid sequence of Gag-derived peptides used for stimulating cytokine 
expression in splenocytes corresponded to BALB/c mouse epitopes in Du422 
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(non-specific assay positive control) or RPMI medium (peptide-free culture 
medium) (background control) (Table 4.2) was included in the assay. Each of 
the peptide stimulants were added to the wells in triplicate at a final 
concentration of 2μg/ml (100μl/well). Con A (Sigma®) (positive non-specific 
stimulant) was added at a concentration of 0.5μg/ml (100μl/well). 
 
Table 4.2 Cytokine stimulants used in ELISPOT assays. 
Stimulant/ 
Control 














H-2Kd binding peptide 
(CD8 peptide) 
TYSTVASSL 2μg/ml  
(100μl/well) 
GagCD8 H-2d –restricted class I 
peptide (CD8 peptide) 
AMQMLKDTI 2μg/ml  
(100μl/well) 
GagCD4(13) H-2d -restricted class II 
peptide (CD4 peptide)  
NPPIPVGDIYKRWIILGLNK 2μg/ml  
(100μl/well) 
GagCD4(17) H-2d -restricted class II 
peptide (CD4 peptide)  




Splenocytes (500 000 cells/100μl) were plated in triplicate (for each stimulant) 
and incubated for 24 hours, at 37oC in a 5% CO2 incubator. Splenocyte 
suspensions were discarded and wells were washed twice with double-
distilled water, followed by 3 washes with wash buffer (1x PBS-0.05 tween 20, 
pH7.4 (Sigma®)). The detection antibody, biotinylated anti-IFN-γ or -IL-2 was 
diluted in dilution buffer (2μg/ml) (PBS with 10% FCS) and 100μl was added 
to each well. Plates were sealed and incubated at ambient temperature for 2 
hours. The detection antibody solution was then discarded and wells were 
washed 3 times with wash buffer. Avidin-horseradish peroxidase (avidin-HRP) 
was diluted (5μg/ml) in dilution buffer and 100μl was added to the wells and 
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HRP solution was discarded from plates, which were then washed 3 times 
with wash buffer followed by another 3 washes with PBS (Sigma®). The Nova 
Red Substrate solution (Southern Cross) was prepared by adding 3 1`drops of 
reagent I, 2 drops of reagent II, 2 drops of reagent III and 2 drops of H2O2 to 
15ml of H2O. This Nova Red solution (100μl/well) was added to the ELISPOT 
plates and spots were allowed to develop in the dark and reactions were 
stopped by rinsing plates with H2O. ELISPOT plates were air-dried at ambient 
temperature overnight in the dark. Plates were analysed by scanning the 
ELISPOT plate wells using the ELISPOT CTL Analyser (Series 3B). Spots 
were counted using the ImmunoSpot Image Analyzer (Cellular Technology 
Ltd, Cleveland Ohio) with ImmunoSpot Version 3.2 software. The mean 
number of spots in triplicate wells was calculated and background subtracted. 
The values were expressed as net antigen-specific IFN-γ or IL-2 spot forming 
units (SFUs) per million splenocytes. Positive responses were determined by 
setting a cut-off value, whereby any values falling below this cut-off were 
considered as negative. The cut-off value was set at the number of SFU/106 
splenocytes stimulated by the no peptide (culture medium) assay control 
added to its corresponding standard deviation. Values displayed on the 



















4.3.1 Summary of ELISPOT results: 
Immunogenicity comparisons of unheated and heated Gag VLPs were 
investigated in BALB/c mice (3 per group) as VLP only inoculations (100, 200 
or 400ng VLP), or in a DNA prime/ VLP boost regimen. BALB/c mice were 
therefore inoculated with varying concentrations of heated and unheated 
VLPs to establish differences to their cellular immunogenicity profiles with and 
without prior priming with the DNA vaccine pTHGagC. A DNA vaccine prime 
was included as VLPs are typically effective as boosts and therefore allowed 
us to determine if heated VLPs are also effective as boosts. VLPs used in this 
study only stimulated weak to moderate cellular immune responses in prior 
studies. Cellular immune responses and hence the frequencies of Gag-
specific CD4 and CD8 T cells secreting IFN-γ and IL-2 after inoculation were 
determined using IFN-γ and IL-2 ELISPOT assays. For this splenocytes 
pooled from each set of inoculated mice were stimulated in the ELISPOT 
assay with two Gag CD4 Du422 peptides and one Gag CD8 derived peptide.  
 
Splenocytes stimulated with the non-specific positive control, Con A 
stimulated high spot counts (~1400 SFU/106 splenocytes) for all sets of 
mouse spleens (not shown). A general overview of all responses including 
background responses and responses to irrelevant peptide for the IFN-γ and 
IL-2 ELISPOT assay is displayed in figure 4.1 (A) and (C), respectively. The 
IFN-γ ELISPOT background controls, generally stimulated low spot counts for 
most splenocyte sets (≤ 25 SFU/106 splenocytes) (Figure 4.1 (A)). However, 
splenocytes isolated from mice given 400ng of unheated VLPs only or a DNA 
prime followed by boosting with 200ng of VLPs or 400ng of heated VLPs, 
yielded relatively high background spot counts (~150 SFU/106 splenocytes). 
In these instances, though, background counts were negligible compared to 
the total spot counts for that particular group of splenocytes stimulated with 
the CD4 and CD8 epitope peptides. These combined results enabled one to 
distinguish between positive and negative responses; therefore, compilation of 
positive responses is displayed in Figure 4.1 (B). The positive result cut-off 
















































Figure 4.1 General overview of the magnitude of HIV-1 Gag-specific CD8 and CD4 T cell responses as 
measured by (A and B) IFN-γ and (C and D) IL-2 ELISPOT assays. Splenocytes used in assay were derived 
from mice inoculated with the pTHgagC DNA vaccine (DNA), with (100; 200 or 400ng) heated or unheated 
Gag VLP (VLP 1, 2, 4 and VLP H1, H2, H4 respectively). Splenocytes were stimulated with the gagCD8, 
gagCD4(13) or gagCD4(17) peptides. Assay controls included an analysis of splenocytes stimulated with 
cell culture medium (med) as well as an irrelevant peptide (Irrel pept). (A and C) Represents All IFN-γ and 
IL-2 ELISPOT results respectively, while (B and D) represents positive results above cut off for a positive 
response from the corresponding ELISPOTs. Error bars are the standard deviation of mean triplicates in the 
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free culture medium control added to its corresponding standard deviation. 
IL-2 ELISPOT background responses were approximately four-fold higher 
than the majority of background responses observed in the IFN-γ ELISPOT. In 
this ELISPOT, the same sets of splenocytes observed in the IFN-γ-specific 
reaction displayed high background spot counts (~250 SFU/106 splenocytes). 
The higher background spot counts therefore made the criteria for qualifying 
as positive IL-2 responses more stringent (Figure 4.2 (D)).  Superficially, the 
frequency of IFN-γ responses appears greater than the frequency of IL-2 
responses. This observation has no particular bearing on the actual immune 
response as it does not take into account the potency and immunologic 
relevance of the concentration of either cytokine required to carry out its 
immunologic function.  
 
4.3.2 VLP-only inoculated mouse ELISPOT results 
Positive IFN-γ and IL-2 ELISPOT data for DNA or VLP-only inoculated mice 
are displayed as cumulative responses for both CD4 and the one CD8 peptide 
in Figure 4.2 (A) and (B) respectively. The IFN-γ ELISPOT results shown in 
Figure 4.2 (A) allowed direct comparisons of the overall immunogenicity of 
heated, unheated or DNA only vaccine inoculations. From this graph it is 
apparent that the DNA vaccine has cumulatively stimulated IFN-γ responses, 
which are stronger in magnitude and broader than VLP-only inoculations. 
Stronger cumulative responses are noted by a higher overall spot count for 
peptides tested (~620 SFU/106 splenocytes). Broader responses are noted as 
the DNA vaccine has stimulated responses to all Gag peptides tested, while 
VLPs display a more limited immunogenicity profile. In particular, it is noted 
that the strongest response (520 SFU/106 splenocytes) stimulated by the DNA 
vaccine was towards the Gag CD8 peptide epitope. Based on studies 
discussed earlier (refer to 4.1.1) this was an expected result, as DNA vaccines 
effectively produce internal antigens and generally induce CD8 T cell 
responses. VLPs (Gp64 pseudotyped, unheated) on the contrary, based on 
earlier discussions (refer to 4.1.2), should also have stimulated responses to 
the CD8 peptide. Instead, both heated and unheated VLPs failed to stimulate 
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background values, and VLP stimulated responses were confined to the 
CD4 peptide epitopes.  
 
The unheated VLPs elicit responses to both CD4 peptides, which was 
consistent with the notion that VLPs are exogenous antigens. Cellular 
responses to the CD4(13) Gag peptide epitope (~ 200 SFU/106 splenocytes) 
appeared independent of the inoculated VLP (unheated) dose as spot counts 
remained consistent over the 100-400ng VLP inoculum range. Cellular 
responses to the CD4(17) peptide epitope were amplified 3 fold (60-180 
SFU/106 splenocytes) when the VLP (unheated) inoculum was increased from 
100ng to 400ng. The strongest cumulative cellular response stimulated by 
unheated VLPs was thus stimulated by the 400ng VLP inoculum. 
 
Comparisons of cumulative responses to heated and unheated VLPs showed 
a distinct reduction of the INF-γ response for heated VLPs. On average, 
responses to heat treated VLPs amounted to ~ 60 SFU/106 splenocytes for 
each of the three tested concentrations. It was first noted that the range of 
CD4 responses was limited to only the CD4(13) peptide epitope. 
Cumulatively, heat treatment of VLPs on average resulted in a 70 – 80% 
reduction in the stimulated response when compared to unheated VLPs. 
Cellular responses to heated VLPs also appeared independent of the size of 
the VLP inoculum (100, 200 or 400ng).  
 
The IL-2 ELISPOT results shown in figure 4.2 (B) allowed direct comparisons 
of the immunogenicity of VLPs (heated, unheated) and DNA-only vaccine 
inoculations. From this graph it is apparent that the splenocytes derived from 
mice following a DNA-only vaccination were able to elicit a broad IL-2 
response to all 3 peptides (two CD4 and one CD8) used to stimulate 
splenocytes. In this instance, stimulation by the CD8 peptide again appeared 
strongest. Despite the broad response to all 3 peptides (130 SFU/106 
splenocytes), cumulative responses from the DNA vaccine were overall 
weaker than those elicited by the unheated VLP inocula as well as the 200ng 





























































































Figure 4.2 Comparative view of heated and unheated Gag VLP stimulated positive CD8 and CD4 
T cell responses as measured by (A) IFN-γ and (B) IL-2 ELISPOT assays. Splenocytes used in 
assay were derived from mice inoculated with 100; 200 or 400ng of heated or unheated Gag VLP 
(VLP 1, 2, 4 and VLP H1, H2, H4 respectively). Splenocytes were stimulated with the gagCD8, 
gagCD4(13) or gagCD4(17 peptides). Error bars are the standard deviation of mean triplicates in 
the ELISPOT assay.   
IL-2 ELISPOT assay 
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Stimulated IL-2 responses for both heated and unheated VLPs were 
observed to be more narrow, as splenocytes only responded to the CD4(13) 
peptide, while other peptides failed to produce any results which could be 
distinguished from ELISPOT background. Responses stimulated by the 
CD4(13)  peptide remained consistent (220-300 SFU/106 splenocytes) over 
the entire range of unheated VLP inoculum doses (100, 200 and 400ng) and 
thus appeared VLP concentration-independent. When stimulated responses 
of heated and unheated VLPs were compared, again a clear depreciation in 
the IL-2 response was observed for the heated VLPs, (~ 100%; 50% and 60% 
decrease between the 100ng; 200ng and 400ng unheated and heated VLP 
inocula respectively). The difference between heated and unheated VLPs was 
most evident for mice inoculated with 100ng of VLPs. In this instance, the 
heated VLPs failed to enable the stimulation of any positive responses which 
could be distinguished above background levels. 
 
The heated 200ng and 400ng VLP inocula displayed a ~ 50-60% reduction in 
IL-2 stimulation when compared to unheated VLP-stimulated responses. From 
these results, with the exception of the 100ng heated VLP inoculum, it 
appeared that cellular responses to heated VLPs also appeared independent 
of the VLP inoculum/dose (200ng or 400ng), which was similar to the IFN-γ 
ELISPOT.  As with the IFN-γ ELISPOT, the 400ng unheated VLP inoculum 
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4.3.3 DNA primed/VLP boosted mouse ELISPOT results: 
Positive IFN-γ and IL-2 ELISPOT data for DNA primed and VLP (heated and 
unheated) or DNA-boosted mice are displayed as cumulative responses for 
the both CD4 and the one CD8 peptide in Figure 4.3 (A) and (B) respectively. 
The IFN-γ ELISPOT results shown in Figure 4.3 (A) allowed direct 
comparisons of cellular responses stimulated by VLPs (heated, unheated) 
inocula, which were assessed as boosts when used in combination with a 
DNA prime. Results showed that DNA vaccine priming prior to boosting with 
VLP (heated/unheated) administration substantially enhanced the magnitude 
of cumulative responses (compare Figure 4.2 and Figure 4.3). The magnitude 
of responses was enhanced in terms of the response breadth, whereby all 
peptides (x1 CD8 and x2 CD4) stimulated responses as well as the overall 
cumulative response (≥ 600 SFU/106 splenocytes). When comparing 
responses from DNA prime/VLP boost (Figure 4.3) to VLP-only (Figure 4.2) 
inoculation regimens, the stark difference observed between immune 
responses stimulated by heated and unheated VLP-only inoculations 
appeared very much diminished when mice were primed with DNA.   
 
 Unlike the case with heated VLP-only inoculations, with DNA priming heated 
VLPs were capable of boosting cellular responses even at the lowest 
inoculum concentration (100ng) to a response equivalent to that stimulated by 
the DNA prime/DNA boost response. In this data set the strongest response 
was observed for the 200ng unheated VLP boost (cumulative response ~2000 
SFU/106 splenocytes). The 200ng unheated VLP boost inoculum also 
displayed an enhanced response to CD8 peptide stimulation, which was not 
observed for any VLP only inoculations or heated VLP boosts. In this data set 
an unexpected response resulted from 400ng heated VLP boosted mice, 
which displayed a stronger IFN-γ response (~1400 SFU/106 splenocytes) for 
heated than the unheated VLP boost (~900 SFU/106 splenocytes). 
Cumulatively this response approached that observed for the optimal 200ng 
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Figure 4.3 Comparative view of heated and unheated Gag VLP stimulated positive CD8 and CD4 T cell 
responses as measured by (A) IFN-γ and (B) IL-2 ELISPOT assays. Splenocytes used in assay were 
derived from mice primed with the pTHgagC DNA vaccine (DNA) and further boosted with 100; 200 or 
400ng of heated or unheated Gag VLP (VLP 1, 2, 4 and VLP H1, H2, H4 respectively). Splenocytes were 
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The IL-2 ELISPOT results of the DNA prime/VLP boost regimen shown in 
Figure 4.3 (B) allowed immunogenicity comparisons of heated and unheated 
VLPs when used as boosts in combination with a DNA prime. The cumulative 
cellular response to DNA prime and DNA boost had practically doubled when 
compared to the DNA only vaccination (~110 – 220 SFU/106 splenocytes). As 
with the corresponding IFN-γ ELISPOT data (Figure 4.3 (A)) from this graph it 
is evident that DNA priming prior to DNA or VLP boosting resulted in an 
increased overall cumulative response. Additionally an enhanced breadth of 
cellular responses was also observed here when compared to DNA- or VLP-
only immunizations. In the prior IL-2 analysis (Figure 4.2 (B)), VLP-only 
inoculations only generated responses to the CD4(13) peptide. In contrast, 
when VLPs- heated or unheated were used to boost DNA-primed mice, the 
cumulative responses were several fold higher than VLP-only or DNA prime-
DNA boost responses. Similarly, in all instances of VLP boosting, the breadth 
of the immune responses were larger than those observed for VLP- and DNA-
only inoculations (responded to all 3 peptides). Unlike the case with VLP-only 
inoculations, CD8 peptide responses were enhanced for all (heated and 
unheated VLP) inoculations. As with the IFN-γ ELISPOT, the difference 
between heated and unheated VLP cellular responses appears diminished by 
use of the DNA vaccine prime. More specifically, 100ng and 200ng of 
unheated VLP responses decreased by ~ 20% and 45% respectively when 
heated. As with the corresponding IFN-γ ELISPOT prime-boost analysis, 
(Figure 4.3 (A)) the strongest VLP boost here too is elicited by 200ng of 
unheated VLPs. On the contrary the largest disparity between corresponding 
concentrations of heated and unheated VLP boost is also noted for the 200ng 
inoculum. As with the IFN-γ ELISPOT, unexpectedly the strong 200ng 
unheated VLP cumulative response was closely reproduced by the heated 






















Immune responses to VLPs presented in this chapter reiterate results 
presented in previous studies with respect to VLP immunogenicity. As with 
previous studies, VLP-only inoculations in the selected mouse model resulted 
in moderate cellular responses (Jaffray et al., 2004; Meyers et al., 2008). 
These responses appeared limited to CD4-specific Gag epitopes when 
assayed by IFN-γ and IL-2 ELISPOT and developed optimal (strongest) 
cumulative ELISPOT results when mice were inoculated with 400ng of 
unheated VLPs. Pseudotyped Gag VLPs, as discussed earlier (refer to 3.1.1),  
should be able to stimulate MHC-1 directed CD8 cellular responses. Both IFN-
γ and IL-2 ELISPOT results from VLP-only inoculated mice though failed to 
demonstrate these responses when splenocytes were stimulated with the 
GagCD8 peptide. When heated VLPs were used for the VLP-only 
inoculations, a substantial decrease in the overall cumulative cellular 
responses was observed (IFN-γ: ~80%; IL-2:~60% ). These responses 
appeared to be unaffected by increased doses of heated VLPs for both IFN-γ 
and IL-2 ELISPOT, with responses limited to the GagCD4(13) epitope. Heated 
VLPs in single dose regimens would not be able to stimulate adequate 
immune responses as their stimulated responses fall short in terms of 
magnitude and breadth of the response.  
 
Immune responses to the DNA vaccine-only inoculated mice are similar to 
those observed in other studies. The pTHGagC DNA vaccine has previously 
been shown to induce moderate levels of Gag-specific cellular immune 
responses in mice inoculated intramuscularly (van Harmelen et al., 2003; 
Jaffray et al., 2004; Meyers et al., 2008). In this study, when heated VLPs 
were used with a DNA vaccine (pTHGagC) in DNA-prime, VLP-boost 
regimens, results also reiterated those observed in previous studies (Meyers 
et al., 2008; Chege et al., 2008). As with previous studies, the overall 
magnitude and breadth of DNA-primed cellular responses stimulated by VLPs 
(heated and unheated) was significantly enhanced when assayed by IFN-γ 
and IL-2 ELISPOT, compared to the VLP-only case. Optimal cumulative IFN-γ 
and IL-2 ELISPOT results were ~ 5 fold higher and were stimulated by 200ng 
of unheated VLPs (half the amount necessary for responses in VLP-only 
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VLPs, unlike the VLP-only immunizations, stimulated responses to all CD4 
and CD8 test peptides. Unheated VLP samples, though, were observed to 
stimulate/enhance the CD8 responses by larger increments when compared 
to equivalent concentrations of heated VLP boosts or the DNA boost. This 
may be a direct result of diminished Gp64 functionality on heated VLPs. As 
demonstrated in Chapter 3, VLP heat treatment had no effect on VLP cellular 
entry and CAT RNA expression in the HEK 293 cell line, possibly as a result 
of an alternate non-Gp64 mediated, non-degradative cell entry pathway. This 
possible alternate cell entry pathway may account for the lower levels of CD8 
response enhancement by heated VLPs. 
 
In general, the difference between cellular immune responses stimulated by 
heated and unheated VLPs was significantly diminished by the DNA boost. 
Heated VLP cellular responses in the prime-boost appeared to be enhanced 
by increasing VLP inoculum concentration in both IFN-γ an IL-2 ELISPOT. 
Specifically heated VLPs at 400ng inocula were observed to stimulate cellular 
responses, which virtually mirrored the optimal 200ng unheated VLP boost. 
Heated VLPs appeared suitable for vaccination when used in prime-boost 
regimens as they were able to stimulate cellular immune responses on par 
with lower concentrations of unheated VLP boosts.  
 
Studies have been conducted to further characterize protective cellular 
immune responses to understand why, in the course of most HIV infections, 
cellular responses fail to protect.  A review by Pantaleo et al. (2004) likened 
HIV infections to other chronic infection viruses like Epstein-Barr virus (EBV) 
and cytomegalovirus (CMV). CMV and EBV represent chronic infection 
viruses, which are successfully controlled by cellular immune responses.  It 
was previously shown that EBV and CMV-specific cellular responses are 
characterized by the presence of 3 functionally distinct virus specific 
polyfunctional cell populations: cells that secrete IL-2 but not IFN-γ, that 
secrete both cytokines and cells that secrete IFN-γ only (Betts et al., 2001; 
Harari et al., 2003; Pitcher et al., 1999). Typically secretion of both cytokines 
is associated with protracted antigen exposure and low antigen load. While 
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and hence high antigen loads and IL-2 only is associated with antigen 
clearance.  
 
HIV infections in which cellular immunity failed to control viraemia have 
characteristically had very low to non-existent titres of virus-specific 
polyfunctional CD4+ and CD8+ T cells that secrete more than one of these 
cytokines. Instead, lack of HIV infection control has been characterized by 
high frequencies of HIV-1 CD4 and CD8 T cells that secrete IFN-γ only. 
  
On the contrary, individuals (humans and macaques) who remained healthy 
and managed to control viraemia (LTNPs), displayed HIV-1 specific CD4 and 
CD8 T cell responses that were polyfunctional (multi-cytokine producing: co-
producing: IFN-γ; IL-2 and tumor necrosis factor (TNF)-α), similar to the 
protective EBV and CMV responses (Harari et al., 2003; Sadagopal et al., 
2005; Kannanganat et al.,  2007(A); (B); Boaz et al., 2003; Boaz et al., 2002; 
Iyasere et al., 2003; Younes et al., 2003; Robinson et al., 2007). The 
relevance of the multiple cytokine-producing T cells was further emphasized 
when individuals who managed to control viraemia developed HIV-specific 
CD4 T cells of which more than 50% produced more than one cytokine (IFN-γ; 
IL-2 and TNF-α) (Kannanganat et al., 2007). Individuals unable to control 
viraemia on the contrary developed HIV-specific T cells of which more than 
75% produced only 1 cytokine; most of which were IFN-γ-positive. 
 
It appears, therefore, that the success of the cellular immune response 
against an HIV infection is more a result of the type of immune response 
(single cytokine producing/multiple cytokine producing) rather than the 
quantity. Thus, multiple cytokine-producing immune T cell responses result in 
a superior level of viraemia control. However, in most cases there is a bias 
towards the development of single cytokine producing HIV-specific T cell 
populations.  
 
Overall, this immunogenicity analysis demonstrated for the first time 
that heated VLPs, which have a limited capacity to deliver encapsidated 
RNAs for expression in mammalian cells are still efficient at stimulating 
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strong IL-2 and IFN-γ responses to multiple HIV Gag epitopes (CD4 
and CD8) when used in DNA prime/VLP boost regimens. These heated 
VLPs were required at higher concentrations when compared to 
unheated VLPs (400ng heated VLPs as apposed to 200ng unheated 
VLPs). The ELISPOT-generated IFN-γ and IL-2 results in this chapter could 
unfortunately not be used to determine co-production of cytokines in the 
splenocyte populations analysed: ELISPOT is a “single dimensional” assay, 
which is only able to determine if a cell population is producing a particular 
cytokine or not. The use of intracellular cytokine staining/flow cytometry is 
therefore recommended as a means of further analyzing heat treated VLP-
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5.1 Annual ARV Investment 
Now, more than ever, there is a pressing need for the development of a 
protective or preventative measure against HIV infection. Infection rates, 
particularly in sub-Saharan Africa, have reached frightening levels. 
Internationally, billions of dollars are required each year for antiretroviral 
treatment of infected individuals. At the end of 2007, it was estimated that the 
global deficit between required and available funding for antiretroviral 
treatment was US $8.1 billion. Based on current infection rate trends it has 
also been estimated that funding will have to more than quadruple to US$ 35 
billion in 2010 and to US$ 41 billion in 2015 (WHO website, 2008). The prices 
of most first-line antiretroviral drugs have decreased from 30% to 64% 
between 2004 and 2007 in the low and middle-income countries. Currently, in 
developing countries, the lowest price for the antiretroviral treatment of a 
single infected individual is around US $100 per person per year, but average 
prices are at least US $200 (WHO website, 2008). Despite the reduction in 
cost, these prices are still not economically viable for the poorest countries 
concentrated in sub-Saharan Africa and South-East Asia, which are affected 
the most by the AIDS pandemic. As these countries are not likely to be able to 
finance the treatment of infected individuals without foreign aid, the pricing of 
the drugs poses a barrier to the availability of antiretroviral treatment.  
 
It has also become apparent that investment in HIV infection prevention 
methods (education, condoms and vaccine development) should ultimately be 
more sensible and cost effective than the partially effective antiretroviral 
treatment of infected individuals which is currently used. Although this study 
does not dispute the importance of continued antiretroviral therapy, it supports 
the use of the alternative protective, novel vaccine strategies against HIV 
infection, which may be more effective in the long term.  
5.2 HIV vaccine Development 
Novel HIV vaccine development has been aided significantly through the 
amalgamation of genetic engineering techniques with other research 
disciplines. The applied synergy of research disciplines and hence the fusion 














technologies. Genetic engineering has played an important role in vaccine 
production and has aided in the development of plant, animal, insect, yeast 
and bacterial expression systems. These expression systems are able to 
express heterologous soluble peptides or protein bodies of interest at high 
concentrations for inoculation. Particular reference is made here to the 
production of inert Gag VLPs by means of the baculovirus-based expression 
vector systems in insect cell lines. When Gag VLPs were first produced in 
insect cells for vaccine purposes (Gheysen et al., 1989), researchers were 
probably oblivious to the high levels of baculovirus Gp64 envelope 
glycoproteins that would pseudotype the VLP when budding from cells. On the 
contrary, as the functionality of Gp64 in mediating virus entry into mammalian 
cells first documented in 1995, this may not have been regarded as a problem 
(Hoffmann et al., 1995). 
 
5.3 HIV VLP candidate vaccines 
These heterologous expression system-produced Gag VLPs have proven to 
be effective vaccine candidates. The primary advantages of VLPs as vaccines 
include that they present epitopes in a particulate form, which the immune 
system responds well to. Additionally, as they lack any replicative nucleic 
acids they avoid any complications typically introduced by the use of live 
attenuated and DNA vaccines. This study, though, has demonstrated the 
presence of large amounts of Gp64 envelope glycoprotein on the baculovirus 
expression system-produced Gag VLP surface. Thus, despite the lack of 
replicative nucleic acids in this system, it was highly probable that these 
pseudotyped Gag VLPs could enter mammalian cells by receptor mediated 
endocytosis as in related studies (Kumar et al., 2003; Oomens et al., 2004; 
Schauber et al., 2004). Recently, studies have suggested an important role for 
these Gp64 and envelope glycoproteins in general in mediating MHC-1 
directed cellular immune responses by enabling VLP cellular entry (Table 1.1; 
Guo et al., 2003; Bellier et al. 2006; Marsac et al., 2002; Kuate et al., 2006; 
Granelli-Piperno et al., 2000; Schauber et al., 2004; Bellier et al., 2006; 
Ludwig et al., 2005). Wong et al. 2005 showed that VLPs that did not display 














were stronger than a DNA vaccine producing soluble peptides that were 
unable to assemble into particles.  
 
5.4 Overview of Results 
5.4.1 Gp64 Quantitation 
Results from work carried out in this study confirmed the presence of Gp64 on 
the baculovirus produced VLPs. While this was not the first time the 
presence of Gp64 has been documented on the Gag VLP surface, it was 
the first time to my knowledge that Gp64 concentration estimates were 
made. Measured Gp64 concentration estimates in this study were fairly 
constant between several VLP preparations and were measured to be in the 
order of ~1650 Gp64 molecules /Gag VLP. This therefore indicated that an 
average VLP which contained ~5000 Gag/VLP would contain a ratio of 1 
Gp64 for every 3 Gag molecules in the VLP. These surprisingly high 
concentration estimates far exceeds recent estimates for the number of native 
HIV Gp120 envelope glycoproteins on the surface of HIV particles, which are 
between 2-14 Gp120 spikes per particle (Chertova et al., 2002; Zhu et al., 
2003; 2006). This finding suggests that Gp64 could function as a more 
effective envelope glycoprotein at mediating cellular entry than Gp120, as it is 
present at much higher concentrations. 
 
5.4.2 CAT RNA Encapsidation 
Related studies have analysed the ability of Gp64 pseudotyped, live lentivirus 
expression vectors assembled and pseudotyped in mammalian cell lines 
(293T cell) to enter mammalian cells and express genomic RNAs (Kumar et 
al., 2003; Schauber et al., 2004). These mammalian cell expression systems 
expressed the Gp64 transgene to enable pseudotyping, while a reporter gene 
(GFP) was embedded in the viral genome. This study on the contrary was 
unique as all work was carried out using a far less complex VLP system 
used to produce inert VLPs used for vaccine purposes. HIV Gag VLPs 
used for vaccine purposes are predominantly produced using the insect cell 
culture-based baculovirus expression system. The expression system used in 














utilizing a baculovirus based, insect cell expression system. In this system, 
unlike previous studies, reporter genes consisted of randomly packaged 
reporter RNAs as no virus genomic RNA was present. This study showed 
for the first time to my knowledge that the Gag VLPs produced in this 
type of expression system encapsidates highly variable levels of the 
CAT reporter RNA species (0.1-11 copies per VLP). 
 
5.4.3 Cell Uptake Assays 
The encapsidated CAT reporter RNAs in this study were shown to be able to 
successfully enter mammalian cell lines (BHK-21; HeLa and HEK 293), where 
they were expressed at comparative levels between the different cell lines 
tested. Surprisingly the VLPs appeared to be more efficient RNA transfection 
agents than the commercially available non-lipid, cationic RNA transfection 
reagent. It was noted that the transfection of in vitro-transcribed CAT RNAs 
required much higher RNA concentrations to attain similar expression levels 
to the VLP encapsidated CAT RNAs (20-fold in some instances). The results 
presented here are the first to my knowledge to have documented the 
Gp64 pseudotyped-VLP mediated transfer and expression of a reporter 
RNA species from the VLP expression system. Results suggest that 
there is a strong probability of the expression of randomly 
encapsidated, expression system-produced CAT RNAs in mammalian 
cell lines following VLP inoculation. The results presented here question 
the definition of baculovirus/insect cell-produced Gag-HIV VLPs as inert 
particles. Typically they could be regarded as inert or non-infectious as they 
lack any replicative nucleic acids. Alternatively, despite not being able to 
replicate, VLPs are able to enter mammalian cell lines and deliver their 
expression system derived RNA contents for expression because of the 
presence of Gp64 on the VLP surface. 
5.4.4 Control of RNA Encapsidation 
Results from this study also therefore suggest that if a level of control can be 
attained with respect to the packaging of specific RNA species, these VLPs 
could serve as highly efficient transduction reagents for the transient 














study it was found that the attachment of the HIV RNA packaging signal 
(ψ-site) to the 5’ or 3’ termini of CAT RNA species (results not shown) was 
unable to confer any bias for encapsidation of ψ-tagged CAT RNA. As 
indicated earlier (refer to 1.3.1), the CAT mRNA concentrations in insect cell 
lines were probably so high that whether or not it had the ψ-site, it would be 
the predominant species encapsidated. As with non-ψ-tagged CAT RNA, ψ-
tagged CAT levels were also variable between VLP preparations. Discussed 
earlier (refer to 1.5.2), HIV-specific RNA packaging involves a complex 
system of functional protein elements and specific RNA sequence elements. A 
more complex system that has incorporated these elements into this VLP 
baculovirus/insect cell expression system could thus function in mediating the 
controlled encapsidation of specific RNAs. This type of system would though 
“blur the line” between a live attenuated viral vector as those used in previous 
studies and an inert VLP (Schauber et al., 2004). A pertinent question with 
respect to RNA packaging arose as to whether unpredictable levels of RNA 
packaging (both ψ-tagged and untagged) was specifically related to 
expression in the insect cell line. It would therefore be of interest to test a 
similar expression system in an alternate cell line.  
 
As a result of the unpredictable levels of RNA packaged in this expression 
system we cannot be sure of how much RNA is being delivered when an 
individual is being inoculated. As discussed earlier (refer to 1.6.5) baculoviral 
nucleic acids are presumed to function as adjuvants as a result of the CpG 
motifs. Thus, if different VLP inocula have variable levels of packaged RNAs 
we cannot be sure if the different VLP preparations, despite being at the same 
concentration, will stimulate an equivalent immune response.  
5.4.5 Virus/VLP inactivation 
The baculovirus expression system used in this study produced Gag VLPs 
with highly variable RNA contents. This would not be a favorable trait with 
regard to vaccine regulatory bodies, which require consistency between VLP 
batches produced for vaccine purposes be shown. As it appears to be 
impossible to exert any particular level of control on the encapsidated RNA 
concentrations the alternative would be to remove the potential for RNA 














techniques were therefore used in the current study to prevent expression 
of the packaged RNAs. The heat inactivation technique traditionally functions 
by the disruption of viral surface envelope glycoproteins. An alternate method 
used short wavelength UV irradiation to disrupt the viral nucleic acids. UV 
treatment of VLPs was shown to only partially reduce CAT expression levels 
(50% of non UV irradiated) in the tested cell line. The UV irradiation of in vitro-
transcribed CAT RNA resulted in a ~80% reduction in CAT expression levels, 
which suggested a possible shielding effect by the VLP. The heat treatment of 
VLPs practically blocked all CAT expression in the BHK-21 and HeLa cell 
lines through the possible disruption of Gp64 envelope glycoproteins. CAT 
expression in contrast in the HEK 293 cell line appeared unaffected by the 
VLP heat treatment.  
 
This finding was extremely interesting as it suggested a possible 
alternate mammalian cell entry pathway exploited by VLPs to gain entry 
into the HEK 293 cell line subsequent to Gp64 disruption. As mentioned 
(refer to 3.3.2) the virus heat inactivation protocol derived from Poon et al. 
(2005) pretreated the virus particles with formaldehyde as a fixing/cross-
linking reagent prior to heating to prevent shedding of envelope glycoprotein. 
As the retention of envelope glycoprotein was of no priority in this study, VLPs 
were not treated with formaldehyde. The finding that HEK 293 VLP uptake 
and hence CAT RNA expression was unaffected by heat treatment suggested 
the presence of an unidentified VLP surface element that is unaffected by 
heat treatment. In retrospect, the addition of formaldehyde during virus 
inactivation could have facilitated the cross linking of such an element and 
could have inactivated cell uptake in this cell line as well. 
 
An additional control for these uptake studies would require parallel heat 
treatment and uptake assays using Gag VLPs produced in different 
expression systems (yeast). Results here would give a good indication of 
whether it is in fact Gp64 inactivation through VLP heat treatment that 
prevents CAT RNA expression. Similarly it would also be of significant interest 
if VLPs derived from an alternate expression system are still capable of 














analysis would indicate whether the alternate cell entry pathway is a 
baculovirus/insect cell element conferred pathway. 
 
Overall, VLP heat treatment did not prevent RNA expression in all cell lines 
but reduced the range of cell lines that the VLPs could enter and express the 
encapsidated RNAs. It is therefore suggested that a combination of the virus 
inactivation methods used in this study be used to inactivate RNA expression 
from these VLPs. Further studies are also recommended using a broader 
range of mammalian cell lines in combination with various cell entry inhibitors 
to determine precise cell entry pathways utilized by the BEVS-produced VLPs.    
 
Other than the Gp64-mediated cell entry ability, it is currently unknown 
whether the high concentration of Gp64 on the surface of the VLP has any 
bias on the stimulated immune response. The deletion of the gp64 gene from 
the baculovirus expression system, from a VLP immunogenicity aspect, 
seems justified as it may have a considerable influence on immunodominant 
epitopes on the VLP. On the other hand, Gp64 on the VLP surface was shown 
to also mediate cellular entry in this and other studies, which could potentially 
stimulate the necessary MHC-1 cellular responses required to control HIV 
infection. Studies have shown that the simple deletion of Gp64 is not a viable 
means of redirecting immune responses towards the Gag epitopes in the VLP. 
Gp64 gene deletion causes a severe reduction in baculovirus virion 
production and virions that are produced are non-infectious (Monsma et al., 
1996; Oomens et al., 1999). Similarly, anti-Gp64 antibodies have been shown 
to neutralize baculovirus infectivity and would therefore negatively affect the 
VLP expression system (Zhou et al., 2006). A study by Zhou et al, (2008) has 
identified the functional domains of Gp64 which, were included in the 
development of a minimal construct that still permitted baculovirus budding 
and infection. The minimal construct (G-stem) is capable of substituting 
functionality of the full length Gp64 consisted of 38 amino acids of the Gp64 
ectodomain in combination with 52 amino acids of the Gp64 transmembrane 
stem domain. The G-stem minimal construct produced in this study can be 
used to display foreign epitopes (eGFP; influenza N-terminal HA ectodomain) 
on the baculovirus virion surface. A recombinant G-stem construct could 














surface if substituted for the native Gp64 in the baculovirus expression 
system. In the quantitation analysis, in this study, Gp64 showed high, 
consistent levels of incorporation into VLPs.   
 
5.4.6 Immunology 
While a vaccine that provides a completely sterilizing protection against HIV 
infection is the ideal (humoral), protective vaccine candidates that stimulate T-
cell based responses have shown promise (Table 1.1; Jaffray et al., 2004; 
Marsac et al., 2002; Bachmann et al., 1996; Buonaguro et al., 2002; 2006; 
Ruedl et al., 2002; 2005, Kuate et al., 2006; Deml et al., 1997; Paliard et al., 
2000; Deml et al 2005). These HIV-specific cellular immune responses may 
not clear an HIV infection but are able to help lower the initial burst viremia 
following infection, slow the progression towards disease and reduce 
transmissibility. 
 
Bearing the significance of cellular immune responses stimulated by 
pseudotyped VLP in mind, this study sought to assess any changes to 
stimulated VLP immune responses subsequent to heat treatment. Heat 
treatment was expected to disrupt the cellular immune response due to the 
absence of functional envelope glycoprotein. On the contrary, the finding of an 
alternate cell entry pathway in the HEK 293 cell line suggested that the 
possibility still existed to stimulate adequate cellular immune responses. Mice 
were therefore inoculated with VLP-only (heated or non-heated) or DNA 
vaccine prime/VLP boost (heated or non-heated) regimens.  
 
Mice inoculated with only heated VLPs displayed a clearly reduced cumulative 
cellular immune responses when compared to mice inoculated with unheated 
VLPs (IFN-γ and IL-2 ELISPOT assays). On average, heated VLPs displayed 
a 60% to 80% reduction in cumulative responses compared to the non-heated 
VLPs. These weak responses were limited to a single CD4-specific epitope 
and appeared unaffected by VLP dose (remained low irrelevant of the heated 
VLP dose). Heated VLPs are therefore unable to stimulate adequate cellular 
immune responses directed at HIV epitopes when immunizing mice with VLP-















In contrast to the heated VLP-only inoculation regimen, the DNA prime/heated 
VLP boost yielded more promising results. The overall magnitude and breadth 
of cellular responses stimulated by heated VLPs in this instance was 
significantly enhanced (IFN-γ and IL-2 ELISPOT responses to all epitopes). 
Inoculation of mice with unheated VLPs though, enhanced responses to the 
CD8 epitope by larger increments than those inoculated with the heated 
VLPs. This may be a direct result of the heat reduced functionality of Gp64 but 
heat treated VLPs were nevertheless able to enhance the cellular response to 
the CD8 epitope stimulated by the DNA vaccine. Interestingly, the difference 
between cellular immune responses stimulated by heated and unheated VLPs 
in the prime/boost inoculation regimen were not as large as the VLP-only 
inoculations. The 100 and 200ng heated VLP boost displayed a 20% and 45% 
reduction in the cumulative response compared to the unheated VLPs. The 
400ng heated VLP boost surprisingly stimulated almost equivalent responses 
to those stimulated by the optimal unheated VLP boost (200ng).   
 
Unexpectedly, when mice were boosted with higher heated VLP doses 
following a DNA prime, cellular responses were almost equivalent to the 
optimal responses stimulated by non-heated VLPs. This novel finding 
therefore suggests that VLPs can be heat treated to reduce its ability to 
transduce mammalian cell lines and express encapsidated RNAs, while 
retaining its immunogenicity. The only proviso would be the use of 
slightly higher inoculation doses of the VLPs in a prime/boost 
inoculation regimen as this reproduces the optimal type of immune 
response resulting from unheated VLP boosts. 
  
5.5 Conclusion 
To conclude, results presented in this study have shown that Gp64 is 
incorporated in high concentrations (~1650 Gp64/VLP) into baculovirus 
produced HIV Gag VLPs. It is evident that VLPs pseudotyped by Gp64 is 
capable of productively entering mammalian cell lines and expressing the 
randomly encapsidated expression system derived RNAs. The range of target 














heat treatment. VLP immunogenicity subsequent to heat treatment can 
still be maintained provided that they are used in highly inoculation doses in a 
prime/boost inoculation regimen. 
 
The development of a prophylactic VLP-based HIV vaccine therefore remains 
a worthwhile endeavour. Typically safety issues concerning vaccines arise as 
we attempt to fully control/manipulate virtually every aspect of the 
administered vaccine. As the delivery of foreign RNA species during 
vaccination remains a contemptuous issue, results from this study have 
shown that it is possible to modulate the transmission of foreign RNAs without 
affecting VLP immunogenicity. As the VLPs produced in this and many other 
studies are produced in insect cell-based expression systems, they are 
unlikely to carry any human pathogens, which also make them viable 
candidates for further investment as long term vaccine prospects.   
   
HIV research, and in particular the development of a protective vaccine has 
become one of the biggest, most well-funded and ambitious endeavours that 
the international scientific community has ever embarked on. Unlike many 
other vaccine types the HIV vaccine has proven highly elusive as the virus 
has surpassed all preconceived notions as to its abilities and with that every 
strategy we have employed to eradicate it. Hence the continued research into 
all aspects of HIV; HIV vaccine development and vaccine safety is paramount 
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1. Bacterial growth media, conditions, antibiotics and strains 
All bacterial cultures were grown in Luria-Bertani (LB) broth (5g bacto-
tryptone, 5g yeast extract, 10g NaCl, 950ml distilled H2O, pH adjusted to 7.4 
using NaOH, made up to 1L and autoclaved.  
 
Luria-Bertani agar was made up with the same constituents as LB, but also 
contained 15g agar/L. 
 
Ampicillin was used as a selective marker at 100μg/ml concentrations in both 
LB media and Luria agar to select for the ampicillin-resistant clones.  
Liquid cultures were all grown at 37oC with agitation. 
 
2. DNA extraction procedures 
2.1 Small-scale plasmid DNA extraction 
Plasmid DNA was isolated from 5ml overnight bacterial cultures according to 
the protocol of the QIAprep Spin Miniprep Kit (Qiagen), which is based on the 
alkaline hydrolysis technique of Sambrook et al. (1998).  
2.2 Large-scale plasmid DNA isolation 
Plasmid DNA was isolated from 100ml overnight bacterial cultures  carried out 
according to the protocol of the Qiagen Plasmid Midi Kit (Qiagen), which is 
based on the alkaline hydrolysis technique of Sambrook et al. (1998). 
 
3. Agarose gel electrophoresis of DNA and RNA 
Gel electrophoresis of both DNA and RNA was carried out using 1% agarose 
gels containing 0.5μg/ml of ethidium bromide in a 1x Tris-Borate EDTA buffer 
at 95 volts. DNA fragment size was estimated using the Hyperladder I DNA 
size marker (Bioline), which gives a size estimation range of between 200bp 
and 10000bp. For RNA electrophoresis, all reagents were prepared under 
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4. Gel and endonuclease reaction purification of DNA 
Purification of DNA from agarose gels or directly from endonuclease reactions 
to remove undesired buffers and enzymes was carried out using the 
QIAquick® gel /PCR extraction kit (Qiagen). To isolate specific DNA 
fragments derived from endonuclease reactions, the DNA was loaded onto a 
1% agarose gel containing 0.5μg/ml ethidium bromide and electrophoresed at 
95 volts. The bands of interest were visualized on a UV transilluminator plate 
(310nm) and excised using a sterile scalpel blade. The excised gel slice was 
placed into a 1.5ml Eppendorf tube and the DNA extraction was carried out 
according to the method outlined in the above-mentioned kit.   
 
5. Transformation 
E.cloni® 10G DUOs (Lucigen®) chemically competent E. coli cells were used 
for transformation, which was carried out using the method of Chung and 
Miller (1989). Transformations were conducted by adding 2μl ligation reaction 
DNA to 20μl of competent cells. The DNA and competent cells were mixed in 
a 1.5ml Eppendorf tube and chilled on ice for 30 minutes. The cells were then 
heat-shocked at 37oC for 25 seconds, followed by incubation on ice for 2 
minutes. 700μl of LB was then added to the transformation mix, which was 
then incubated at 37oC for 1 hour 30 minutes. 100μl volumes of each 
transformation mix was then plated on Luria agar plates containing 100μg/ml 
ampicillin as a selective marker.  
 
6. DNA sequencing 
Purified miniprep (small scale plasmid DNA extraction) DNA was used for the 
sequencing reactions by means of a technique derived form the dideoxy chain 
terminating method of Sanger et al. (1977). This service was provided by the 
Macrogen Inc DNA sequencing service, Gasan-dong Geumchun-gu Seoul, 
Korea 153-021. Analysis of the generated sequences was done using the 
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6.1 Sequencing primers used:  
 
P10 forward: 5’ AGA TCT ATG TCG TAC TAC CAT CAT CAC CAC CAC 3’ 
P10 reverse: 5’ AGA TCT CAT AGC GCG GGT TCC TTC CGG TAT TG 3’ 
 
PH forward: 5’ AGA TCT TAC TAC CAT CAC CAT CAC CAT CAC G 3’ 
PH reverse: 5’ AGA TCT TTA TGA TCC TCT AGT ACT TCT CGA C 3’ 
 
7. SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
SDS-PAGE was carried out as described by Laemmli (1970). Approximately 
1.5mm thick gels comprised of a 10% resolving gel and a 4% stacking gel 
were poured into a Hoefer SE-600 vertical slab gel apparatus (Hoefer 
Scientific Instruments). Protein samples were denatured by mixing with an 
equal volume of protein loading buffer (10% [w/v] SDS, 15% glycerol, 15% 2-
mercaptoethanol, 0.01% bromophenol blue, 0.125M Tris-HCl pH6.8) and 
heating to 100oC for 10 minutes. Electrophoresis was carried out at 20mA/gel 
until the dye front reached the bottom of the gel. Gels were blotted as follows 
(western blot) or stained with 0.2% (w/v) PAGE blue 83 (BDH chemicals) 
dissolved in a 45:45:10 (v/v) mixture of methanol, water and glacial acetic 
acid. Stained gels were destained with a destain solution consisting of 
65:25:10 (v/v) mixture of methanol, water and acetic acid. 
8. Western Blot 
Protein from SDS-PAGE gels was transferred onto Hybond™-ECL™ 
nitrocellulose membranes (Amersham Biosciences) using a semi-dry blotting 
electroblotter (BioRadTM). Blotting was carried out for 60 minutes at 15 volts, 
after which membranes were blocked for 30 minutes at room temperature in a 
1% Tween-20, 5% milk powder in phosphate buffered saline solution. 
Membranes were probed overnight in an appropriate dilution of primary 
antibody at 4oC. Blots were subsequently washed with blocking buffer 4X for 
15 minutes/wash before being probed with an appropriate dilution of alkaline 
phosphatase conjugated secondary antibody (Sigma-Aldrich) for 2 hours at 
room temperature. The blots were next washed with blocking buffer lacking 
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SIGMAFAST™, 5-Bromo-4-chloro-3-indolyl phosphate/Nitro blue 
tetrazolium (BCIP/NBT) containing tablets as per supplier’s directions 
(Roche). 
 
9. CAT ELISA 
A CAT ELISA kit (Roche) was used for this assay, according to the 
manufacturer’s protocol. ELISA plates were analysed using the PowerWave™ 
XS ELISA plate reader (BioTek®) and results were analysed using the KCL™ 
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2. Sequence of hmGag ORF in pGem®-T easy cloning vector 
 
 
                                        pGEM®-T-easy multiple cloning site                                   NcoI site               
1     TGTAATACGA CTCACTATAG GGCGAATTGG GCCCGACGTC GCATGCTCCC GGCCGACCAT +  
                                                                Start codon 
                                  hmGag ORF 
61     GG GTGCTCGC GCATCTATCC TCAGAGGCGA AAAGTTGGAT AAGTGGGAAA AAATCAGACT 
121    CAGGCCAGGA GGTAAAAAAC ACTACATGCT GAAGCATATC GTGTGGGCAT CTAGGGAGTT 
181    GGAGAGATTT GCACTGAACC CCGGACTGCT GGAAACCTCA GAGGGCTGTA AGCAAATCAT 
241    GAAACAGCTC CAACCAGCCT TGCAGACCGG AACAGAAGAG CTGAAGTCCC TTTACAATAC 
301    CGTGGCAACC CTCTATTGCG TCCACGAGAA GATCGAGGTG AGAGACACAA AGGAGGCCCT 
361    GGACAAAATC GAGGAGGAGC AGAATAAGTG CCAGCAGAAG ACCCAGCAGG CAAAGGCTGC 
421    TGACGGAAAG GTCTCTCAGA ACTATCCTAT CGTTCAGAAC CTTCAGGGGC AGATGGTGCA 
481    CCAAGCAATC AGCCCTAGAA CCCTGAACGC ATGGGTGAAG GTGATCGAGG AGAAAGCCTT 
541    TTCTCCCGAG GTTATCCCCA TGTTTACCGC CCTGAGCGAA GGCGCCACTC CTCAAGACCT 
601    GAACACTATG CTGAACACAG TGGGAGGACA CCAGGCCGCT ATGCAGATGT TGAAGGATAC 
661    CATCAACGAG GAGGCAGCCG AATGGGACCG CCTCCACCCC GTGCACGCCG GACCTATCGC 
721    CCCCGGACAA ATGAGAGAAC CTCGCGGAAG TGATATTGCC GGTACTACCA GCACCCTTCA 
781    AGAGCAGATT GCTTGGATGA CCAGCAACCC ACCCATCCCA GTGGGCGATA TTTACAAAAG 
841    GTGGATTATT CTGGGGCTGA ACAAAATTGT GAGAATGTAC TCCCCCGTCT CCATCCTCGA 
901    CATCCGCCAA GGACCCAAGG AGCCTTTTAG GGATTACGTG GACAGATTCT TCAAAACCCT 
961    TAGAGCTGAG CAAGCCACTC AGGAGGTTAA GAACTGGATG ACAGATACTC TGCTCGTGCA 
1021   AAACGCTAAC CCCGATTGCA AAACCATCTT GAGAGCTCTC GGTCCAGGTG CCACCCTTGA 
1081   GGAAATGATG ACAGCATGTC AAGGCGTGGG AGGACCTGGG CACAAGGCCA GAGTTCTCGC 
1141   TGAGGCCATG AGCCAGACAA ACTCAGGCAA TATCATGATG CAGAGGAGTA ACTTTAAGGG 
1201   TCCCAGGAGA ATCGTCAAGT GCTTCAATTG TGGCAAGGAG GGTCACATTG CCAGGAACTG 
1261   CCGCGCCCCC AGGAAGAAAG GCTGCTGGAA GTGTGGCAAA GAGGGCCACC AGATGAAGGA 
1321   TTGCACCGAG CGCCAAGCAA ACTTCCTGGG AAAGATTTGG CCCAGTCATA AGGGCCGCCC 
1381   TGGCAACTTC CTTCAAAACA GACCCGAGCC TACCGCCCCC CCCGCTGAGT CTTTCAGATT 
1441   TGAGGAGACC ACCCCCGCTC CAAAGCAGGA GCCAATTGAG AGAGAGCCTC TCACCAGTCT 
1501   CAAAAGCCTC TTTGGTAGCG ACCCCCTCAG CCAATAAGAA TTCAATCACT AGTGATAAGC 
                                        Stop codon 
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1561   GCCGG ATGCAT AGCTTGAGT ATTCTATAGT GTCACCTAAA T 
                            NsiI site        pGEM®-T-easy multiple cloning site 
3. pcDNA3.1/Zeo/CAT cloning vector map                                              
























4. Sequence of CAT ORF in the pcDNA3.1/Zeo/CAT cloning vector  
 
 
              NotI site                                                                                Start codonCAT ORF 
1      GCGGCCGC TCGAGCTTCGAC GAGATTTTCA GGAGCTAAGG AAGCTAAAATG GAGAAAAAA 
61     ATCACTGGAT ATACCACCGT TGATATATCC CAATGGCATC GTAAAGAACA TTTTGAGGCA 
121    TTTCAGTCAG TTGCTCAATG TACCTATAAC CAGACCGTTC AGCTGGATAT TACGGCCTTT 
181    TTAAAGACCG TAAAGAAAAA TAAGCACAAG TTTTATCCGG CCTTTATTCA CATTCTTGCC 
241    CGCCTGATGA ATGCTCATCC GGAATTCCGT ATGGCAATGA AAGACGGTGA GCTGGTGATA 
301    TGGGATAGTG TTCACCCTTG TTACACCGTT TTCCATGAGC AAACTGAAAC GTTTTCATCG 
361    CTCTGGAGTG AATACCACGA CGATTTCCGG CAGTTTCTAC ACATATATTC GCAAGATGTG 
421    GCGTGTTACG GTGAAAACCT GGCCTATTTC CCTAAAGGGT TTATTGAGAA TATGTTTTTC 
481    GTCTCAGCCA ATCCCTGGGT GAGTTTCACC AGTTTTGATT TAAACGTGGC CAATATGGAC 
541    AACTTCTTCG CCCCCGTTTT CACCATGGGC AAATATTATA CGCAAGGCGA CAAGGTGCTG 
601    ATGCCGCTGG CGATTCAGGT TCATCATGCC GTCTGTGATG GCTTCCATGT CGGCAGAATG 
661    CTTAATGAAT TACAACAGTA CTGCGATGAG TGGCAGGGCG GGGCGTAATT TTTTTAAGGC 
                                                        Stop Codon 
721    AGTTATTGGT GCCCTTAAAC GCCTGGTGCT ACGCCTGAAT AAGTGATAAT AAGCGGATGA 
781    ATGGCAGAAA TTCGTCGAAG CTCTAGA 





 Figure B3 Map of the pcDNA3.1/Zeo/CAT cloning vector containing the CAT ORF used for 
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Figure B5 pFastBac™ Dual insect cell expression vector. (A) Vector map, (B) Position of 
restriction sites in the PH and p10 promoter multiple cloning sites (Vector map and multiple 
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6. Sequence of the hmGag ORF in the pFastBac™ dual insect cell   
….expression vector under the p10 promoter multiple cloning site 
 
 
             p10 promoter MCS 
1      TATACGGACC TTTAATTCAA CCCAACACAA TATATTATAG TTAAATAAGA ATTATTATCA 
61     AATCATTTGT ATATTAATTA AAATACTATA CTGTAAATTA CATTTTATTT ACAATCACTC 
 
                                                                              NcoI site +Start codon        hmGag ORF                                     
121    GACGAAGACT TGATCACCCG GGATCTCGAG CCATGGGTGC TCGCGCATCT ATCCTCAGAG 
181    GCGAAAAGTT GGATAAGTGG GAAAAAATCA GACTCAGGCC AGGAGGTAAA AAACACTACA 
241    TGCTGAAGCA TATCGTGTGG GCATCTAGGG AGTTGGAGAG ATTTGCACTG AACCCCGGAC 
301    TGCTGGAAAC CTCAGAGGGC TGTAAGCAAA TCATGAAACA GCTCCAACCA GCCTTGCAGA 
361    CCGGAACAGA AGAGCTGAAG TCCCTTTACA ATACCGTGGC AACCCTCTAT TGCGTCCACG 
421    AGAAGATCGA GGTGAGAGAC ACAAAGGAGG CCCTGGACAA AATCGAGGAG GAGCAGAATA 
481    AGTGCCAGCA GAAGACCCAG CAGGCAAAGG CTGCTGACGG AAAGGTCTCT CAGAACTATC 
541    CTATCGTTCA GAACCTTCAG GGGCAGATGG TGCACCAAGC AATCAGCCCT AGAACCCTGA 
601    ACGCATGGGT GAAGGTGATC GAGGAGAAAG CCTTTTCTCC CGAGGTTATC CCCATGTTTA 
661    CCGCCCTGAG CGAAGGCGCC ACTCCTCAAG ACCTGAACAC TATGCTGAAC ACAGTGGGAG 
721    GACACCAGGC CGCTATGCAG ATGTTGAAGG ATACCATCAA CGAGGAGGCA GCCGAATGGG 
781    ACCGCCTCCA CCCCGTGCAC GCCGGACCTA TCGCCCCCGG ACAAATGAGA GAACCTCGCG 
841    GAAGTGATAT TGCCGGTACT ACCAGCACCC TTCAAGAGCA GATTGCTTGG ATGACCAGCA 
901    ACCCACCCAT CCCAGTGGGC GATATTTACA AAAGGTGGAT TATTCTGGGG CTGAACAAAA 
961    TTGTGAGAAT GTACTCCCCC GTCTCCATCC TCGACATCCG CCAAGGACCC AAGGAGCCTT 
1021   TTAGGGATTA CGTGGACAGA TTCTTCAAAA CCCTTAGAGC TGAGCAAGCC ACTCAGGAGG 
1081   TTAAGAACTG GATGACAGAT ACTCTGCTCG TGCAAAACGC TAACCCCGAT TGCAAAACCA 
1141   TCTTGAGAGC TCTCGGTCCA GGTGCCACCC TTGAGGAAAT GATGACAGCA TGTCAAGGCG 
1201   TGGGAGGACC TGGGCACAAG GCCAGAGTTC TCGCTGAGGC CATGAGCCAG ACAAACTCAG 
1261   GCAATATCAT GATGCAGAGG AGTAACTTTA AGGGTCCCAG GAGAATCGTC AAGTGCTTCA 
1321   ATTGTGGCAA GGAGGGTCAC ATTGCCAGGA ACTGCCGCGC CCCCAGGAAG AAAGGCTGCT 
1381   GGAAGTGTGG CAAAGAGGGC CACCAGATGA AGGATTGCAC CGAGCGCCAA GCAAACTTCC 
1441   TGGGAAAGAT TTGGCCCAGT CATAAGGGCC GCCCTGGCAA CTTCCTTCAA AACAGACCCG 
1501   AGCCTACCGC CCCCCCCGCT GAGTCTTTCA GATTTGAGGA GACCACCCCC GCTCCAAAGC 
1561   AGGAGCCAAT TGAGAGAGAG CCTCTCACCA GTCTCAAAAG CCTCTTTGGT AGCGACCCCC 
1621   TCAGCCAAT A AGAATTCAAT CACTAGTGAT AAGCGCCGGA TGCATCGGTA CCGGGAGATG 
           Stop codon                             NsiI site    
 
1681   GGGGAGGCTA ACTGAAACAC GGAAGGAGAC AATACCGGAA GGAACCCGCG CTATG 
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7. Sequence of the CAT ORF in the pFastBac™ dual insect cell 





             PH promoter MCS 
1      ATGGAGATAA TTAAAATGAT AACCATCTCG CAAATAAATA AGTATTTTAC TGTTTTCGTA 
61     ACAGTTTTGT AATAAAAAAA CCTATAAATA TTCCGGATTA TTCATACCGT CCCACCATCG 
121    GGCGCGGATC CCGGTCCGAA GCGCGCGGAA TTCAAAGGCC TACGTCGACG AGCTCACTAG 
 
                      NotI site                                                                                      Start codonCAT ORF 
181    TC GCGGCCGC TCGAGCTTCG ACGAGATTTT CAGGAGCTAA GGAAGCTAAA ATGGAGAAAA 
241    AAATCACTGG ATATACCACC GTTGATATAT CCCAATGGCA TCGTAAAGAA CATTTTGAGG 
301    CATTTCAGTC AGTTGCTCAA TGTACCTATA ACCAGACCGT TCAGCTGGAT ATTACGGCCT 
361    TTTTAAAGAC CGTAAAGAAA AATAAGCACA AGTTTTATCC GGCCTTTATT CACATTCTTG 
421    CCCGCCTGAT GAATGCTCAT CCGGAATTCC GTATGGCAAT GAAAGACGGT GAGCTGGTGA 
481    TATGGGATAG TGTTCACCCT TGTTACACCG TTTTCCATGA GCAAACTGAA ACGTTTTCAT 
541    CGCTCTGGAG TGAATACCAC GACGATTTCC GGCAGTTTCT ACACATATAT TCGCAAGATG 
601    TGGCGTGTTA CGGTGAAAAC CTGGCCTATT TCCCTAAAGG GTTTATTGAG AATATGTTTT 
661    TCGTCTCAGC CAATCCCTGG GTGAGTTTCA CCAGTTTTGA TTTAAACGTG GCCAATATGG 
721    ACAACTTCTT CGCCCCCGTT TTCACCATGG GCAAATATTA TACGCAAGGC GACAAGGTGC 
781    TGATGCCGCT GGCGATTCAG GTTCATCATG CCGTCTGTGA TGGCTTCCAT GTCGGCAGAA 
841    TGCTTAATGA ATTACAACAG TACTGCGATG AGTGGCAGGG CGGGGCGTAA TTTTTTTAAG 
                                                          Stop Codon 
901    GCAGTTATTG GTGCCCTTAA ACGCCTGGTG CTACGCCTGA ATAAGTGATA ATAAGCGGAT 
961    GAATGGCAGA AATTCGTCGA AGCTCTAGA GCCTGCAGTCT CGACAAGCTT GTCGAGAAGT 
                                                     XbaI site 
 
1021   ACTAGAGGAT CATAATCAGC CATACCACAT TTGTAGAGGT TTTACTTGCT TTAAAAAACC 
1081   TCCCAC 







8. CAT open reading frame 
                Start of Psi sequence 
                  BamHI 
61    TCGGGATCCC GGGTCTCTCT GGTTAGACCA GATCTGAGCC TGGGAGCTCT CTGGCTAACT 
121   AGGGAACCCA CTGCTTAAGC CTCAATAAAG CTTGCCTTGA GTGCTTCAAG TAGTGTGTGC 
181   CCGTCTGTTG TGTGACTCTG GTAACTAGAG ATCCCTCAGA CCCTTTTAGT CAGTGTGGAA 
241   AATCTCTAGC AGTGGCGCCC GAACAGGGAC CTGAAAGCGA AAGGGAAACC AGAGGAGCTC 
301   TCTCGACGCA GGACTCGGCT TGCTGAAGCG CGCACGGCAA GAGGCGAGGG GCGGCGACTG 
361   GTGAGTACGC CAAAAATTTT GACTAGCGGA GGCTAGAAGG AGAGAGATGG GTGCGAGAGC 
421   GTCAGTATTA GGAATTCCAA TCACTAGTGA ATTCGCGGCC GCCTGCAGGT CGACCATATG 
  NdeI 
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